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Abstract
Effectiveness and cost-effectiveness of arthroscopic 
lavage in the treatment of osteoarthritis of the knee:  
a mixed methods study of the feasibility of conducting 
a surgical placebo-controlled trial (the KORAL study)
MK Campbell,1* ZC Skea,1 AG Sutherland,2 BH Cuthbertson,1 
VA Entwistle,3 AM McDonald,1 JD Norrie,1 RV Carlson,4 S Bridgman5 
and the KORAL study group
1Health Services Research Unit, University of Aberdeen, Aberdeen, UK
2Department of Surgery, University of Aberdeen, Aberdeen, UK
3Social Dimensions of Health Institute, Universities of Dundee and St Andrews, UK
4Department of Molecular and Clinical Medicine, University of Edinburgh, Edinburgh, UK
5University Hospital of North Staffordshire NHS Trust, Stoke-on-Trent, UK
specialist reassessment.
Main outcome measures: The acceptability and 
feasibility of mounting a placebo-controlled trial for the 
evaluation of knee arthroscopic lavage.
Results: There was broad acceptance across all 
stakeholder groups of the need to find out more about 
the effectiveness of arthroscopic lavage. Despite this 
there was variation in opinion within all the groups 
about how researchers should approach this and 
whether or not it would be acceptable to investigate 
using placebo surgery. Within the health professional 
groups, there tended to be a split between those who 
were strongly opposed to the inclusion of a placebo 
surgery arm and those who were more in favour.  For 
prospective trial participants who had osteoarthritis 
of the knee, the acceptability of the trial was discussed 
from a more individual perspective – reflecting on 
their personal reasons for or against participating. 
The majority of this group said they would consider 
taking part. The pilot study showed that, in principle, a 
placebo-controlled trial could be conducted. It showed 
that patients were willing to participate in a trial which 
would involve a placebo-surgical arm and that it was 
possible to undertake placebo surgery successfully 
and to blind patients to their allocation – although 
once patients knew their allocation, some patients 
allocated to surgery became more concerned about the 
possibility of undergoing placebo surgery, and withdrew. 
The experience of the pilot, however, showed that, 
despite full MREC approval, the study required major 
discussion and negotiation before local clinical approvals 
could be obtained. The fact that ethics approval had 
*Corresponding author
Objectives: To ascertain the acceptability of a 
randomised controlled trial comparing arthroscopic 
lavage with a placebo-surgical procedure for the 
management of osteoarthritis of the knee; and to assess 
the practical feasibility of mounting such a multicentre 
placebo-controlled trial.
Design: Mixed methods study including: focus groups 
with surgeons and anaesthetists; focus groups and 
interviews with potential participants; interviews 
with chairpersons of UK Multicentre Research Ethics 
Committees (MRECs); surveys of surgeons and 
anaesthetists; and a two-centre, three-arm pilot.
Setting: UK secondary care.
Participants: Members of the British Association 
of Surgeons of the Knee and members of the British 
Society of Orthopaedic Anaesthetists took part in the 
focus groups and surveys.  Surgeons and anaesthetists 
from two regional centres in the UK also contributed 
to focus groups, as did patients from consultant lists 
in two UK regional centres, and members of Arthritis 
Care. Chairpersons of six UK MRECs were interviewed. 
Participants were eligible for the pilot if they were 
adults (18 years or older) with radiological evidence of 
osteoarthritis of the knee who might be considered for 
arthroscopic lavage, and were fit for general anaesthetic 
(defined by the American Society of Anaesthesiologists 
grades 1 and 2), and able to give informed consent.
Interventions: Participants in the pilot study were 
randomised to arthrosocopic lavage (with or without 
debridement at the clinical discretion of the surgeon); 
placebo surgery; or non-operative management with Abstract
iv
been granted did not mean that clinicians would 
automatically accept that the process was ethical.
Conclusions: The study showed that, in principle, a 
placebo-controlled trial of arthroscopic lavage could 
be conducted in the UK, albeit with difficulty. Against 
the background of falling use of arthroscopic lavage 
the decision was, therefore, taken not to proceed to 
full-scale trial for this procedure. The study showed 
that for some health professionals the use of placebo 
surgery can never be justified. It highlighted the 
importance of the surgeon–anaesthetist relationship 
in this context and how acceptance of the trial design 
by both parties is essential to successful participation. 
It also highlighted the importance of informed consent 
for trial participants and the strength and influence of 
individuals’ ethical perspectives in addition to collective 
ethics provided by MRECs.
Trial registration: Current Controlled Trials 
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Background
Osteoarthritis is the most common form of arthritis 
in Western populations. When medication for 
osteoarthritis of the knee does not sufficiently 
relieve symptoms, the surgical procedure 
of arthroscopic lavage may be undertaken. 
Arthroscopic lavage involves washing out the 
joint space during arthroscopy, with additional 
debridement (the mechanical removal of debris 
and the trimming of rough surfaces) if deemed 
necessary. The evidence for the effectiveness 
of arthroscopic lavage is variable, however, and 
the largest trial conducted to date showed no 
evidence of a benefit of arthroscopic lavage or 
debridement over placebo. The generalisability 
of the results of this trial has been questioned 
as all procedures were performed by a single 
surgeon, a significant proportion of patients 
had severe arthritis, and the primary outcome 
was based on a non-validated instrument. Given 
the widespread use, high cost and continuing 
uncertainty around the effectiveness of arthroscopic 
lavage for osteoarthritis of the knee, the Health 
Technology Assessment (HTA) programme sought 
to commission a similar placebo-controlled trial of 
arthroscopic lavage in the UK. Recognising that 
there might be difficulties of mounting such a trial 
(in terms of perceived acceptability of the placebo 
design) the research was commissioned with an 
integrated, yet discrete, feasibility study, which is 
described in this monograph.
Objectives
The objectives of the feasibility study were two-fold: 
(a) to ascertain the acceptability of a randomised 
controlled trial comparing arthroscopic lavage with 
a placebo surgical procedure for the management 
of osteoarthritis of the knee; and (b) to assess 
the practical feasibility, through the conduct of a 
formal pilot study, of mounting such a multicentre 
placebo-controlled trial. This included assessing 
the acceptability of the proposed trial processes to 
patients and staff, to estimate the proportion of 
patients who would accept randomisation within 
the trial, and to examine the acceptability of the 
trial information material to patients.
Methods
The initial exploration of acceptability comprised: 
focus groups with surgeons and anaesthetists; focus 
groups and interviews with potential participants; 
interviews with chairpersons of the UK Multicentre 
Research Ethics Committees (MRECs); and surveys 
of surgeons and anaesthetists.
The pilot study was designed as a two-centre, three-
arm trial of arthroscopic lavage (with or without 
debridement at the clinical discretion of the 
surgeon); placebo surgery; and non-operative (i.e. 
medical) management with specialist reassessment.
Results
There was broad acceptance across all stakeholder 
groups of the need to find out more about the 
effectiveness or otherwise of arthroscopic lavage. 
Despite this there was, however, variation in 
opinion within all the groups about how researchers 
should approach this and about whether or not it 
would be acceptable to investigate using placebo 
surgery. Within the health professional groups, 
there tended to be a split between those who were 
strongly opposed to the inclusion of a placebo 
surgery arm (on the grounds that it could lead 
to potential harms among individuals who could 
expect no personal benefit) and those who were 
more in favour on the grounds that they believed 
the small risks that relatively few people in a 
placebo surgery trial arm would be exposed to 
were justified because they were outweighed by the 
potential benefit (i.e. potential benefit to future 
patients and broader society through helping 
to ensure either that a demonstrably effective 
surgical procedure was used or that a demonstrably 
ineffective procedure was not). For prospective trial 
participants who had osteoarthritis of the knee, 
the acceptability of the trial was discussed from a 
more individual perspective – reflecting on their 
personal reasons for or against participating. The 
majority of this group said they would consider 
taking part. As well as expressing a desire to help 
others through their participation, there was a 
general tendency to down play any potential risk of 
harm from their participation whilst emphasising 
Executive summaryExecutive summary
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the potential to gain some form of personal 
benefit. Given the nature of the proposed design, 
the health professionals and MREC chairpersons 
recognised that particular attention should be paid 
to the informed consent process when attempting 
to recruit participants.
The pilot study showed that, in principle, a 
placebo-controlled trial in surgery could be 
conducted. It showed that patients were willing to 
participate in a trial that would involve a placebo 
surgical arm, and that it was possible to undertake 
placebo surgery successfully and to blind patients 
to their allocation – although once patients knew 
their allocation, some patients allocated to surgery 
became more concerned about the possibility of 
undergoing placebo surgery, and withdrew. The 
experience of the pilot, however, showed that, 
despite full MREC approval, the study required 
major discussion and negotiation before local 
clinical approvals could be obtained. Many of the 
arguments raised at MREC level were raised again 
at local level, and the fact that ethics approval had 
been granted did not mean that clinicians would 
automatically accept that the process was ethical.
National trend data showed a slow decline in the 
usage of arthroscopic lavage over recent years.
Conclusions
The feasibility study showed that, in principle, 
a placebo-controlled trial of arthroscopic lavage 
could be conducted in the UK, albeit with difficulty. 
Against this background and a falling use of 
arthroscopic lavage, the decision was taken not 
to proceed to full-scale trial for this particular 
procedure.
The study showed that the placebo-controlled 
design remains controversial, and for some health 
professionals the use of placebo surgery can never 
be justified. It highlighted the importance of the 
surgeon–anaesthetist relationship in this context 
and how acceptance of the trial design by both 
parties is essential to successful participation. 
It also highlighted the importance of informed 
consent for trial participants and the strength and 
influence of individuals’ ethical perspectives in 
addition to collective ethics provided by MRECs.
The wider lesson from the study is that the most 
favourable circumstances for a placebo-controlled 
trial in surgery are those where: (a) alternative 
designs would provide inferior (and potentially 
biased) results, particularly where the primary 
outcome is of a subjective nature and blinding 
cannot be sustained beyond the time of any 
placebo effect; (b) a placebo surgical procedure 
and type of anaesthesia can be devised that 
adequately mimic the active intervention with a 
level of intrusiveness and risk that is acceptable 
to surgeons, anaesthetists, ethics committees, and 
potential participants; (c) appropriate practical 
arrangements can be instituted in local centres to 
ensure that the delivery of such a design would 
be feasible; (d) sufficient numbers of potential 
participants (after assessment of clear descriptions 
and careful explanations in patient information 
leaflets of the advantages and disadvantages of 
taking part) judge for themselves that the risk-to-
benefit ratio of participation is acceptable to them; 
and (e) levels of compliance with the allocation are 
sufficiently high to sustain scientific rigour.
Implications for practice
•  A placebo-controlled trial of arthroscopic 
lavage could be conducted in the UK, albeit 
with difficulty.
•  Those conducting trials in surgery must 
consider surgeon–anaesthetist partnerships 
when planning clinical trials, especially trials 
including a placebo arm.
•  People taking part in, and those responsible 
for, authorising the conduct of trials have their 
own individual ethical perspectives which 
can influence their attitudes to research (in 
addition to the collective ethics assessment 
provided by MRECs). Researchers need to 
be aware of these, and work with them when 
planning clinical trials – especially trials 
involving a placebo arm.
•  Terminology referring to ‘placebos’, 
‘shams’, ‘dummies’, etc. each have different 
connotations that may influence participation.
•  The importance of including clear descriptions 
and careful explanations in patient information 
leaflets was reinforced in this study. All trials 
should ensure that any advantages and 
disadvantages of participation are explained as 
fully as possible.
•  Patient information leaflets within placebo-
controlled trials should explicitly state that 
whilst benefit might be seen within a placebo 
group, the underlying mechanism of the 
placebo has no known direct effect.
•  National arrangements for indemnity and 
non-negligent harm should be clarified for all 
researchers involved in the conduct of clinical 
trials, particularly those trials that might 
involve a placebo arm.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
xi
•  The HTA programme should consider the 
routine use of staged funding (with integrated 
rapid decision-making) for more complex 
research projects.
•  The optimal place for a placebo-controlled 
trial in surgery is likely to be where the strict 
conditions listed above can be satisfied.
Implications for research
•  Research is required into the impact of 
different terminology referring to placebos 
(e.g. placebo, sham, dummy) on the 
understanding of the role and function of a 
placebo.
•  Research is required into the usefulness of 
formal decision aids to aid participant consent 
in the context of a placebo-controlled trial.
•  Research is required into the impact of 
individual versus collective ethics on the 
conduct of placebo-controlled trials.
Trial registration
This trial is registered as ISRCTN 02328576DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
1
Clinical background
Osteoarthritis
Osteoarthritis is a common and important cause of 
pain and disability and is the most frequent form 
of arthritis in Western populations.1,2 Osteoarthritis 
of the knee results in disabling knee symptoms in 
an estimated 10% of people aged over 55 years.3 
A report from the World Health Organization, 
published in 1997,4 suggested that osteoarthritis 
of the knee is likely to become the fourth most 
important cause of disability in women and the 
eighth most important in men. The aetiology 
of osteoarthritis of the knee is reported to be 
multifactorial, including general factors (such as 
age, sex and obesity), mechanical factors (such as 
trauma, recreational activities and alignment)5,6 
and genetic factors.7 Knee osteoarthritis is 
characterised both by focal loss of articular 
cartilage and by central and marginal new bone 
formation (subchondral sclerosis, osteophytosis), 
but affects the whole joint.5 There is often an 
associated low grade synovitis, but ligament laxity 
and muscle weakness about the joint are secondary 
changes, due to articular cartilage loss and disuse 
respectively. Clinically, knee osteoarthritis is 
associated with pain, joint stiffness and deformity, 
which lead to limitations of activities for sufferers. 
In 1977, Hernborg and Nilsson8 demonstrated 
that the natural history of untreated osteoarthritis 
of the knee was one of gradual decline for most 
patients (over 10–18 years, 17% were improved, 
26% unchanged and 56% worse clinically).
There is a range of treatment options available 
for the management of osteoarthritis of the knee, 
including non-pharmacological interventions 
(such as education, exercise, orthotic devices); 
pharmacological treatments (such as non-steroidal 
anti-inflammatory drugs, paracetamol, topical 
treatments); intra-articular modalities (such as 
corticosteroid and hyaluronic acid injections 
and tidal irrigation); and, surgical interventions 
(including therapeutic arthroscopy and ultimately 
joint replacement).3 Current evidence to support 
the use of the various treatments is variable, 
although guidelines for the management of knee 
osteoarthritis have been produced.3,9–11
When pharmacological and non-invasive non-
pharmacological treatments do not sufficiently 
relieve symptoms, arthroscopic lavage (with 
or without debridement) may be undertaken. 
Arthroscopic lavage involves washing out the 
joint space during arthroscopy with several litres 
of saline solution. Any intra-articular debris is 
then flushed out via arthroscopic cannulae. In 
addition, debridement may be undertaken during 
the same procedure. This involves the mechanical 
removal of debris and the trimming or shaving of 
rough surfaces that may interfere with the smooth 
movement of the joint. Arthroscopic debridement 
aims to remove any chemical or mechanical 
component that could contribute to the symptoms 
of osteoarthritis. It is reported that more than 
650,000 of these procedures are performed each 
year in the USA – costing more than US$3.5 billion 
annually.12 Hospital episode statistics (HES) for 
England for the financial year 2002–03 (the start 
of the project) indicated that approximately 34,000 
therapeutic arthroscopic procedures of the knee 
were undertaken at an estimated annual cost to the 
NHS of over £34M13 (although it is not possible to 
determine from the coding whether all procedures 
were for knee osteoarthritis).
Evidence for use of arthroscopic 
lavage
The evidence for the effectiveness of arthroscopic 
lavage is variable. The majority of reported studies 
of arthroscopic lavage are uncontrolled (mainly 
case series). Single studies have suggested that 
arthroscopic lavage and physiotherapy have benefit 
persisting to 6 months14 when compared with 
physiotherapy alone, and simple (unguided) tidal 
irrigation is superior to medical management15 and 
equivalent to arthroscopic debridement16 in early 
osteoarthritis of the knee.
As arthroscopic treatment developed with the 
addition of debridement over lavage alone, further 
observational studies suggested that benefits 
persisted for up to 5 years,17 particularly in knees 
with normal alignment,18 minimal osteoarthritis19 
and meniscal tears,20 and for patients with short-
lived mechanical symptoms.21 Different surgeons 
use ‘debridement’ to describe different procedures, 
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the studies are often small, with limited follow-
up, and it is difficult to control for the placebo 
effect of any surgical intervention. The overall 
effect of generally positive results in 40–85% of 
patients is also not very different from the natural 
history outlined by Hernborg and Nilsson,8 and 
many surgeons had come to the conclusion that 
arthroscopy and debridement should be reserved 
for those groups most likely to benefit (e.g. for 
those with meniscal tears).
More recently, however, there has been a small 
number of randomised controlled trials (RCTs) 
reported in the literature. In contrast to the 
uncontrolled studies, systematic reviews of these 
trials provide little evidence to support the 
routine use of arthroscopic lavage.22,23 We have 
provided a brief summary of the trials14,16,17,24–29 of 
arthroscopic lavage (with or without debridement) 
as identified from a search of MEDLINE and 
EMBASE until June 2008 in Table 1. We have not 
presented the details of trials of unguided lavage 
or trials that did not assess the independent effect 
of arthroscopic lavage from other treatments, e.g. 
trials of arthroscopic lavage plus intra-articular 
corticosteroids. Both a recent Cochrane review30 
and the National Institute for Health and Clinical 
Excellence (NICE) guidance31 (both of which were 
published after the empirical research presented in 
this study was completed) also do not support the 
use of arthroscopic lavage, in non-discriminated 
osteoarthritis.
Specific studies have included trials of arthroscopic 
lavage against a placebo procedure, arthroscopic 
lavage against unguided irrigation, and 
arthroscopic lavage against other interventions 
for the management of knee osteoarthritis. Most 
of these trials involved small and selected groups 
of patients. For example, Forster and Shaw26 
reported an RCT of 32 patients randomised to 
arthroscopic lavage (with or without debridement 
as deemed necessary) versus hyaluronic acid intra-
articular injection. This study showed no evidence 
of benefit of arthroscopic lavage at 12 months. 
Similarly, Chang et al.16 compared arthroscopic 
lavage (with or without debridement as deemed 
necessary) against tidal irrigation in 32 patients, 
which again showed no evidence of greater 
improvement following arthroscopic lavage. Ward 
et al.27 undertook a similar RCT in 51 patients 
comparing arthroscopic lavage with cannula lavage 
and also concluded that there was no evidence of 
a difference between the groups. In a controlled 
study by Livesley et al.,14 however, which compared 
arthroscopic lavage plus physiotherapy with 
physiotherapy alone in 61 patients, the authors 
found a statistically significantly greater reduction 
in pain in the lavage group.
The largest trial to date was conducted by Moseley 
et al.24 in 2002. In this trial, 180 participants were 
randomised to arthroscopic lavage, arthroscopic 
debridement or placebo procedure. This trial is 
described in more detail in the following section.
The Moseley trial
In the trial by Moseley et al.,24 180 patients were 
recruited from a single Veterans Affairs Medical 
Centre and randomised to arthroscopic lavage, 
arthroscopic debridement or placebo procedure. 
Patients were deemed eligible for inclusion in 
the trial if they were: 75 years old or younger; 
had osteoarthritis of the knee as defined by the 
American College of Rheumatology; reported, 
on average, at least moderate knee pain (≥ 4 on 
a visual analogue scale ranging from 0 to 10) 
despite optimal medical treatment for at least 6 
months; and had not undergone arthroscopy of 
the knee during the previous 2 years. Patients were 
stratified into three groups according to severity of 
osteoarthritis, and randomised within strata with 
a fixed block size of six using sealed, sequentially 
numbered stratum-specific envelopes. Treatment 
assignment was not revealed to the patient. The 
trial was initially designed as a superiority trial 
to detect the superiority of the arthroscopic 
procedures over the placebo procedure. When no 
evidence of superiority was observed (see results 
below) the trial team changed to the use of an 
equivalence testing framework.
Of the 180 patients who were randomised, 61 were 
allocated to the arthroscopic lavage group, 59 to 
the arthroscopic debridement group and 60 to the 
placebo group. Baseline characteristics were similar 
across trial groups. Across the trial, the majority of 
participants were male (93%) and had an average 
age of 52 years. Approximately 29% had early 
arthritis, 46% had moderate arthritis and 25% had 
severe arthritis.
All procedures were undertaken by a single 
surgeon. Patients in the lavage and debridement 
groups received standard general anaesthesia 
with endotracheal intubation whilst patients in 
the placebo group received a ‘… short-acting 
intravenous tranquilizer and an opioid and 
spontaneously breathed oxygen-enriched air …’. 
Lavage consisted of joint flushing with at least 
10 litres of fluid, whereby any loose debris was DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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TABLE 1  Randomised controlled trials of arthroscopic lavage (with or without debridement) in osteoarthritis patients
Trial Comparators Primary outcome Result
Moseley et al., 
200224
Double-blind 
RCT
Arthroscopic lavage (61 participants) vs 
arthroscopic lavage + debridement (59 
participants) vs placebo (60 participants)
Pain at 24 months All groups got better compared 
with baseline
Neither active treatment differed 
from placebo at 12 months
Moseley et al., 
199625
RCT, pilot
Arthroscopic lavage (3 participants) 
vs arthroscopic debridement (2 
participants) vs placebo (5 participants)
Various pain measures All groups did well
Forster and 
Straw, 200326
RCT
Arthroscopic washout (± debridement 
as deemed necessary, n = 15 participants) 
vs 5 × weekly Hyalgan intra-articular 
injections (n = 17 participants)
Pain and function at 6 
weeks, and 3, 6, and 12 
months
Both groups improved pain from 
baseline
No significant difference between 
groups at 12 months for pain
Suggestion of improved function 
with injection
Livesley et al., 
199114
Controlled 
clinical trial
Arthroscopic lavage + physiotherapy  
(37 participants) vs physiotherapy only 
(24 participants)
Pain at 3, 6 and 12 
months
Statistically significant greater 
reduction in pain in favour of lavage 
at 3 and 6 months
No significant difference at 12 
months
Clinical importance unclear
Chang et al., 
199316
Blinded RCT
Arthroscopic lavage (± debridement) 
(18 participants) vs tidal irrigation (14 
participants)
Pain and function All groups improved compared 
with baseline
No apparent difference between 
procedures at 12 months
Ward et al., 
199827
Abstract only, 
RCT
Arthroscopic lavage (n = 51 participants 
in total) vs cannula lavage
Pain and function No significant difference in 
outcome
Gibson et al., 
199228
RCT
Arthroscopic lavage (10 participants) 
vs arthroscopic debridement (10 
participants)
Quadriceps and 
hamstring power
No clinical improvement after 
either procedure
Some improvement in muscle 
torque following lavage but not 
debridement
Hubbard, 199617
RCT
Arthroscopic lavage (36 participants) vs 
arthroscopic lavage + debridement (40 
participants)
Pain at 1 year More people pain-free in 
debridement group (5/36 vs 33/40) 
at 1 year (p = 0.05)
Kalunian et al., 
200029
Double-blind 
RCT
Arthroscopic lavage (full irrigation) (41 
participants) vs arthroscopic lavage 
(minimal saline) (49 participants)
Pain All groups improved compared 
with baseline
Statistically significant difference 
in favour of full irrigation at 12 
months (p = 0.02)
removed through arthroscopic cannulae. The 
debridement group also had any rough articular 
cartilage shaved, all torn or degenerated meniscal 
fragments trimmed and the remaining meniscus 
smoothed. For the placebo group, the knee 
was prepared for lavage and draped, and three 
1-cm incisions made in the skin. To simulate the 
procedure, the surgeon asked for all instruments 
and manipulated the knee as if arthroscopy was 
being performed. Saline was splashed to simulate 
the sounds of lavage; however, no instruments 
entered the portals for arthroscopy. The patient 
was kept in theatre for the amount of time a 
standard debridement would take.
The primary outcome for the study was knee-
specific pain (measured over 24 months using a 
12-item self-reported Knee Specific Pain Scale Introduction
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created specifically for the study). Pain scores 
ranged from 0 to 100, with higher scores indicating 
more severe pain. The results showed that all 
groups improved from baseline at both 12 and 24 
months. No significant differences were observed at 
follow-up, however, between the placebo group and 
either ‘active’ surgery group. For example, mean 
(± standard deviation) pain scores at 12 months 
were 48.9 ± 21.9, 54.8 ± 19.8 and 51.7 ± 22.4 
for the placebo, lavage and debridement groups 
respectively. Scores at 24 months showed similar 
results, with pain scores of 51.6 ± 23.7, 53.7 ± 23.7 
and 51.4 ± 23.2 for the placebo, lavage and 
debridement groups respectively.
Whilst the Moseley trial displayed high 
methodological rigour, the generalisability of 
the results has been questioned by a number of 
authors.32,33 In particular, it was noted that only 
56% of those eligible agreed to participate, and 
that participants had more severe arthritis, were 
younger, and were more likely to be white than 
non-participants. The lack of detail about the 
presence of mechanical symptoms, the degree 
of misalignment or limitation of motion and 
the grade of articular cartilage degeneration 
was also questioned,33 as well as the potential 
generalisability of results from a population of 
elderly male veterans. The use of a non-validated 
instrument to assess pain (the Knee Specific Pain 
Scale), and the statistical appropriateness of 
converting what started as a superiority trial to an 
equivalence trial, with attendant issues over power 
calculation, were specifically challenged,34 although 
these were defended by the Moseley group.35
The commissioned research
It was against this background that the National 
Institute for Health Research (NIHR) Health 
Technology Assessment (HTA) programme sought 
to commission a new RCT of the effectiveness and 
cost-effectiveness of arthroscopic lavage for the 
treatment of patients with osteoarthritis of the 
knee. Given the widespread use, high cost and 
uncertain effectiveness of arthroscopic lavage for 
osteoarthritis of the knee, there was a clear need 
for further robust research if future policy and 
practice relating to the use of this intervention were 
to be based on reliable evidence. Given the results 
of the Moseley trial, the HTA programme sought 
to commission a similar placebo-controlled trial of 
arthroscopic lavage in the UK.
Recognising that there may be potential difficulties 
in mounting a placebo-controlled surgical trial 
(in terms of perceived acceptability of such a trial 
design), the HTA programme commissioned the 
research with an integrated, but discrete, feasibility 
study. Progression to a full-scale placebo-controlled 
trial would only go ahead if the feasibility study 
showed that this was appropriate. For a full-scale 
trial to be conducted successfully in the UK, it 
would be necessary to identify enough surgical 
teams willing to deliver arthroscopic lavage 
(and a placebo version of it) in the context of 
a randomised trial, and to be confident that a 
sufficient proportion of eligible patients would, 
when well informed, be willing to take part in such 
a trial.
This monograph presents the findings of the 
feasibility study.
The research project
Reflecting the commissioning brief, the feasibility 
study – known as KORAL (Knee Osteoarthritis: the 
Role of Arthroscopic Lavage) – developed in four 
distinct phases:
•  Formal exploration of the acceptability of a placebo-
controlled trial – the aim of this phase was to 
ascertain the acceptability of a proposed RCT 
comparing arthroscopic lavage with a placebo 
surgical procedure for the management of 
osteoarthritis of the knee to key stakeholder 
groups. This involved four components: focus 
groups with health professionals; focus groups 
(and interviews) with potential participants; 
interviews with chairpersons of the UK 
Multicentre Research Ethics Committees 
(MRECs); and, surveys of surgeons and 
anaesthetists.
•  Obtaining ethics approval to mount a pilot RCT – 
having identified the components of a possible 
placebo procedure, we sought ethics approval 
to conduct a formal pilot study to assess the full 
feasibility of mounting a multicentre placebo-
controlled trial to evaluate the effectiveness 
of arthroscopic lavage for osteoarthritis of the 
knee. As it sought to reflect the design of a full 
trial, the pilot was to include full consent and 
randomisation to a placebo surgical arm. This 
raised a number of significant ethical issues.
•  The formal pilot – the aim of the pilot study was 
to assess the practical feasibility of mounting a 
multicentre placebo-controlled trial to evaluate DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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the effectiveness of arthroscopic lavage for 
osteoarthritis of the knee. This included 
assessing the acceptability of proposed trial 
processes to patients and staff, to estimate 
the proportion of patients who would accept 
randomisation to the trial, and to examine the 
acceptability of the trial information material 
to patients. The pilot was designed as a two-
centre, three-arm trial of: a) arthroscopic 
lavage (with or without debridement at the 
clinical discretion of the surgeon); b) placebo 
surgery; and c) non-operative (i.e. medical) 
management with specialist reassessment.
•  The decision-making process as to whether to progress 
to full trial – based on the insights gained from 
the previous three phases and from external 
evidence, a decision was made jointly with the 
HTA programme on whether a full placebo-
controlled trial should be mounted.
At the start of the project, the KORAL team 
convened a study day for the grant applicants, 
project staff and invited experts to further develop 
the study protocol. This study day (held in March 
2005) benefited significantly from a presentation 
and discussion by Dr Nelda Wray, who was the 
chief investigator (and Dr Carol Ashton, a co-
investigator) of the Moseley trial.24 Professor 
Paul Dieppe (an acknowledged UK expert on 
osteoarthritis) also contributed.
The four phases of the feasibility study are 
described in Chapters 2–5. In Chapter 6, the 
implications of the project are discussed as a whole, 
finishing with a summary of the implications for 
practice and recommendations for further research.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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Aim
The aim of this first phase of the research was 
to ascertain the acceptability of a proposed RCT 
comparing arthroscopic lavage with a placebo 
surgical procedure for the management of 
osteoarthritis of the knee to key stakeholder groups 
(in particular surgeons, anaesthetists, prospective 
participants and members of research ethics 
committees).
Objectives
•  To ascertain what is the range of placebo 
procedures that could be considered for a trial 
comparing arthroscopic lavage with a placebo 
procedure.
•  To describe the attitude of important 
stakeholder groups (in particular, surgeons, 
anaesthetists, prospective participants and 
members of ethics committees) to the use of a 
placebo procedure in the proposed evaluation.
•  To clarify whether attitudes to the proposed 
trial differ depending on the type of placebo 
proposed and/or key trial design features.
This initial phase of research comprised four main 
components that sequentially allowed us to build 
a picture of the likely acceptability of a trial to 
evaluate the effectiveness of arthroscopic lavage in 
comparison with a placebo procedure:
•  Component 1: Focus groups with health professionals 
– we conducted exploratory focus groups with 
health-professional stakeholders (surgeons and 
anaesthetists) to identify the range of placebo 
procedures that may be used, and to appraise 
their strengths and weaknesses from a clinical 
perspective.
•  Component 2: Focus group and interviews with 
people with osteoarthritis – we also conducted 
exploratory focus groups and interviews with 
people with osteoarthritis of the knee to allow 
us to identify the types of judgements, beliefs 
and attitudes (including concern) that patients 
and prospective trial participants may hold in 
relation to a proposed trial; to identify features 
of the placebo procedure and trial design that 
could enhance the acceptability of the trial to 
potential participants; and to test and refine an 
initial draft of written information for potential 
participants. (The initial draft was developed 
taking into account the views expressed by 
the surgeons and anaesthetists on the most 
appropriate form of placebo surgery. It was 
designed with input from Arthritis Care.)
•  Component 3: Interviews with chairpersons of 
UK MRECs – chairpersons of MRECs were 
interviewed by telephone. Their opinions 
were sought on the ethical issues raised by the 
research proposal. Twelve ethics committee 
chairpersons were invited to take part in the 
research.
•  Component 4: Surveys of health professionals – 
Postal surveys of orthopaedic surgeons (all 
members of the British Association of Surgeons 
of the Knee; BASK) and anaesthetists (all 
members of the British Society of Orthopaedic 
Anaesthetists; BSOA) were conducted. 
The aim of these surveys was to investigate 
the distribution of attitudes towards the 
proposed trial and ascertain rates of expressed 
willingness among these groups to support the 
trial in their professional capacity.
The methods and findings of each component are 
described in separate sections below.
Full MREC approval was received for this phase of 
the study. To preserve independence with regard 
to any future ethics decisions about KORAL, the 
chairperson of the MREC who approved this part 
of the study was not interviewed for Component 3 
of the study.
Chapter 2  
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Component 1A – Focus groups 
with health professionals: the 
orthopaedic surgeons
Methods
Two surgeon focus groups were conducted at 
the annual meeting of the British Orthopaedic 
Association meeting, which was held in 
Birmingham in September 2005. Three 
orthopaedic surgeons contributed to the first focus 
group (‘Group A’) held at the British Orthopaedic 
Association meeting, only one of whom had no 
prior association with the KORAL team. Fifteen 
orthopaedic surgeons contributed to the second 
focus group (‘Group B’) held at this meeting – 
giving a total of 16 surgeons. In addition, we held 
a focus group (‘Group C’) in a regional centre in 
October 2005 where 25 local orthopaedic surgeons 
contributed.
Focus group content
The focus groups with orthopaedic surgeons 
were facilitated primarily by the lead orthopaedic 
surgeon on the KORAL team (AGS), with assistance 
from a selection of other members of the research 
team (ZCS, MKC, VAE or JDH). The topic guide 
formulated for use within this focus group is 
presented in Appendix 1.
After initial introductions, an orthopaedic 
surgeon from the KORAL team gave a short 
presentation (see Appendix 2) that summarised 
the current research evidence of the effectiveness 
of arthroscopic lavage (including a description of 
the process and findings of the trial conducted 
by Moseley et al.24); presented the rationale for 
conducting another placebo-controlled RCT to 
evaluate the procedure; and explained that the 
current discussion was being conducted to help 
assess the acceptability and feasibility of such a 
trial and help inform the development of the 
placebo procedure. Focus group participants were 
made aware that approximately 34,000 of these 
procedures were being carried out annually at 
a cost to the NHS of approximately £34M. The 
groups were then encouraged to discuss their views 
about the acceptability of the proposed placebo-
controlled trial, design features that would make it 
more or less acceptable, and what kind of placebo 
would be most appropriate if the trial went ahead. 
Throughout the discussions, the facilitator(s) 
answered questions of clarification and repeated 
information about the Moseley trial and the 
current feasibility study as required.
We did not attempt to elicit individuals’ attitudes 
towards the proposed trial in a systematic 
and quantifiable way, focusing at this stage 
on identifying the types of consideration that 
could contribute to their assessments of the 
trial’s acceptability and feasibility. However, the 
facilitators did on several occasions ask for a ‘show 
of hands’ indication of agreement with specific 
proposals, and impressions of consensus are 
indicated in the findings below.
Analytic procedures
The three focus group discussions were recorded 
and transcribed. The transcripts were then 
analysed thematically using a modified Framework 
approach.36 Following initial familiarisation with 
the transcripts, the data were coded according to 
a series of broad themes that reflected both the 
main research questions and the key issues that 
emerged in discussions. Charts were created to 
summarise the data relating to each broad theme, 
and these were used to develop a characterisation 
of the range of beliefs and opinions expressed 
by the orthopaedic surgeons on issues salient to 
the acceptability and feasibility of the proposed 
placebo-controlled trial.
Findings
The balance of attitudes towards the proposed trial 
differed across the three discussion groups. In the 
first focus group, the only surgeon who did not 
have a previous association with the KORAL team 
accepted the rationale behind the proposal, but 
was uncomfortable with the inclusion of a placebo 
surgery arm; whilst in the second focus group, 
the majority of the participants spoke in favour 
of the proposed trial and indicated willingness 
to participate. At the regional centre discussion, 
attitudes were more mixed and, in a show of hands 
at the end of the discussion, about half of those 
present indicated potential willingness to recruit 
patients to a two-arm trial (arthroscopic lavage 
versus placebo surgery), and a few more indicated 
potential willingness to recruit patients to a three-
arm trial (arthroscopic lavage versus placebo 
surgery versus conservative management).
The key considerations that featured in discussions 
about the acceptability of a trial that included a 
placebo surgery arm included:
•  surgeons’ current practices and beliefs about 
the effectiveness of arthroscopic lavage and 
alternativesDOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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•  surgeons’ beliefs about the acceptability of 
conducting placebo surgery
•  concerns about the usefulness of information 
that might be generated by a placebo-
controlled trial of arthroscopic lavage
•  aspects of trial methodology/trial results that 
would be necessary to convince surgeons to 
modify practice.
Surgeons’ current practices and beliefs 
about the effectiveness of arthroscopic 
lavage and alternatives
Most participating surgeons stated that they did 
not routinely perform arthroscopic lavage for 
therapeutic purposes, although one surgeon did 
offer it routinely, others performed it occasionally, 
and several had conducted it previously or had 
worked for consultants who did.
The reasons given for not routinely performing 
arthroscopic lavage included a conviction that 
the procedure was ineffective for symptom 
improvement. For example:
I think we do accept that by just washing it out, 
what we call lavage, is not clinically effective. 
I mean that’s almost accepted practice … we 
think its actually quite pointless washing a fully 
worn out [joint] at all.
(Surgeon 6, Group B)
Beliefs about the lack of effectiveness of 
arthroscopic lavage derived from several sources, 
including the surgeons’ own or others’ clinical 
observations of patients ‘all coming back’ with 
continuing problems after the procedure. Some 
surgeons thought these observations had caused 
a decline in the use of arthroscopic lavage that 
started before the publication of the Moseley trial, 
although for others, the findings of this trial had 
been influential.
There was some disagreement within the groups 
about how the findings of the Moseley trial should 
be interpreted and responded to, and several 
surgeons pointed out that there was some evidence 
(from both the scientific literature and their own 
observations) that arthroscopic lavage might offer 
at least short-term pain relief. They were thus 
reluctant to dismiss it as always or completely 
ineffective:
Well there is some proof. There’s limited proof 
it’s beneficial. There are some papers that say 
it is …
(Surgeon 2, Group B)
If … you end up washing the knee out, 
sometimes the symptoms do improve and make 
it pseudo-working. We had a lady recently, and 
she had a defect, and she’s a lot better since we 
washed the knee out, that’s 3 weeks ago now.
(Surgeon 1, Group C)
The potential usefulness of arthroscopic lavage 
was in part considered in relation to other options 
for managing osteoarthritis of the knee. There 
was consensus that conservative management, 
including physiotherapy, often did not provide 
satisfactory long-term pain relief. There was also 
consensus that knee replacements could provide 
effective relief – although they also carried 
significant risks and had a limited lifespan. In this 
context, some surgeons considered arthroscopic 
lavage (positively) as an intervention that may 
be used to delay knee replacement surgery, or 
that could be offered as ‘something’ to patients 
whose pain and/or mobility problems had 
not been adequately relieved by conservative 
management but who might not be eligible for 
knee replacement. For example:
Surely 6 months of free from symptoms 
for people with early OA [osteoarthritis] 
who wouldn’t be going on to get a surgical 
procedure to help them is actually worthwhile 
isn’t it?
(Surgeon 7, Group C)
But if you take the alternative view that there 
are patients at present who are having knee 
replacements with all the potential risks of 
those unnecessarily, because they could have 
been, sort of, lasted out with a couple of wash 
outs then, that’s quite a …
(Surgeon 4, Group B)
The one surgeon who clearly stated that he 
routinely performed arthroscopic lavage explained 
that, whilst he accepted that the scientific evidence 
was unclear with regard to the procedure’s long-
term effectiveness, he thought the intervention was 
theoretically plausible, and was inclined to accede 
to requests from patients who believed or hoped 
that some kind of surgery would help relieve their 
symptoms:
But at present we believe that it does at least 
theoretically you wash out the synovial and you 
see physically that … the synovial fluid does 
not look healthy somehow, it looks murky, so 
it must do some good. So we think it must do 
some good to this patient.
(Surgeon 1, Group A)Formal exploration of the acceptability of a placebo-controlled trial
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If you tell them that you don’t need an 
operation then they go to the doctor [saying] 
‘You want me to live with the pain like this?’ … 
They want something positive from it, whether 
it works or not that is a different matter … All 
that we can offer is to give them some kind of 
surgical procedure that we think might help … 
If you don’t offer them operation they don’t 
like you at all, they want an operation.
(Surgeon 1, Group A)
For others, however, using arthroscopic lavage 
as a ‘delaying’ intervention (in terms of knee 
replacement procedures) carried significant 
opportunity costs:
If the trial shows they have got short-term 
relief of symptoms after the lavage or 
debridement you know the thing then is we are 
postponing their total knee replacement for 
maybe 6 months or 12 months at the expense 
of doing many more extra operations using 
good time … and hence we’ve wasted valuable 
resources and time to postpone the inevitable 
for about 6 or 12 months … If after 6 months 
their symptoms come back to the same level 
then do you then contemplate arthroplasty 
of any form or do you do a total knee 
replacement. You’ve in fact just postponed the 
surgery for 6 months. At the expense of an 
extra operation and then you are going to do 
much more extra operations.
(Surgeon 2, Group C)
One surgeon also commented that providing 
(ineffective) arthroscopic lavage procedures 
would encourage patients to want more (knee 
replacement) surgery:
Trouble is, once you’ve operated, even if they 
get better for a while, when they then come 
back, they are very reluctant to be put off for 
any longer, you know, they’ve got the notion 
that surgery is the answer to their problem, 
even if they are not really quite at the stage 
where they would appreciate a disappointing 
result from a knee replacement, you know, but 
by that time, they have had an operation, and 
you have then convinced them that surgery is 
a good thing to do, and they won’t be put off, 
that’s why I’ve stopped doing it.
(Surgeon 8, Group B)
Surgeons’ beliefs about the acceptability 
of conducting placebo surgery
All the surgeons, whether they were more or less 
inclined to be optimistic about the effectiveness of 
arthroscopic lavage, generally supported the view 
that it was important to conduct research to remove 
the current uncertainty about this. Their support 
derived from a conviction that surgery should be 
more evidence-based, and from a concern that if 
significant numbers of surgical procedures were 
being conducted that were delivering little or no 
benefit, this could represent a serious waste of NHS 
resources:
Well, the general principle. A lot of what we do 
is completely unproven and we need to accept 
that as surgeons. Our physician colleagues, 
however much we slag them off, do actually 
use drugs which have been proven to have an 
effect … We are doing some procedures for 
which there is no evidence at all, except ‘I’ve 
got this great operation’ and then its such and 
such’s operation forever more. So I think there 
is a strong need for better control, blinded 
trials in surgery … It is important. This needs 
to be done. Long overdue, long overdue.
(Surgeon 8, Group B)
Health services resources. Because if you are 
doing an operation that has very marginal 
benefit, it’s entirely placebo benefit, can we 
afford to be doing 34,000 operations a year 
that are essentially glorified acupuncture?
(Surgeon 4, Group C)
However, not everyone agreed that a placebo-
controlled RCT was either appropriate or feasible. 
Objections to the inclusion of a placebo surgery 
arm were based on ethical concerns about exposing 
people in this arm to the risk of anaesthesia 
and possibly health-care acquired infection, and 
concerns about the practical implications and 
usefulness of the findings of such a trial.
Some surgeons were strongly opposed to the 
inclusion of a placebo surgery arm on the grounds 
that it could lead to potential harms among 
individuals who could expect no benefit:
Theoretically there is the possibility of harming 
the patient. Without deriving any benefit from 
it. Somebody could die from it.
(Surgeon 1, Group A)
I’ve got serious concern by doing a placebo, 
sham operation, and I would never participate 
as a patient in that and I would never like to 
subject a patient to that. Because there is no 
surgical operation or anaesthetic that is risk 
free. And even if 1 out of 100,000 patients, 
or 10,000 patients should suffer from an DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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anaesthetic, I think that raises a whole range 
of ethical issues … It’s not a non-invasive 
procedure that you do,… even a placebo is 
invasive. It’s not like giving glucose tablets 
which are non-invasive. It is not withholding 
treatment, it is invading somebody, it is in fact 
doing something, which can be potentially 
harmful which is the contentious and ethical 
issue for me.
(Surgeon 2, Group C)
(This latter surgeon did not think his ethical 
concerns would be removed if there was evidence 
that patients experienced symptomatic relief from 
the placebo procedure.)
Some surgeons’ general inclinations to be 
concerned about placebo surgery were mitigated 
in the specific context of the proposed trial to 
evaluate arthroscopic lavage because the subjective, 
and perhaps subtle, nature of the effects of the 
procedure made it harder than other surgical 
interventions to evaluate without a placebo and 
because the procedure could be mimicked relatively 
easily:
If you are looking at trials where people have 
carpal tunnel release to people who have not 
had carpal tunnel release etc. carried out, 
the benefits gained from the release is not 
marginal. What most people would describe as 
marginal. Whereas we are looking at a situation 
here where the benefit is so marginal, we need 
this sort of study to find out.
(Surgeon 3, Group C)
[Facilitator] So you think that basically a 
placebo surgery would only be appropriate in a 
situation where the benefit of the operation is 
relatively marginal? And where there is a clear 
benefit it will be inappropriate? [Sounds of 
agreement from participants]
Where there is a clear benefit you don’t need 
these sorts of studies. It’s ethically unacceptable 
to do it.
(Surgeon 3, Group C)
Some surgeons were less concerned about the 
ethics of placebo surgery when they focused 
primarily on a procedure that involved them 
making skin-deep incisions only (thus reducing the 
risk of introducing infection into the knee joint, 
which some thought was low anyway):
To get back to the question, from a purely 
surgical viewpoint, would we be happy to 
make two nicks and do nothing else, from a 
surgical viewpoint? I mean I would. [Sounds of 
agreement from around the table] I don’t have 
any problems with the ethics … There are guys 
who have done probably 5000 arthroscopies 
and never had a single problem.
(Surgeon 7, Group B)
The sham incision is nothing, I mean who cares 
if you have a little scratch on your knee …
(Surgeon 2, Group B)
Arthroscopies are relatively easy compared 
with others because you are only making 
small cuts, but for many other operations, 
knee replacements, hip replacements, you’d 
be making a very large incision, and I think 
making a large incision would be ethically less 
acceptable to many surgeons, including me …
(Surgeon 3, Group C)
However, they did acknowledge that the risks of 
general anaesthesia would make the use of placebo 
surgery less acceptable to anaesthetists and ethics 
committees.
Some surgeons who did not routinely offer 
arthroscopic lavage themselves (or worked in 
centres where arthroscopic lavage was rarely 
performed) raised particular concerns about the 
ethics of their own (or their centre’s) participation. 
Their concerns related to (1) the potential lack of 
equipoise locally, (2) the fact that if they or their 
centre were to participate in the proposed trial, 
patients in both placebo and active surgery arms 
would be exposed to risks that they would not 
normally have been exposed to, (3) the potential 
lack of (or lesser) skill among surgeons who had 
not been offering the procedure, and (4) the 
implications for surgical waiting lists of adding 
extra procedures to theatre lists.
For example:
We are a unit who do very few of these 
procedures, so we are going to be recruiting 
people who another time would never have the 
operation at all, whether or not they get the 
placebo. And that’s one of the problems about 
doing it in this unit is we start off by doing very 
few of these procedures deliberately and so we 
would be recruiting people we wouldn’t have 
ever been subjecting to an anaesthetic.
(Surgeon 4, Group C)Formal exploration of the acceptability of a placebo-controlled trial
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Concerns about the usefulness of 
information that may be generated by a 
placebo-controlled trial of arthroscopic 
lavage
The surgeons who spoke in favour of a placebo-
controlled trial tended to focus on a consideration 
of the potential benefits to future patients and 
broader society (at least a national level) of 
helping to ensure either that a demonstrably 
effective surgical procedure was used or that a 
demonstrably ineffective procedure was not. For 
some, consequentialist reasoning made the small 
risks that relatively few people in a placebo surgery 
trial arm would be exposed to justifiable because 
they were outweighed by the potential benefit:
Some people will perhaps have an anaesthetic 
complication who has had a placebo operation. 
But if the trial is a useful trial, then in the 
grand scheme of things it may actually prevent 
many people having anaesthetic risks or deaths 
for a procedure that may not actually have any 
benefit.
(Surgeon 1, Group C)
However, not all were convinced that the proposed 
trial would deliver such useful knowledge. In part, 
their views depended on the kinds of findings they 
envisaged, and on their views of how these would 
or should be interpreted.
Although no surgeon disputed the rationale for 
wanting to investigate the effectiveness or otherwise 
of arthroscopic lavage, there was extensive debate 
among the surgeons about whether comparing 
arthroscopic lavage with conservative management 
might be more appropriate from an ethical and/
or methodological perspective. Some focused on 
the potential of this design to avoid the ethical 
issues surrounding placebo surgery, whereas others 
questioned whether incorporating placebo surgery 
would really provide a ‘definitive’ answer about 
effectiveness. For example:
It would be more ethically correct to compare 
doing nothing to a lavage first and then look 
at the results and see … You don’t need to 
know the benefits of the placebo, it’s irrelevant. 
When you make a clinical decision, you have 
to decide whether it’s lavage or not. And so all 
you need to know is benefit from lavage and 
benefit from not doing anything and if the 
benefit from the lavage is marginal, then you 
don’t do lavage and that’s all that you need to 
do …
I think what we need to establish first of all is 
what benefits if any you get from arthroscopic 
lavage is essentially small studies and if you do 
a larger study to confirm that you do get some 
benefits from arthroscopic lavage then you 
need to establish is it the placebo or is it not. 
You need to establish first of all that you do get 
benefit from arthroscopic lavage.
(Surgeon 3, Group C)
I was just wondering what we are actually 
trying to prove by having a placebo arm in 
arthroscopic lavage? Whether arthroscopic 
lavage work better than placebos? At the end 
of the day we don’t even know if arthroscopic 
lavage is better than leaving the patient on the 
conservative treatment.
(Surgeon 11, Group C)
What you need to do first is a decent study to 
actually look at conservative versus operative 
and then once you’ve done that decent study, 
can you consider putting people at risk of 
placebo operations.
(Surgeon 10, Group C)
Other surgeons disagreed, however, arguing firstly 
that there was no need to make this comparison 
because: (a) conservative management would have 
already proven ineffective in patients considered 
suitable for lavage; and (b) this comparison has 
already been made in previous research. Some 
also argued that there was a methodological need 
for a placebo surgical trial because: (a) a placebo 
component is needed to detect a small difference 
between the groups; and (b) a placebo is needed to 
attempt to disentangle what (if any) aspect of the 
arthroscopic lavage procedure is having a positive 
effect. For example:
(a)  Conservative management would have 
already proven ineffective in patients 
considered suitable for lavage:
That should have already been worked through 
because the indication would be the failure of 
management. Everyone gets the same sort of 
spiel when they come to my clinic and I’m sure 
we all do that, registrars might forget to do it 
but …
(Surgeon 4, Group B)
[Facilitator] So that should be dealt with 
already, because the reason they come to you 
are because medical management has failed?
Yes
(Surgeon 7, Group B)DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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(b)  Comparison of arthroscopic lavage 
with conservative management has 
already been done:
But that work [trials of arthroscopic lavage 
versus conservative management] has been 
done in the past …
(Surgeon 2, Group C)
That’s been done hasn’t it? Somebody’s looked 
at the effect of physio on this kind of stuff so 
you don’t need to go over that ground, because 
we are trying to answer the question that we 
started asking.
(Surgeon 4, Group C)
(c)  A placebo component is needed to detect 
a small difference between the groups:
What you are saying is, the reason for using 
a placebo is that you’re taking out another 
variable if your results are close. If your results, 
say you hadn’t used a placebo and you just 
used a group that hadn’t had an operation and 
you had enough numbers and there was a big 
enough difference it wouldn’t matter that you 
hadn’t had a placebo, what you are assuming 
by using a placebo is that your going to prove a 
smaller difference possibly.
(Surgeon 2, Group B)
[Responding to being asked what would 
convince him that the ‘best’ trial had been 
conducted] If there is no placebo it’s not a trial.
(Surgeon 4, Group B)
(d) A placebo is needed to attempt to 
disentangle what (if any) aspect of 
the arthroscopic lavage procedure 
is having a positive effect:
Well then you don’t know whether or not it’s 
washing out the knee or the fact they have got 
three cuts.
(Surgeon 4, Group C)
Within these discussions about whether or not the 
proposed trial should omit the placebo component, 
there was also some discussion about the rationale 
of adding a third non-surgical management arm to 
a trial of arthroscopic lavage versus placebo. There 
was no clear consensus reached in the discussions 
about this, although arguments for the addition of 
a non-surgical management arm related to whether 
comparing placebo surgery alone with arthroscopic 
lavage would really provide a ‘definitive’ answer 
about effectiveness. For example:
The thing is if, and lets say it finds out you 
just do a placebo with lavage or debridement 
and it says there is no difference between 
the two you’re still none the wiser because 
actually people may still be better off having a 
debridement or nothing compared to actually 
having absolutely nothing. So the fact they 
think they have had surgery, you know the 
placebo effect has actually helped them, in 
which case they are actually better off having a 
lavage than nothing at all. You know. Was that 
not … You would have to conduct [a three-arm 
trial]. If you are trying to make decisions about 
what people do clinically later, I mean you 
are better off having. If they are no different 
between placebo and lavage we still don’t 
know whether we are better off doing a lavage 
compared to doing absolutely nothing at all.
(Surgeon 7, Group C)
So a three arm? [Several sounds of agreement 
around table.]
(Surgeon 12, Group C)
Aspects of trial methodology/trial results 
that would be necessary to convince 
surgeons to modify practice
When those who did not currently perform 
arthroscopic lavage were asked what kinds of effects 
they would need to see robustly demonstrated to be 
confident that it should be used in the NHS or to 
persuade them to reintroduce the procedure, they 
suggested they would be looking for significant 
symptom relief over a reasonable length of time:
I think it’s very important, in surgery more 
than anything, as compared with taking a 
tablet, I think it’s quite appropriate for us 
to assume you get much bigger return for 
treatment, and hence I think, you are perfectly 
valid to say we will expect quite a sizeable 
difference in outcomes.
(Surgeon 6, Group B)
I think the most important thing would 
probably be a sustained integration of patients 
being symptom free …
(Surgeon 2, Group C)
However, there was no clear consensus about the 
duration of benefit that would make arthroscopic 
lavage worthwhile, with opinions ranging from Formal exploration of the acceptability of a placebo-controlled trial
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3–4 months to 3–4 years. In part this reflected the 
divergence of views about the value of ‘delaying’ 
knee replacement surgery (as discussed above):
… and then how long do the symptoms, how 
long is the patient symptom free for, is it 6 
months, 12 months, 24 months? And whether 
that delay incoming to a joint replacement is 
worthwhile just for a 6-month benefit going 
through an extra procedure just for a benefit of 
6 months, is that worthwhile as well?
(Surgeon 2, Group C)
Participating surgeons were asked to consider what 
aspects of trial methodology would need to be 
put in place to convince them of the robustness 
of research investigating the effectiveness of 
arthroscopic lavage and, following on from this, to 
convince them to modify their practice in line with 
the results (whether favouring arthroscopic lavage 
or not). There tended to be agreement about the 
‘core’ aspects that would make the trial a ‘good’ 
one. In addition to thinking that the trial should 
be conducted across multiple centres and large 
enough to be statistically powerful, the surgeons 
also discussed the following:
(a)  Careful patient selection (age range, 
osteoarthritis status, symptoms, 
previous surgery):
The case mix, you know the case selection 
would have to be very controlled, because 
they are a fairly wide spread bunch, you know, 
you’ve got things that enter into the equation 
like body mass index, whether they’ve got any 
joint space on weight-bearing films, have they 
got any mechanical symptoms?
(Surgeon 11, Group B)
The likely age group that you can manage in 
this way, there’s no good answer to any way, is 
there. You know, so, the, if you’re going to stick 
age limits on it, which I think would probably 
be a good idea … 40–55 or whatever, where 
there is, at the minute, there is that grey area, 
and it’s very grey!
(Surgeon 4, Group B)
I think before you do that you need to classify 
what is early degenerative change you know, 
the criteria will have to be there because 
what may be early degenerative change for 
person A may not be early degenerative 
change for person B … And what is early OA 
[osteoarthritis]? The Americans do a joint 
replacement at a very earlier stage than we do. 
For us, what is early OA, advanced?
(Surgeon 2, Group C)
(b)  Being allowed to do what they 
normally do (importance of 
reflecting current practice, but 
acknowledgement that surgeons 
who do not routinely perform 
arthroscopic lavage would also need 
to be involved):
If you’re not doing what people are normally 
doing then you’re not going to get an answer 
that means anything are you really? The only 
way that you’re getting an answer that means 
anything is by including what people do 
normally, warts and all.
(Surgeon 2, Group B)
But if you’ve got a big enough trial, and you’re 
looking at standard practice, and you add 
different types of hospitals, different types of 
surgeon, then you’d get the real answer then, 
because it’s what’s happening in the NHS 
practice.
(Surgeon 4, Group B)
Oh no, I agree. But I think it’s fundamental for 
those of us who are a bit cynical about it to get 
involved.
(Surgeon 8, Group B)
As part of this discussion, some surgeons also 
argued for a placebo component, but not everyone 
agreed (for the reasons outlined in the sections 
below).
Views about the design of the placebo
During the focus groups, there was extensive 
discussion of what an appropriate placebo might 
consist of (assuming that the proposed trial was to 
go ahead). Focusing on ways in which the placebo 
could best mimic arthroscopic lavage, whilst still 
ensuring that any risks of harm were minimised, 
the consensus was for three superficial cuts that 
would just pierce the epidermis. Avoidance of 
penetration of the knee capsule would reduce the 
risk of introducing infection, and help ensure that 
a lavage ‘type’ procedure was not inadvertently 
performed:
No, you’d have to do the dermis … just enough 
to make it bleed.
(Surgeon 8, Group B)DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
15
If you put the scope in you introduce fluid 
therefore technically it becomes a lavage even if 
it’s a tiny amount, doesn’t it?
[Several ‘yes’s]
(Surgeon 7, Group C) 
There was also some discussion about whether the 
placebo group might receive a local rather than 
a general anaesthetic. The general view was that 
whilst this may carry the potential for less risk from 
harm for the placebo group, differences between 
the two groups should be minimised as far as 
possible:
[Facilitator] So do you think the patients 
should have identical anaesthesia regardless of 
which of those two?
From a research point of view, ignore the 
ethics, but if you want to do this as a pure 
research thing then yes.
(Surgeon 10, Group B)
There was also some discussion about what should 
be said to the patient prior to and after their 
surgery in order to avoid the ethical dilemma of 
perhaps having to ‘lie’ to patients about the surgery 
they had received. A consensus was reached that 
some sort of standardised procedure would need to 
be put in place so that the patient would be aware 
that the doctor was not allowed to disclose details. 
For example:
That’s what my question is. You don’t speak to 
the patient at all after the operation? Or you 
read from a same script sheet? Which may, 
then there is the ethical issue, are you lying 
to the patient? Or are you not disseminating 
information to the patient, and I’ll have 
concerns about that as well.
(Surgeon 12, Group C)
They’ll know they may or may not have had 
it. But you don’t have to have that ethical 
dilemma because before the start you say 
we won’t tell you whether you’ve had the 
operation. We will just come up to you and 
check that things look all right, we won’t 
speak to you in any very useful way, we will 
be reading from a script. The patients will be 
expecting that the surgeon will turn up and say 
‘everything went fine, see you in clinic’.
(Surgeon 4, Group C)
Component 1B – Focus groups 
with health professionals: the 
anaesthetists
Methods
An informal discussion session was held with 
anaesthetists in a regional centre in Scotland 
(with 45 attendees) to help shape our topic guide. 
Following this we presented the KORAL study in 
a plenary session at the BSOA annual meeting, 
which was held in London, UK, in November 2005. 
The presentation (attended by approximately 130 
anaesthetists) generated lively discussion, and eight 
anaesthetists from the meeting also contributed to 
an in-depth focus group session (‘Group A’) held 
on the same day. A further focus group (‘Group 
B’) with five consultant anaesthetists in a regional 
centre in the south of England was also held in 
November 2005.
Focus group content
The focus groups with anaesthetists were facilitated 
by the lead anaesthetist (BHC) on the KORAL 
team (MKC assisted at the focus group held at 
the BSOA annual meeting). The topic guide 
formulated for use within this focus group is 
presented in Appendix 3.
As with the surgeon focus groups, the facilitator 
gave a short presentation (see Appendix 4) that 
summarised the current research evidence about 
the effectiveness of arthroscopic lavage (including 
a description of the process and findings of the 
trial conducted by Moseley et al.24); presented 
the rationale for conducting another placebo-
controlled RCT to evaluate the procedure; and 
explained that the current discussion was being 
conducted to help assess the acceptability and 
feasibility of such a trial and help inform the 
development of the placebo procedure. As before, 
focus group participants were made aware of the 
approximate number and associated costs of these 
procedures undertaken in the UK. The groups were 
then encouraged to discuss their views about the 
acceptability of the proposed placebo-controlled 
trial and design features that would make it more 
or less acceptable, and what kind of anaesthetic it 
would be most appropriate to use in the placebo 
surgery group if the trial went ahead. Throughout 
the discussion, the facilitator(s) answered questions 
of clarification and repeated information about the 
Moseley trial and the current feasibility study as 
required.Formal exploration of the acceptability of a placebo-controlled trial
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As with the surgeon focus groups, we did not 
attempt to elicit individuals’ attitudes towards 
the proposed trial in a systematic or quantifiable 
way, focusing at this stage on identifying the types 
of consideration that could contribute to their 
assessments of its acceptability and feasibility.
Analytic procedures
A similar analytic procedure was adopted for 
the anaesthetist focus groups as for the surgeon 
focus groups with use of the modified Framework 
approach.36
Findings
The key considerations that featured in discussions 
about the acceptability of a trial that included a 
placebo surgery arm included:
•  anaesthetists’ beliefs about the acceptability of 
conducting placebo surgery
•  views about what would constitute the ‘best’ 
anaesthesia for a placebo surgery group
•  views about which patients should be deemed 
eligible for participation.
These are discussed in turn below.
Beliefs about the acceptability of 
conducting placebo surgery
After the initial presentation, there was general 
agreement among anaesthetists in both focus 
groups that the scientific uncertainty about the 
effectiveness of arthroscopic lavage, together 
with the large volume, high cost and risk of these 
procedures, made further research important. For 
example:
And the fact is this [Moseley] study has been 
done. There is a strong suggestion in this study 
that this therapy is of no benefit. So you come 
back to the conclusion that it really is very 
important.
(Anaesthetist 1, Group B)
I mean first of all is this a real question? Is 
there equipoise? Is there uncertainty? And 
there may be. And I think there is a cost. 
If there are 34,000 people in this country 
[undergoing arthroscopic lavage], it’s a lot of 
money, and there are risks from them having 
the anaesthetic and the procedure may not be 
of benefit. So it’s a worthy question …
(Anaesthetist 6, Group A)
The anaesthetists also recognised the significant 
ethical and practical issues raised by the fact that 
the proposed trial included a placebo surgery arm. 
They discussed these extensively, but their opinions 
varied and no clear consensus was reached about 
the acceptability of the proposed trial.
The main and obvious concern was the inclusion 
of a placebo surgery arm, which would require 
anaesthetists to expose patients to an anaesthetic 
risk, possibly for no benefit (although as discussed 
below, some anaesthetists accepted that some 
patients with osteoarthritis might experience 
symptom relief after placebo surgery). Key issues of 
tension related to the uncertainty about the relative 
benefits and harms of arthroscopic lavage and a 
placebo version of it, and the competing interests 
of future patients (and the NHS) and potential trial 
participants.
Although attitudes towards the proposed trial 
were not systematically elicited on an individual 
basis, it was clear that both discussion groups 
included some people who might be characterised 
as broadly in favour of it and some who might 
be characterised as broadly (and in a few cases 
strongly) opposed to it. It was also possible to 
identify clear clusters of interlinked reasons 
associated with these two main stances – although 
it should be stressed that the participants who were 
broadly in favour of the trial could nonetheless ‘see’ 
that there were significant and legitimate concerns 
about the proposed placebo arm that would need 
to be addressed carefully.
Those who spoke in favour of the trial tended to 
highlight its potential benefits at a population or 
societal level. They were generally more sceptical 
about the effectiveness of arthroscopic lavage, and 
emphasised the possibility that, as currently used 
in practice, it could be doing harm (or at least 
that it involved exposing people to the risks of 
anaesthesia for no benefit), and might represent an 
unnecessary drain on NHS resources. They were 
not unconcerned about the individuals who might 
participate in the placebo arm of the proposed 
trial (and all participants agreed on the need to 
minimise anaesthetic risk in this context), but 
they stressed that it was not clear that those who 
received arthroscopic lavage would benefit from it, 
or that those who received placebo surgery would 
not benefit. Their comments reflected an emphasis 
on consequentialist ethical reasoning (where 
the morality of an action is determined by the 
overall balance of its consequences), although they DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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recognised that aspects of their professional codes 
of conduct were in tension with this.
Those who spoke against the trial were perhaps 
more inclined to think that arthroscopic lavage 
could be effective, seeing a clearer differentiation 
between the benefit/harm profiles of the genuine 
procedure and a placebo version of it. They 
expressed strong concerns about exposing patients 
to (any) anaesthetic risk for placebo surgery for 
research purposes, drawing on principlist (the 
ethical approach where the principles of respect 
for autonomy, non-maleficence, beneficence, 
and justice act as critical directives in bioethical 
reflection) or deontological (where the rightness 
or wrongness of an act is determined by the 
characteristics of the act itself rather than 
the consequences of it) ethical reasoning and 
emphasising their professional responsibilities to 
individual patients.
The key reasons that served to support and to 
argue against the acceptability and feasibility of 
a placebo-controlled trial are discussed in more 
detail below.
(a)  Doubts about the effectiveness of 
arthroscopic lavage and beliefs 
about the benefits of finding out
As noted above, although there was general 
agreement among the anaesthetists that it would be 
desirable to know more about the effectiveness of 
arthroscopic lavage and to bring clinical research 
into line with robust research evidence, not all of 
them were in favour of the proposed trial. Those 
who were more supportive of the inclusion of a 
placebo surgery arm tended to be more sceptical 
about the effectiveness of arthroscopic lavage, 
and thus more concerned about the potential 
harmfulness and cost of current practice. They saw 
the trial as a means of generating knowledge that 
could potentially prevent significant harm being 
done in future generations – including harm due to 
unnecessary anaesthesia. Although they recognised 
that people who were randomised to the placebo 
surgery arm of a trial would be exposed to the risks 
of anaesthesia, they suggested that this could be 
justified (for patients who consented) because it 
was a risk to which many people were already being 
exposed for the sake of a procedure of questionable 
effectiveness; the effectiveness of the surgery could 
not be ascertained without doing this, and the 
risk was outweighed by the scale of the potential 
benefit:
… 34,000 people in this per year are having a 
procedure which has no proof to it. So you’re 
already doing the ladies with the crappy hearts, 
putting the tourniquets up, giving them the 
drugs for absolutely no proven evidence … at 
the moment if there are 34,000 of these 
procedures being done and we are exposing 
that number of patients to all the risks of 
anaesthesia then we need to know the answer.
(Anaesthetist 5, Group A)
Again it is a question of degree isn’t it? … What 
you are doing is exposing the group of people 
to risk where there is no potential benefit and 
that is your placebo group. It is just that you 
are going to save a whole load of people in the 
future the risk of an unnecessary procedure, 
if your hypothesis … You are doing harm to 
a small number for the benefit of many, you 
know, a lot of fat people who are going to get 
unnecessary anaesthetics in the future.
(Anaesthetist 6, Group B)
For some, concerns about the risks of placebo 
surgery could also be compensated for to some 
extent by the belief (and evidence from the 
Moseley trial) that placebo surgery could lead to 
improvements in patients’ symptoms:
Can I just ask, as soon as you make a skin 
incision what are you doing to endorphins and 
things like that? So even though you’re saying 
that this is a placebo, you may actually be 
achieving some form of treatment.
(Anaesthetist 3, Group A)
… we know that even the placebo group got 
some benefit.
(Anaesthetist 4, Group B)
You could argue that there is an effect in the 
placebo and so in fact some of those in the 
control group may well have had benefit, in 
that they are symptomatically better – and 
clearly they are.
(Anaesthetist 1, Group B)
For those who thought that patients might derive 
benefit from placebo surgery, the perceived benefit-
to-harm ratios of the placebo intervention and the 
trial as a whole were improved, and the differences 
between the benefit-to-harm profiles of genuine 
arthroscopic lavage and a placebo version of it were 
relatively small, so concerns about people allocated 
to the placebo arm of a trial were lessened:Formal exploration of the acceptability of a placebo-controlled trial
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I don’t have any qualms with that [likelihood 
of a person in the placebo group having 
anaphylaxis under anaesthetic if there is a 
low risk of anaphylaxis and lots of people are 
operated on]. I still believe at the end of the 
day the placebo effect is very powerful. You 
are giving three skin incisions to somebody 
who believes that they had an operation, and a 
certain percentage of those will be better, will 
feel symptomatically better … And if we are 
querying whether the whole surgical procedure 
is effective anyway, then the people who are 
having the active surgical procedure with their 
anaesthetic, who is to say, how are we to say 
whether they are benefiting or not? That is the 
whole point of the study.
(Anaesthetist 1, Group B)
(b)  Concerns about using placebo 
surgery and contravening 
professional ethical codes
The anaesthetists who spoke against the 
acceptability of a trial involving placebo surgery 
tended to focus on the interests of prospective 
individual trial participants. They were more 
inclined to think that arthroscopic lavage might 
offer some benefit whilst a placebo procedure 
would not offer benefit and would still carry a 
degree of risk. For example:
You don’t know if it’s [arthroscopic lavage] not 
beneficial … Nobody can really say that making 
a couple of incisions in somebody’s skin and 
not doing anything to them is necessarily 
beneficial … And you know if I had arthritis 
in my knee, I would expect to be offered an 
arthroscopy and there is no way I’d agree to 
have somebody make two little nicks in my 
knee under a general anaesthetic!
(Anaesthetist 6, Group A)
They were also more likely to emphasise 
professional codes of ethics and their obligation to 
do no harm to individuals:
As an anaesthetist I would not anaesthetise 
someone for sham surgery. I just couldn’t! I 
just think it’s immoral and unethical … But the 
Helsinki declaration I mean it’s as simple as 
that, you wouldn’t do it.
(Anaesthetist 1, Group A)
The fact that clinical professional guidelines 
would tend to counsel against the acceptability of 
a placebo-controlled trial was also acknowledged 
by some of those who were themselves broadly in 
favour of the trial on consequentialist grounds:
Interesting though isn’t it because the ethos 
is the need, your [facilitator’s] ethos which I 
accept is completely logical is the needs of the 
many outweigh the needs of the few but the 
GMC [General Medical Council] don’t see that 
do they? The GMC make it very specific in 
their guidance to us that it is the needs of the 
individual which is your primary concern.
(Anaesthetist 4, Group B)
This contributed to concerns that there would 
be significant practical obstacles to running such 
a trial because it would be difficult to recruit 
anaesthetists to it:
The number who will do it this willingly will be 
very, very small, most of my colleagues would 
say ‘no you’re joking’ …
(Anaesthetist 6, Group A)
In one focus group, some participants drew on 
another ethical norm that is strongly emphasised 
in clinical professional guidelines to question 
the significance of their own views about the 
acceptability of the proposed placebo-controlled 
trial. They suggested that, as long as participating 
health professionals had attempted to minimise 
the possible risks to trial participants, it was the 
securing of informed consent from patients that 
would be key. For example:
From the ethical point of view as well, I mean 
as long as you have been shown to, if you have 
chosen okay we are going to give both sort of 
cohorts a general anaesthetic, as long as you 
have been shown to limit the amount of risk 
within that, and you have quantified the risk 
and the patients have signed informed consent 
then they have consented take on that risk.
(Anaesthetist 3, Group B)
If the patient is prepared to accept that risk 
in order to have the operation and they 
are prepared to enter into the trial on the 
understanding that they might not have an 
operation, are we all being a bit precious? Is it 
really not down to the patient?
(Anaesthetist 4, Group B)
If the patients agreed to it, then it is 
acceptable.
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(c)  Consideration of alternative study 
designs
The general consensus that further information 
about the effectiveness of arthroscopic lavage 
would be useful, combined with recognition of the 
ethical concerns raised by the proposal to include a 
placebo surgery arm in an RCT, led anaesthetists in 
both discussion groups to consider alternative study 
designs. They suggested, for example: long-term 
follow-up studies (retrospective or prospective) 
to assess outcomes among people who had 
arthroscopic lavage; comparisons of arthroscopic 
lavage with no treatment; and conducting the trial 
among people with osteoarthritis who would be 
undergoing general anaesthesia for a procedure 
relating to another condition. In each case, 
other members of the discussion group pointed 
out limitations in terms of the robustness of 
the knowledge that the suggested design would 
generate.
Consideration of what would constitute 
the ‘best’ anaesthesia for a placebo 
surgery group
Once the groups had debated the acceptability 
of an RCT comparing arthroscopic lavage with 
placebo surgery, the facilitator(s) asked them to put 
their particular opinions about this aside and to 
assume that the trial was going ahead. They were 
asked to consider which type of anaesthetic they 
thought would be most appropriate for the placebo 
surgery group given both the methodological need 
to ‘mimic’ the anaesthetic that would be used in 
the arthroscopic lavage group and the clinical/
ethical need to minimise the risk of harming trial 
participants.
A few anaesthetists who had argued strongly 
against the proposed trial expressed some 
discomfort about identifying the best anaesthetic 
for a piece of research they did not think should 
proceed, but in both discussion groups a clear 
consensus was reached that, if the trial proceeded, 
participants in both trial arms (the active surgery 
and the placebo surgery) should receive the same 
general anaesthetic regimen, and this should 
be the regimen the individual anaesthetists who 
participated in the trial would customarily use for 
a simple arthroscopic procedure. The primary 
reasons given for this were that: (1) general 
anaesthesia would usually be used for arthroscopic 
lavage; (2) the use of general anaesthesia in the 
placebo surgery group would help ensure the 
placebo procedure mimicked the active procedure 
as closely as possible; and (3) general anaesthesia 
would be the safest option for patients in the 
placebo group. They rejected the idea of using 
hypnotic agents (as in the Moseley trial), which 
might superficially be considered to be ‘less risky’ 
than general anaesthesia, because they were 
not all convinced they would produce adequate 
anaesthesia for the proposed placebo surgery, and 
they did not consider them to be safer than general 
anaesthesia:
Hasn’t the starting point got to be, you should 
do the same [as for the active surgery group] 
unless there is a really good reason not to? 
And if the really good reason is all about risk 
then you have to show that their [Moseley trial] 
intervention has less risk than the standard full 
anaesthetic. I am convinced that that is not the 
case. So therefore you should do the standard 
straightforward general anaesthetic.
(Anaesthetist 5, Group B)
Statistically, [the sedation procedure used by 
the Moseley trial] is more dangerous than a 
general anaesthetic.
(Anaesthetist 6, Group A)
The anaesthetists favoured having each 
anaesthetist who participated in the trial use 
the form of general anaesthesia that they used 
regularly, because they had more experience with 
this and thus would be less likely to make errors 
when administering it. They acknowledged that 
this would mean there was some variation across 
trial centres, but argued that this would not pose 
significant methodological problems:
If each centre is randomising then does 
it matter because as long as each centre is 
presumably giving anaesthesia to suit that 
centre and they are randomising so maybe it 
doesn’t make much difference, we could as a 
department decide how we want to anaesthetise 
them according to what we have got.
(Anaesthetist 4, Group B)
Patient inclusion criteria
The anaesthetists in both discussion groups 
discussed which patients should be deemed eligible 
for participation in the trial, taking into account 
the potentially competing needs to minimise the 
risk of harm to participants and to ensure that trial 
findings would be generalisable to broad patient 
populations.
The fact that the likelihood of experiencing an 
adverse event during anaesthesia was higher for Formal exploration of the acceptability of a placebo-controlled trial
20
patients with known risk factors for anaesthetic 
problems supported a general consensus that one 
of the inclusion criteria for the trial should be 
having a relatively low grade of risk for general 
anaesthesia. However, there were differences of 
opinion around which grading scheme should 
be used and where the threshold should be set. 
The American Society of Anaesthesiologists (ASA) 
grades are in widespread use in practice, and 
several anaesthetists thought that only patients in 
the two lowest risk grades, 1 and 2 (i.e. ‘normal 
healthy patients’ and ‘patients with mild systemic 
disease’ respectively), should be included. Several 
were keen to further restrict this group to exclude 
heavier patients (whom they would normally 
intubate, and who might have problems with 
reflux) on safety grounds:
I would be very happy to do the ASA 1 and 2 
[on] thin people but the fat people who need a 
tube, I would just feel a bit more nervous.
(Anaesthetist 5, Group B)
But the exclusion of (all) patients with an ASA score 
of 3 or above and the imposition of additional 
restrictions were seen by others to unduly 
compromise the generalisability of the study as 
they might tend to exclude people with more 
severe arthritis:
[Facilitator] So could I exclude everyone above 
ASA 2, for instance? Would that help?
Yes that would help but then the arthritis 
is not going to be very severe … you won’t get 
very much arthritis, you’re more likely get 
sports injuries than trauma in that group.
(Anaesthetist 1, Group A)
The trouble with that, sorry, if you do introduce 
those exclusion criteria, then you are going to 
have the same problem as the Moseley trial, 
which is generalisability.
(Anaesthetist 4, Group B)
However, there was no clear consensus about how 
well or how poorly the distribution of experiences 
of osteoarthritis would correspond to the 
distribution of anaesthetic risk along the lines of 
ASA scores.
Some anaesthetists wondered whether a more 
specific set of criteria relating to anaesthetic risk 
could be used instead of the ASA scoring system. 
They proposed, for example, subdividing the 
‘broad’ group of people who would be classified 
as ASA grade 3, and excluding people who had 
experienced severe anaesthetic reactions in the 
past and those with respiratory problems or heart 
disease. However, these alternatives could not 
escape concerns about their implications for the 
generalisability of the findings of the proposed 
trial, and in practical terms it was suggested that 
they would create more work for anaesthetists who 
might consider participating in the trial:
ASA I think is frequently used as a score [so] 
it is going to be very easy to do. I mean it just 
makes the whole protocol much easier. If you 
end up with a list of 50 things in it …
(Anaesthetist 1, Group B)
Component 2 – Focus group 
and interviews with people 
with osteoarthritis
Methods
Within the patient stakeholder group we set out to 
purposively sample patients for inclusion in our 
study – efforts were made to include a broad range 
of participants for the interviews, including some 
participants who may possess special expertise. In 
doing this, we were thinking about the variables 
that might influence an individual’s contribution, 
and this was based to a large extent on our practical 
knowledge of the area.37 For example, we were 
keen to speak with people who had osteoarthritis 
of the knee (and who therefore would potentially 
be eligible for participating in the proposed trial); 
both males and females; people who had and who 
had not undergone previous knee surgery; and 
people who had been treated in centres that did 
and did not routinely offer arthroscopic lavage as 
a treatment option. Members of the support group 
Arthritis Care were also targeted for inclusion 
in this stakeholder group, as we anticipated that 
these people may have a particular interest in and 
knowledge of the issues that affect people with 
arthritis.
Thirty-three eligible patients from consultants’ lists 
in a regional centre in Scotland and 26 patients 
from consultants’ lists in a regional centre in central 
England were approached to take part in focus 
groups via letters sent out from two consultants; 
these centres included one that offered lavage 
relatively routinely and one that did not. The 
patient sample included both genders and people 
who had/had not undergone previous surgery 
for osteoarthritis. Patients were asked to return a 
form to the research team if they were willing to DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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be contacted about participating in a focus group 
discussion (or an interview) for the study.
Ten patients from consultants’ lists in the Scottish 
centre agreed to be interviewed and five from 
the English centre. All participants gave written 
consent.
In addition to the interviews, Arthritis Care 
distributed invitations to Arthritis Care volunteers 
and members. These were relatively well-informed 
individuals who provide information and advice 
to other people with arthritis. They were asked 
to return a form to the research team if they were 
willing to be contacted about participating in a 
focus group discussion for this study after their 
scheduled monthly meeting. We received seven 
positive responses and held two focus groups in 
the north (n = 3) and south of Scotland (n = 4). 
All participants gave written consent before 
participating in the focus groups.
The interviews with people with osteoarthritis of 
the knee lasted between 30 minutes and 1 hour 
and both focus groups lasted about 90 minutes 
each. The topic guide formulated for use within 
these focus groups is presented in Appendix 5.
Interview and focus group content
Interview participants were sent an information 
leaflet (see Appendix 6) about the proposed trial 
in advance of their interview, and focus group 
participants were given a slide presentation (see 
Appendix 7) before discussions commenced. The 
leaflet and slide presentation was developed on the 
basis of key findings from the focus groups with the 
health professionals. In particular, a description 
of the proposed placebo surgery was incorporated 
that best reflected the consensus that was reached 
(among health professionals) as how best to 
minimise potential risk from harm, whilst still 
ensuring a good mimic of the arthroscopic lavage 
procedure. Also based on our discussions with the 
health professionals, the draft information leaflet 
and slide presentation included details of a third 
non-surgical management arm.
Participants were initially asked to provide 
background information about their condition, and 
their perceptions about arthroscopic lavage were 
explored. They were then asked to discuss their 
initial views about the rationale for the proposed 
trial, including their first thoughts about whether 
they might be willing to participate in such a trial, 
and why or why not. The summary of the main 
issues/dilemmas as perceived by the research team 
were then introduced to explore any issues not 
spontaneously suggested and probe them in more 
detail. Finally, participants were asked to comment 
on key content features of the draft information 
leaflet.
Before the focus groups and interviews 
commenced, the researcher (ZCS) stressed that she 
and the research team were not wedded to the idea 
of running the trial, but rather wanted to find out 
what people thought about it. It was stressed that 
people were likely to have various reasons for and 
against participating in trials and that responses 
were not going to be judged.
Analysis procedures
The interviews and focus group discussion were 
recorded and transcribed. The transcripts were 
then analysed thematically using the Framework 
approach.36 The research team familiarised 
themselves with the transcripts and identified sets 
of themes/subthemes (reflecting both research 
questions and emerging themes).
Two researchers were involved in the analysis to 
ensure reliability of interpretation and coding (ZCS 
and VAE). The primary focus of our analyses was 
the a priori study objectives. Particular attention 
was paid to: the types of judgement, belief and 
attitude (including concern) that people express 
in relation to the proposed trial; their expressed 
willingness to participate and factors affecting 
this; their views on how the precise nature of the 
simulated procedure and particular features of trial 
design or delivery might make a proposed trial 
‘as good as possible’ for participants; and their 
views on what information should be presented 
and how in the written materials for potential trial 
participants.
Findings
Sample characteristics
Nine men and 13 women contributed to 
discussions (15 took part in an individual interview 
and seven took part in the focus groups). All but 
one of the participants was aged over 50 years. 
All but two reported having osteoarthritis either 
in their knees or in other parts of their body (one 
participant in one focus group was a carer for her 
son, who had osteoarthritis of the knee, and one 
man from the other focus group had received a 
diagnosis of knee osteoarthritis, but was not himself 
convinced of this).Formal exploration of the acceptability of a placebo-controlled trial
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Perceptions of arthroscopic lavage/
debridement
The participants reported having tried a range 
of treatments (including surgery) for their 
osteoarthritis. Some reported having undergone 
‘wash out’ procedures and debridement in the past. 
Some also knew of friends and/or family members 
who had undergone ‘wash out’ procedures for their 
osteoarthritis. Participants who had experienced 
surgery discussed how it had provided some relief 
from pain in the short term. One woman who 
received a ‘wash out’ procedure a few months 
before being interviewed described how she was 
continuing to experience considerable relief from 
pain. Two participants seemed very sceptical about 
the long-term effectiveness of arthroscopic lavage.
The key considerations that featured in discussions 
with prospective participants included:
•  initial views about/reactions to the proposed 
trial
•  views about their own potential participation in 
the trial
•  views about what information should be 
presented and how in the written materials for 
prospective participants.
Views about the rationale for proposed 
trial
When asked for their initial views about the 
proposed trial given what they had already read 
and/or heard from the researcher, it was not 
uncommon for people to comment about research 
in ‘general’ indicating that in their opinion 
research was necessary for ‘progress’:
It’s only by doing these sorts of surveys and 
experiments that you are going to be able to do 
anything long term isn’t it.
(Participant 11)
… you certainly need studies into all aspects 
of different ailments and whatever and I think 
there is a need for it …
(Participant 9)
You need to find something to help people 
that’s got bad knees … How would they find 
out about anything if they didn’t do trials?
(Participant 17)
Some participants made more specific comments 
relating to the proposed trial, expressing their 
views about the need for answers to questions that 
the trial was intended to answer. For example, 
one person mentioned the scientific uncertainty 
surrounding the effectiveness of arthroscopic 
lavage, and another highlighted the need for 
research into the long-term effectiveness of such 
surgical procedures:
Well, we have got to find out, you know, it has 
been going on for years and years and no one 
has ever found a complete answer so things 
have got to be tried, you know … If you want to 
advance that is what you have to do.
(Participant 1)
I certainly think it is worthwhile because at 
the end of the day … I don’t think that people 
should undergo surgery unless it was having 
some long-term benefit to them … it should 
only be done when it is going to have a positive 
effect and a long lasting effect.
(Participant 2)
Two participants also discussed how, from a 
research point of view, including a placebo surgical 
component could be very useful. They explained 
that this would allow researchers to see if any 
perceived benefit from arthroscopic lavage was 
simply the result of a placebo effect. For example:
… if the Americans [talking about the study 
by Moseley] are anything to go by, either the 
lavage is useless or there is a mental stimulus 
somewhere … I would say it is important to 
have the placebo in it because if there is a sort 
of mind set that it does help to heal you, I 
mean it has been proven over the years that 
placebos do benefit in certain things, I am not 
saying all by any means but some of the things 
can work so it is possible that can work. Maybe 
that is all you need to do, put everyone under 
the anaesthetic and then go.
(Participant 1)
I think a placebo group is a very good idea 
because it is all about a lot of problems that 
people have with their performance and their 
own problems do come from your own mind 
and if you think something is helping you 
then you won’t feel the pain so I think the 
placebo group is a very good idea because it 
can almost fool somebody into thinking they 
have had a procedure when they haven’t and 
basically prove to some people that you think 
you are better because you think you have had 
this procedure but in fact you didn’t have any DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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treatment done at all so it is all in the mind 
that you think you have had some sort of 
procedure if that makes sense.
(Participant 2)
However, in contrast to the above participants who 
recognised that pain can be subjective, another 
two participants reported that any pain relief 
experienced from a given treatment could not 
simply be a ‘placebo effect’ given the ‘very real’ 
pain of osteoarthritis. These people were keen to 
point out that people who experience pain from 
osteoarthritis are not simply ‘hypochondriacs’. 
They questioned the rationale for the placebo 
component (given that in their opinion it would 
not result in any perceived improvement in 
symptoms), and expressed concerns therefore that 
the study was a waste of resources:
Now to do this placebo thing which is not of 
any benefit, I can’t see it is because it’s not 
like a psychological pain, if you know what I 
mean? … some people are going to be given 
this, they are going to be given a anaesthetic so 
you need an anaesthetist or whoever else there, 
it’s taking up a bed, it’s taking up space in the 
hospital and nurses time whatever. I know you 
are only going to be put under and brought 
back round again but even so I mean our 
hospital at the moment is in crisis. The placebo 
thing doesn’t make sense.
(Participant 13)
[Talking about the proposed trial] I hesitate 
to say this but is it a waste of money? … there 
are so many people on waiting lists across the 
country that I think there is enough people 
there to do a study from … That placebo to me 
infers that it’s all in our minds, to me that’s 
what any placebo infers. If the doctor gives 
you … when you get placebo tablets off your 
doctor he’s keeping it quiet and saying you are 
being a hypochondriac but I’ll give you this to 
shut you up. That’s what a placebo is to me.
[Asked if she thinks others would hold similar 
or different views] I think people who have had 
the kind of pain I’ve had would [be] angry if 
they were offered a placebo that didn’t work.
(Participant 14)
Views about their own potential 
participation in trial: those who stated 
they would consider participating
After they were questioned about their initial 
thoughts on the proposed trial, participants were 
asked if they would consider taking part in the 
proposed trial. The majority said that they would 
consider participating, and most gave more than 
one reason. The reasons related broadly to: (a) an 
expressed desire to help others; and (b) perceptions 
about the potential for some form of personal 
benefit to be gained from participation because 
of either the interventions being given within the 
trial (i.e. arthroscopic lavage, placebo surgery) or 
trial processes (e.g. diagnosis, information). These 
themes are discussed in more detail below.
(a)  An expressed desire to help others
Contributing to furthering medical knowledge 
and helping future patients was an important 
consideration for several of those who stated that 
they would consider participating in the trial. For 
example:
I certainly would be willing to give it a go if at 
the end of the study something definitive came 
out of it and the management of osteoarthritis 
is going to be better in future. The treatments 
are going to be better for people.
(Participant 2)
I would be more than willing to take 
part … anything that improves the 
management and care of osteoarthritis in the 
future can’t be anything but a good thing to be 
honest.
(Participant 2)
Well if it is going to help somebody else, yes, I 
would. The study well you can’t do like a study 
unless somebody like myself would contribute 
and participate and people be like a guinea pig 
sort of thing, yes.
(Participant 3)
I’m not against anybody, I’ll let anybody try 
anything. I always say if I die before I’m 70 
I shall donate my body to science! If I think 
it’s going to help anybody else, yes … Yes, I 
would take part. I would take part in anything. 
They could do anything to me, anything they 
wanted! … I am thinking of other people along 
the line. My mother had MS [multiple sclerosis] 
for 19 years, they didn’t know anything about it 
for when mama had it … but it would have been 
great if they could have got a cure and it’s just 
the same as this now … I’ve had many strokes 
and I was in hospital and they asked me to take 
a trial test of things and I’ve done that and all. 
If I think any is going to help anybody I’ll do 
it.
(Participant 18)Formal exploration of the acceptability of a placebo-controlled trial
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However, this desire to help others was commonly 
juxtaposed with expectations of potentially 
benefiting personally from participation:
If it means that it is going to help somebody or 
help me, yes.
(Participant 3)
It can benefit my kids [who she stated also have 
osteoarthritis] then fine! If it can benefit me it 
would be even better!
(Participant 4)
I’ll maybe get some relief from the pain which 
will help other people as well
(Participant 18)
I would have it because it’s going to help other 
people … And if I was going to get relief, with 
just even getting them washed out
(Participant 16)
(b)  Perceptions about the potential for 
some form of personal benefit to be 
gained from participation
Everyone who stated that they would consider 
taking part discussed the potential for some form 
of personal benefit to be gained from participation. 
For several, the potential for some form of personal 
benefit to be gained from participation related 
to perceptions that the interventions being given 
within the trial might result in an improvement in 
their symptoms:
if it worked out that way, that it did help 
[symptoms] it would be fine, it is a bonus, isn’t 
it, but if it didn’t well that is the chance you are 
taking, you know.
(Participant 1)
I really can’t see many disadvantages in having 
the procedure done because it is going to 
because it will or I would say in some cases it 
will provide them with certainly temporary 
relief of discomfort in the knee if you are 
having a washing out because that is the theory 
behind it at the moment.
(Participant 2)
Well as I said if I am going to take part in it 
and if they do, if I’m one of the lucky ones and 
they manage to do something about it.
(Participant 8)
When participants talked about the ‘chance’ 
that taking part might result in an improvement 
in their symptoms, the majority seemed to be 
focusing on being randomised to the arthroscopic 
lavage procedure. In other words, there was a 
tendency to hope that they would be allocated to 
arthroscopic lavage rather than placebo and that 
the intervention would/might be beneficial. For 
example:
It doesn’t concern me but it doesn’t, you 
have to be, how do I put it, its a trial and like 
anything else you get the lucky one that gets 
the actual procedure and if you are not the 
lucky one you get the placebo but …
(Participant 3)
[asked by facilitator if not knowing what she 
would get would affect her decision to take 
part] I think I would still go through with it but 
if I discovered that I wasn’t getting help, you 
know that my knee was still as bad I would want 
to go through the wash out to get relief.
(Participant 19)
However, only one participant discussed how being 
randomised to the placebo might still result in 
symptom improvement:
… if it helped, even if it was only mentally, you 
know, it would probably be a good thing … 
Well I mean obviously with the results they 
[Moseley trial] came up with, they got just as 
good a result on the placebo so obviously it is 
a mental thing rather than a physical thing on 
that score you know, so possibly it would help 
you, you don’t know, so you maybe mentally 
think yourself better, I mean it has been proven 
hasn’t it, that the mind is part of the body, if 
you know what I mean it runs the body.
(Participant 1)
For some other participants, the potential for 
some form of personal benefit to be gained related 
to trial processes, such as getting an ‘official’ 
diagnosis:
I would find out if I had it in my knees or if it 
was just wear and tear – that would help.
(Participant 3)
Now I don’t know that I should benefit from it 
at all. The only thing I should be going for to 
fathom out what this is, what is wrong with my 
knee … Well you can’t get no further forward 
at all with this lot around here but I will quite 
willingly have a go like you know.
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For another, this related to the potential to become 
more informed about the most effective ways to 
manage osteoarthritis:
I would know or that I would hope to sort of 
at the end of the study to be aware of the best 
ways of, what would be the best management of 
my problem would be. I would know that well 
either arthroscopic lavage was a possibility if 
my knee did get any worse if it was seen to be 
a worthwhile procedure or whether it was just 
going to be a case of effective management 
myself. My personal view is that anybody taking 
part in the study would get some benefit from 
it because going through like a study like that 
they are going to understand what they need to 
do, what the doctors are seeking to achieve so.
(Participant 2)
Potential to be harmed by the 
interventions
When discussing their reasons for possibly taking 
part in the proposed trial, participants focused 
on the ‘chance’ that the interventions being 
given in the trial might improve their symptoms 
without a corresponding focus on the ‘chance’ that 
participation might result in some harm. Instead, 
participants tended to argue that their taking part 
(and being randomised to either lavage or placebo) 
would likely not cause any deterioration in their 
current symptoms. In other words they seemed to 
think that ‘at worst’ participation would result in no 
harm. For example:
I would be willing to take part in the study to 
be honest, I will, I am sceptical about whether 
surgery helps, I don’t think it would do you any 
harm … I don’t think my knee could get much 
worse to be perfectly honest.
(Participant 2)
The only possible disadvantage was if it made 
anything worse really. I would expect it to 
get better, to improve things, but if it didn’t I 
wouldn’t really expect … for arguments sake if 
it was the placebo procedure … That I wouldn’t 
expect things to be any worse after that. I 
would expect it to be the same as previously 
you know.
(Participant 11)
Only one participant, who stated that she would 
consider taking part, mentioned the possibility 
(which she considered unlikely) that her 
participation might lead to a worsening of her 
pain symptoms. She associated this possibility with 
arthroscopic lavage, not placebo surgery:
Well, the only disadvantage would be if, not 
that it wouldn’t work, but that it made you 
worse, but I can nae see that. But maybe it 
would, maybe I don’t know enough about 
it. But that would be the only disadvantage, 
maybe if you came out and thought ‘oh well, 
aye, its OK’ and then maybe the next month 
you’re in more pain than you were.
(Participant 4)
However, she pointed out that she tends not to 
focus on what might go wrong:
But do you think with any surgery, they ever 
really know that its going to work? I’ll go back 
to my [previous foot surgery], the amount of 
people that were saying ‘Oh I wouldn’t get that 
done, such and such is crippled and has never 
walked’ you know what I mean … the scare 
stories you get beforehand and the ones you 
get after, you’ve just got to ignore them and 
maybe some people cannot.
(Participant 4)
Participants who stated that they would 
consider taking part did acknowledge that their 
participation might involve some harm: (a) from 
receiving the arthroscopic lavage, (b) from the 
placebo procedure, and (c) from the general 
anaesthetic procedure, with some stating that 
it ‘would worry you a little bit’. However, these 
harms tended to be downplayed in discussions in 
comparison with the potential benefits that might 
be gained. For example:
(a)  Harm from arthroscopic lavage 
procedure:
There’s a very slight risk, but chance also the 
symptoms would be held at bay, and then, you 
know, for a few more years I could be enjoying 
my bike rides and my walks … please, God, and 
I might be able to start running again.
(Participant 10)
(b)  Harm from placebo surgery:
… that would worry you a little bit obviously, 
you know, you go in there and somebody cuts 
your knee for really no reason you know, that 
would sort of bother you but if it helped …
(Participant 1)Formal exploration of the acceptability of a placebo-controlled trial
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Well, I’ve got a lot of marks, marks on my face 
and my body so, I mean not tattoos and that, 
but scars and that … So another couple of scars 
wouldn’t matter!
(Participant 6)
(c)  Harm from general anaesthetic:
I mean, if you are getting an anaesthetic there 
is always, albeit I think it is quite small, risk 
of complications with anaesthesia but I mean 
that is, I would say unless there are figures I am 
unaware of, there is very, there is, there can be 
problems but they are very few and far between 
and if the right patients are selected then I 
don’t think there would be any problems.
(Participant 2)
The only down side is the only risk is basically 
the anaesthetic procedures that I can see … I 
think the only down side to the placebo aspects 
of it are the slight risks of the anaesthetic. I 
mean you are not going to get any after effects 
and if the anaesthetics procedure go okay, then 
I can’t see any disadvantages to that.
(Participant 2)
However, although not apparently overly 
concerned with any risks specifically associated 
with the surgery or anaesthesia, one of these 
participants did mention being concerned about 
possibly acquiring a hospital-associated infection 
whilst in hospital:
The only thing is that bothers me about going 
into a hospital and having a nick in your leg 
somewhere or other, I’ve got two friends who 
went in to have knees done and they both got 
this MRSA [methicillin-resistant Staphylococcus 
aureus] and they are both on sticks completely 
now and they’ve been told it will probably get 
gradually worse.
(Participant 15)
Several of the participants who downplayed the 
significance of any potential harms for their own 
participation in the proposed trial nevertheless 
acknowledged that other prospective patients, 
depending on individual circumstances, might be 
more concerned about potential harms from the 
interventions being given in the trial (both lavage 
and placebo groups). For example:
I mean maybe I am a bit laid back when 
it comes to that [the possibility of being 
randomised to placebo surgery], it doesn’t 
bother me but I know a lot of people would 
hesitate to have surgery just for the sake of 
surgery …
(Participant 1)
[discussing risk associated with general 
anaesthesia] It is a thought that one, you 
know, that would probably be a stumbling 
block for both groups [surgery and placebo 
groups] … you would cut your number of 
people willing to do it by the fact that you do 
that … no one wants to put themselves under 
an anaesthetic for nothing basically, they would 
have to weigh the advantages against the 
disadvantages in their own specific case … if 
they are really bad they would be going for it in 
the hope that they would benefit.
(Participant 1)
Definitely some people would be scared, I’m 
thinking of my mother and my sister, they, 
they certainly wouldn’t take part … Firstly, they 
hate being in hospital … some people they 
depend on their job and they probably would 
be reluctant to take time off work, although it’s 
just a few days.
(Participant 10)
Potential to be inconvenienced by 
participating
Some of those who had stated that they would 
consider participating did, however, recognise that 
participation might be inconvenient:
It’s not even that, it disrupts what they’re doing 
within the family. You know the likes of you 
watching your grand bairns [grandchildren]. It 
could disrupt you for a while.
(Participant 17)
Some thought that the inconvenience would be 
greatest for those randomised to the proposed 
third arm of the trial, management without surgery, 
e.g. physiotherapy. Several were of the opinion 
that those randomised to the third arm would be 
more inconvenienced than those randomised to the 
other groups, particularly if they were required to 
attend regular physiotherapy appointments:
To go up and get appointments and things 
like that, maybe twice a week or something like 
that, me personally I’ve not got enough time in 
my life to do this once or twice a week.
(Participant 4)
So, if it’s younger people that work … as I said, 
I work Monday, Tuesday, Thursday, Friday, 
but a Wednesday is the day I take my mother DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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out so really if I get a chance of a couple of 
hours to myself on a Wednesday I take it and 
I don’t want to be going up to the hospital for 
physiotherapy to be quite honest.
(Participant 4)
One participant who indicated that they would 
prefer to be allocated to the arthroscopic lavage 
group also questioned whether physiotherapy 
would personally benefit them:
I’d like to think that I would be in the lavage 
group but if I am not, as I say so be it. … if 
it was physio, if it was anything like what I 
experienced previously I don’t feel that I got 
any real benefit from that.
(Participant 11)
Whilst another expressed some reservations 
about being potentially asked to take tablets if 
randomised to the third arm:
the only reservation I have got against it is that 
it seems to me there are three options, that 
one of the options was taking tablets. Well I 
am actually one of the world’s worst for taking 
tablets. I am very fortunate that I come from 
good stock because I don’t need to take tablets.
(Participant 15)
Views about their own potential 
participation in trial: those who stated 
they would not participate
Although most of the participants interviewed 
stated that they would consider taking part for the 
reasons outlined in the sections above, a minority 
expressed reluctance. Despite expressing a desire 
to help other people by becoming involved in 
research, perceptions of uncertainty regarding the 
potential to benefit from the interventions being 
given within the trial as well as the potential to be 
harmed by the interventions was a concern.
Unlike the majority of the participants for whom 
the potential to personally benefit from the 
interventions was enough to make them consider 
participating, for this group of participants the 
lack of a ‘guarantee’ of personal benefit seemed to 
dissuade them:
It’s no use me taking part in anything that isn’t 
guaranteed to help me … The only thing that is 
stopping me from definitely saying yes I’ll take 
part is … it won’t do me any good at the end of 
it, it’s the uncertainty. If I knew that it would do 
me good then yes I would do it because I’m a 
great believer in helping other people in years 
to come … as I say if it was certain that it would 
help then yes I’d say I would go ahead with it 
but the uncertainty, no.
(Participant 12)
If I was informed then that I had had the 
placebo and I realised that I had still got the 
pain I would be so furious … So angry. I’m 
afraid that whoever was involved their feet 
wouldn’t touch the ground!
(Participant 14)
For them, the potential for some harm to result 
from the interventions also appeared to be a 
deterrent:
If I could do it without harming me then I 
would take part …
(Participant 12)
One thing that really did concern me was 
the fact that it would have to be a general 
anaesthetic even for the placebo. I mean 
I don’t want to have an anaesthetic for 
nothing … Well I just think it’s risky anyway. 
It’s not something that anyone will want to put 
themselves through for no reason.
(Participant 13)
Despite expressing reservations about taking part 
in the trial, like those who stated that they would 
consider participating, these people nevertheless 
made positive statements about research and 
expressed some ‘regret’ at feeling unable to take 
part:
… I’ve got a lot of things wrong with me but 
if it benefit other people and it didn’t harm 
myself then yes I would … If I knew that it 
would do me good then yes I would do it 
because I’m a great believer in helping other 
people in years to come.
(Participant 12)
I think the advantages obviously would be 
helping the people who have helped me over 
the years. I was saying to my husband I’ll do 
anything. I fill in forms regularly for doing 
research at the hospital now. Those are the 
advantages, helping other people to gain 
something from it I suppose in the years to 
come or whenever … giving something back … 
I can’t agree to do it and I’m really sorry about 
that because like I say I would like to help, I Formal exploration of the acceptability of a placebo-controlled trial
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would like to give something back for all that’s 
been done for me but I can’t do that.
(Participant 13)
Views about what information should 
be presented (and how) in the written 
materials for potential trial participants
All the participants reported that they had 
understood the information that was presented in 
the information leaflet (that was sent to them in 
advance of the interview), and that they understood 
what was being proposed. Most participants made 
general comments relating to the information 
being ‘easy to understand’ and ‘clear’. For example:
Aye, it’s quite explicit, it’s telling you, it’s the 
dummy [referring to placebo].
(Participant 18)
… or the real thing [referring to lavage].
(Participant 16)
[Showed leaflet to wife (nurse)] I think she 
knew exactly what was being set out here I 
think.
(Participant 9)
I think the information that is on here for 
somebody that would take part is excellent. 
It says it all it is very good at saying just 
exactly what they would want to know and the 
questions have been answered, in my opinion.
(Participant 22)
However, some of the participants’ comments 
during the interviews suggested they had not fully 
appreciated all the key points. This is illustrated 
by the following quotes which suggest that some 
participants made assumptions about arthroscopic 
lavage being an effective treatment:
Could I keep this to show my sister [draft of 
information leaflet]? It’s not going ahead. Yes, 
it’s just to show her that she could maybe ask 
for that.
(Participant 3)
I had it in my knees I would certainly go for 
it … I think I would still go through with it but 
if I discovered that I wasn’t getting help [if 
allocated to the placebo group], you know that 
my knee was still as bad I would want to go 
through the wash out to get relief.
(Participant 19)
Others perceived that treatment assignment 
would not necessarily be random and that health 
professionals and/or patients themselves could have 
a say:
Would that not depend on how bad, you know, 
when you get the x-ray and everything. How 
bad it looked from inside? No?
(Participant 4)
She [pointing to facilitator in focus group] 
could put down next to the name, this lady 
would like wash out!
(Participant 16)
If people thought they could sort it without 
the operation they would go for that 
[physiotherapy].
(Participant 4)
Only two participants made specific suggestions 
about how they thought the information leaflet 
could be improved. These suggestions related 
to providing more information to prospective 
participants about what is meant by placebo surgery 
(and how many operations a participant would 
expect to receive within the trial) and making it 
clear that they would receive a general anaesthetic. 
A suggestion was also made that the information 
leaflet should include more detail of the nature 
of any proposed follow-up appointments. For 
example:
Possibly an explanation, I understand what a 
placebo is but an explanation about the word 
placebo quite a lot of the people wouldn’t 
understand what a placebo is, I think that 
is about the only thing if you could explain 
clearly that nothing will be done other 
than that, the placebo … I am not saying I 
am brilliant but the word placebo is not in 
common use it is only in the sort of, medical 
circles.
(Participant 1)
I mean I don’t know the only other thing that 
I did wonder was would there be more than 
one surgery or one pretend surgery if you like, 
during the course of the 2 years.
(Participant 2)
[suggesting that the words general anaesthetic 
are highlighted] [so that] the eye is drawn to 
it … you don’t want people turning up for the 
‘oh general anaesthetic, oh no no not for me! I 
thought it was just, you know!’
(Participant 1)DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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You could put in there is maybe more 
information about what the follow-ups would 
be and stuff like that to be honest aye what the 
follow-up sort of appointments would entail.
(Participant 2)
Component 3 – Interviews 
with chairpersons of the UK 
Multicentre Research Ethics 
Committees
Methods
Full MREC approval was received for this phase 
of the study. To preserve their independence with 
regard to any future ethics decisions about KORAL, 
the MREC that approved this part of the study 
was excluded from the interviews of chairpersons 
of research ethics committees. Twelve ethics 
committee chairpersons were invited by letter to 
take part in a telephone interview. Of these, six 
replied and agreed to be interviewed. Interviews 
lasted between 45 and 90 minutes.
Interview content
The interviews with MREC chairpersons were 
conducted by one researcher on the KORAL team 
(ZCS). The topic guide formulated for use within 
these interviews is presented in Appendix 8. All 
interviewees received written information about 
the proposed trial before the interviews took 
place. The researcher also briefly summarised 
the proposed trial at the start of the interview, 
providing an overview of key findings from the 
previous discussions with other stakeholder groups. 
The interviewees offered their personal opinions 
on various aspects proposed but also attempted to 
reflect broadly what their committee would want to 
know.
The interviewees were encouraged to discuss their 
views about the acceptability of the proposed 
placebo-controlled trial, and the criteria that the 
trial would need to satisfy to be considered ethically 
acceptable. Throughout the discussion, the 
interviewer answered questions of clarification and 
provided/repeated information about the Moseley 
trial and the findings of the current feasibility study 
as required.
Analytic procedures
The interviews were recorded, transcribed and 
analysed thematically using a modified Framework 
approach.36 Following initial familiarisation with 
the transcripts, the data were coded according to a 
series of broad themes that reflected both the main 
research questions and key issues that emerged in 
discussions. Charts were created to summarise the 
data relating to each broad theme, and these were 
used to develop a characterisation of the range 
of beliefs and opinions expressed by the MREC 
chairpersons on issues salient to the acceptability of 
the proposed placebo-controlled trial.
Findings
The key considerations that featured in discussions 
about the acceptability of a trial that included a 
placebo surgery arm included:
•  the chairpersons’ perceptions of how their 
committees would view the proposal
•  the design/methodological criteria that the 
proposed trial would need to satisfy to be 
considered ethically acceptable
•  the nature of information that should be 
provided to prospective participants.
These are discussed in turn below.
Likely ethics committee response to the 
proposal
Views were broadly consistent with regard to 
how the chairpersons thought their committees 
would view our proposal. The chairpersons did 
not think that their committees would necessarily 
immediately dismiss the proposal on the basis that 
researchers were planning to incorporate placebo 
surgery. Rather, they thought they would focus 
instead on how researchers had attempted to justify 
their proposed design. The fact that our research 
team had accessed and considered the views of 
key stakeholders was considered favourably. For 
example:
I like that. That will get you lots of brownie 
points in that you’ve asked the participants, 
in that you have involved the participants in 
finding out what they want to know.
(MREC 6)
All the MREC chairpersons agreed that the 
scientific uncertainty about the effectiveness 
of arthroscopic lavage, together with the large 
volume, high cost and risk of these procedures, 
made further research important. For example:
[facilitator pointing out that because of the 
uncertainty of effectiveness of arthroscopic 
lavage, one could argue that patients out with 
the trial having lavage face potential of risks 
for no benefit] Yes, I do yes, that is a very good 
argument for doing it. One in fact, one of the Formal exploration of the acceptability of a placebo-controlled trial
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best arguments for doing it … Yes, the point, 
the reason that why it is a good argument is 
that as you say, we might be doing thousands 
and thousand of general anaesthetics for a 
procedure which is absolutely useless.
(MREC 2)
… long term if you are carrying on it is 
unethical to carry on cutting open peoples’ 
knees … when it may or may not work and 
shoving stuff into their knees when it may or 
may not work.
(MREC 4)
I can’t speak for the committee, but I know 
how people to a large extent think and I think 
that if there is a treatment that you are doing 
with all the risks inherent in it and you don’t 
know whether its any good or not you have a 
duty to find out whether there is evidence for 
doing it. So there is an impetus to do it.
(MREC 6)
The chairpersons also acknowledged that there 
were ‘good’ ethical and methodological arguments 
for incorporating a placebo component into the 
proposed design, including for example, that 
current uncertainty of scientific benefit meant 
any potential risks and benefits were arguably 
equivalent between the groups. Furthermore, there 
was also an argument for placebo surgery given 
that pain was to be an outcome. For example:
… what we would probably say is that we would 
not be running away from saying it is a ‘no-go’ 
[to do] a sham surgical procedure, we look at 
everything on its merits … I can see no reason 
why in sort of in principle, I mean that it 
should not go ahead and I think it is probably 
very important that it does … one cannot say 
that they [placebo group] are getting lower 
than the standard of care because we don’t 
even know whether that [arthroscopic lavage] 
works … I think in a sense they are all, they 
are a whole equal pool if you like at the start 
because one needs to know whether we should 
be doing this to them … at the moment we 
don’t know if it is even effective or not one 
cannot say that therefore we know that it 
[arthroscopic lavage] is an advantage because 
we don’t know whether it works or not so there 
are probably equal points for these people as 
well … and also because of having self-reported 
patient outcome one sees the need for a 
placebo group.
(MREC 1)
However, the chairpersons argued that whilst, 
in principle, the trial would not necessarily be 
dismissed, particularly if good justification for 
aspects of the study design were provided by the 
research team, members of ethics committees 
would tend to focus on the interests of prospective 
trial participants (particularly those in the placebo 
group), and the fact that they would be exposed to 
risk (for no personal benefit) would be particularly 
problematic and would result in a ‘rough journey’ 
getting through a committee:
I fully appreciate that, thousands of them could 
be done and an awful lot of time and money 
could be saved if you don’t need to do them. 
I couldn’t agree more but that is obviously 
your point but again that doesn’t get over the 
problem of anaesthesia, does it?
(MREC 2)
And without going into too much background 
I would have to say that I would have to think 
extremely laterally to envisage that this would 
get through without a very rough journey on 
the way … We have one committee in particular 
which anything placebo can solve is evaluated 
with a fine tooth comb and there we’re talking 
little white tablets … The prospect of using 
a surgical approach I think raises the stakes 
enormously.
(MREC 3)
There does seem to be, there really is an issue 
about participating in something that you are 
not immediately going to benefit from … and 
carrying some risk which is I think the 
anaesthetists would say is unquantifiable.
(MREC 4)
Whereas most placebos are no drug, or no 
procedure, no risk this does carry a risk 
because of other things that you’re doing. 
Clearly if we’re going to protect a patient we 
need to look at the risk or the risk/benefit ratio. 
The benefit is not obvious, because you are 
really seeing whether you have a problem with 
the existing treatment.
(MREC 6)
There was also acknowledgement that there would 
likely never be consensus among ethics committee 
members about the acceptability of the proposed 
trial, and that a decision one way or another 
would probably be heavily influenced by particular 
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I imagine what usually happens in these sort 
of things which are highly controversial is that 
even if you talk to medical ethicists, you would 
never get a consensus of an answer, and you 
will get some that say it is okay and some that 
say it is not.
(MREC 2)
My experience with something like this, which 
is quite vast actually, is that you would have 
different views from different people and 
coming from different directions. On a research 
ethics committee the slightly ironic thing is 
that you don’t always have people who have 
got a vast number of research experience … 
Now the way discussions usually go is that they 
are very open and occasionally opinionated 
and you do get views as I said coming from 
different directions but if you find any two of 
those gelling then usually that is enough to 
carry a decision or carry the argument in one 
direction or the other … you often get a very 
strong voice from, not an interested party, 
but a knowledgeable party on what’s going 
on and a committee can be swayed very, very 
easily towards one decision or another … And 
research might not actually come into it.
(MREC 3)
Design/methodological criteria that a 
proposed trial would need to satisfy to be 
considered ethically acceptable
Several of the interviewees argued that because 
there is a justification for the proposed research, 
ethics committee members tend to focus on the 
potential risks participants in the placebo group 
might face. In similarity to some of the findings 
reported from the health professional focus groups, 
it was reported that committee members would be 
inclined to think that a placebo procedure would 
not carry any benefit to the individual (but would 
carry a degree of risk):
Obviously the risks to them first of all … I 
would think that in conclusion is probably 
the general anaesthesia that will cause ethics 
committees the most problems because then 
they will say now is this really too much 
of a risk to be giving somebody a general 
anaesthetic for nothing … I can see everybody 
say, oh oh no way not general anaesthetics.
(MREC 1)
Interviewees also stated that committees 
would consider whether adequate indemnity/
compensation procedures were in place to support 
both patients and the clinicians who treated 
them, should someone be seriously harmed by 
participation in the trial. They tended to focus on 
those receiving placebo, rather than arthroscopic 
lavage, despite their own suggestions that 
participants are potentially being exposed to the 
same risk–benefit ratios:
The other thing which I would think about, 
is what would happen to whom if there was 
shall we say a disaster, a fatality in one of the 
sham procedures … I would certainly want 
you to have thought it through. Because, you 
know the worst-case scenario, you are going to 
anaesthetise a fit, healthy, 30 year woman who 
then dies on the table under the anaesthetic 
you know, they, God she has got two young 
children and this that and the other and we 
find out it is the placebo and all the rest of it 
or the legal implications of it could be huge, 
couldn’t they?
(MREC 2)
And that brings me back to the vulnerability 
of the anaesthetist if everything goes pear 
shaped … Yes, and I would think I would think 
it could even be a good idea to have a consent 
form for the anaesthetist … That would be a 
good idea because that would ensure that the 
anaesthetists are acutely aware of everything 
and that he is officially sanctioned to do it.
(MREC 2)
If you cause harm are you indemnified or the 
folk doing it under the non-negligent or the 
negligent provision? The trust will indemnify 
you for negligent harm, universities are 
constrained to indemnified for non-negligent 
harm, but [what] happens when it’s deliberate 
harm? In other words you’re doing something, 
you’re damaging the patient for no benefit 
deliberately … The anaesthetist would probably 
be alright that would be either negligent 
because they are not causing harm deliberately 
so they are probably covered by NHS 
indemnity but the surgeon who actually causes 
harm by inflicting a wound which was not part 
of any treatment is that actually non-negligent 
or is that deliberate?
(MREC 6)
Nature of placebo
The chairpersons were asked to give their opinions 
about the nature of the placebo that was being 
proposed. It was made clear that details of what 
the placebo might consist of had already been Formal exploration of the acceptability of a placebo-controlled trial
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extensively discussed with orthopaedic surgeons 
and anaesthetists (from the point of view of 
attempting to maximise the mimic but also to 
ensure that any risks were minimised). Although 
the interviewees had expressed some concern about 
how the trial would be received by an MREC (for 
reasons discussed above), their opinions about 
how best to minimise risks to participants (and 
therefore standing a better chance of being viewed 
favourably by members of an MREC) were broadly 
consistent with those expressed by the health 
professionals. For example, the proposed three 
superficial cuts that would just pierce the epidermis 
(with no penetration of the knee capsule) was 
regarded as acceptable, as was the plan not to 
insert a scope into the incisions:
… actually doing little cuts? No, I don’t. I don’t 
have a lot of trouble with that. I suppose you 
could get round that by bandaging the knee 
can’t you?
(MREC 2)
The brief skin incisions I think is acceptable 
but anything further than that probably 
wouldn’t be.
(MREC 1)
There was general agreement that participating 
surgeons should be allowed to perform additional 
debridement procedures if they believed that 
they were necessary for an individual patient. For 
example:
If you actually did insert an arthroscope and 
take it out again then once you have actually 
seen what the knee was like inside, you would 
probably be ethically bound to do something 
about it if it needs it. So really anything that 
actually meant that you actually invade with an 
arthroscope it couldn’t really be ethical if you 
actually then do nothing.
(MREC 1)
The chairpersons did express concern about the 
need to give placebo patients a general anaesthetic, 
but accepted that we had explored possible 
alternatives with anaesthetists and that from a risk 
minimisation point of view they were probably 
better performing a familiar procedure:
[after interviewer summarises findings from 
focus groups] Yes, well I would agree with that. 
I can speak to you with a degree of authority 
on that.
(MREC 2)
Also in similarity to the views expressed within 
our focus groups with health professionals, MREC 
interviewees highlighted the need to minimise any 
specific anaesthetic risk by paying careful attention 
to the patient inclusion/exclusion criteria, with 
one interviewee suggesting that an ‘independent’ 
anaesthetist should be involved in the selection of 
suitable patients:
I think the inclusion and exclusion criteria 
would have to be very carefully designed if 
these people are going to be given general 
anaesthetic … that would be quite a major 
ethical point.
(MREC 1)
I would think that people would need to be 
reviewed … by either, I’m thinking laterally you 
understand, whether even an independent, 
whether people having, considering entering 
the study should have an independent 
anaesthetic assessment … I mean I think that 
might weigh with me. I mean I would want 
to make sure you know I think I would feel 
happier if an independent anaesthetist not 
connected with the study was asked quite 
simply to review the suitability of the patient 
for an anaesthetic.
(MREC 4)
Other trial design issues
The focus of the discussions with the MREC 
chairpersons tended to be less about specific 
methodological aspects of the trial and more 
about the key ethical dilemmas involved (it was 
highlighted that methodological issues should have 
already been scrutinised at the funding stage):
They will look at the science obviously at that 
stage and make sure that what you saying 
you are doing you are powered to do and you 
are going to be able to do it. If that has been 
done then the research ethics committee can 
normally say ‘good that has been done we don’t 
have to look at that again’.
(MREC 1)
However, as one chairperson indicated, there is 
an inevitable overlap between methodological and 
ethical issues, and so certain general trial design 
issues (that could have ethical implications for 
any trial) were highlighted as being important 
for ethics committees to focus on. For example, 
the need for an interim analysis to monitor trial 
results; different approaches to recruitment (and 
how this might affect recruitment rates); and DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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the role/motivation of the postoperative assessor 
(i.e. are they likely to be involved in the patient’s 
care or simply interested in research outcomes). 
Interviewees stated that committee members do 
not always have the methodological expertise 
required to judge the appropriateness of certain 
aspects of trial design and so therefore frequently 
rely on the justifications provided by the research 
team (and need to have confidence in the research 
team’s competence in being able decide the most 
appropriate approach). These justifications are 
particularly important when they involve exposing 
prospective participants to risk from harm:
… and I mean the other question which I would 
ask would be is that is there any other way of 
tackling the equipoise, is this the only way you 
have available, to which I am sure … I would 
also, let me put another … I’d want a very 
robust justification for tackling the equipoise 
in this rather risky, in this potentially risky way. 
I think any self-respecting committee that is 
the question they would ask. I would certainly 
be weighed by what risks our anaesthetic 
colleagues thought fair. I mean you’ve got to, 
you can’t negate the risk … If the study is going 
ahead, there is a risk, you can’t negate it … I 
think I’d want evidence that the risks had been 
fully considered and minimised … I’ve just 
you know and my experience is you know are 
anaesthetists are a very ethical lot indeed … 
And they serve as a very useful counterbalance 
to the surgeons … I can see the surgeons are 
faced with people in awful, intractable pain and 
they want to do something about it.
(MREC 4)
It would be a very important issue that we 
would want to look at in detail and of course 
having advice already from anaesthetists is very 
important for research ethics committees … To 
know what the professions would have to be 
dealing with this, considered to be the relative 
risks of a general anaesthetic.
(MREC 1)
The information that should be provided 
to prospective participants
All the chairpersons argued that (assuming 
researchers had successfully convinced them that 
the potential for personal risk of harm had been 
minimised) a very important consideration for 
the committee members would be the nature 
and extent of information given to prospective 
trial participants, and the consensus was that 
researchers should be as ‘transparent’ as possible. 
One chairperson stated that this focus was because, 
ultimately, ethics committees exist to protect the 
rights of patients – they need to be assured that 
prospective participants know the risks involved 
and that consent will be truly ‘informed’.
For example:
I am a great believer in the fact that if consent 
is properly informed then you can do just 
about anything you want to anyone … Well you 
would have to have an absolutely impeccable 
patient information sheet, you would have to 
make sure that the patients had probably a 
reasonably amount of time, shall we say a week 
or 10 days to think about it and so I would 
say more than 24 hours and they should be 
encouraged to discuss it with other people, 
their doctor, their family, their friends and 
things like that … it is only when …you have got 
a very open patient information sheet … then 
you know, I don’t think you would have a 
problem …you wouldn’t have a problem with 
MREC.
(MREC 2)
I suppose my view is that it would for me 
it would stand or fall on the quality of the 
patient information, and that if the patients 
knew and accepted the risks then for what 
I would guess are the lowest risks attached 
to an anaesthetic, I might be prepared to 
suggest the Committee take a favourable view 
of it … Now I think sometimes we represent 
the public in a more important way than user 
groups … Well you see it is our most common 
reason for bouncing a study is poor patient or 
participant information … But I mean I also 
don’t think we can be too paternalistic you 
know we, one of the things we have to do is use 
our commonsense and use our expertise and 
also we do have also have to also say what’s 
reasonable.
(MREC 4)
However, there was also acknowledgement that 
ensuring informed consent had been obtained 
from participants is not always a straightforward 
process of providing information because of 
issues relating to the public’s understanding of 
science (which is sometimes exacerbated further if 
a trial includes older patients). In particular, the 
tendency for trial participants to believe that their 
participation will result in personal benefit was Formal exploration of the acceptability of a placebo-controlled trial
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mentioned, as was their understanding of concepts 
such as randomisation:
I think what I would comment is the tried 
old phrase that the good old therapeutic 
misconception, is the minute you ask some 
people to go into a trial whenever you tell 
them they are not going to get any treatment 
or they could even get worse, they seem to still 
believe that they will get some benefit and in 
something like this where you know we really 
do not know what benefits they will get and 
they may get none what so ever and they will 
still have to go through 2 years of follow-ups.
(MREC 1)
I mean we have conducted surveys ourselves 
with people coming out of their interview in 
which they have signed up for a randomised 
trial and you say, you do understand what 
it means don’t you and they say, yes, he 
explained it all to me, and we say well you do 
understand that you have a one in two chance, 
oh no I know I am not going to get the drugs. 
I have already and I know the doctor and she 
told me that but I know I am not getting it 
really and I think, this is the awful problem, the 
younger generation come up through schools 
now and have actually done proper controlled 
sort of … The older generation … by 75 year 
olds still wishing to please their doctor and 
will virtually agree to anything if they think it 
is actually helping other people … they may be 
gritting their teeth and carrying on with pain 
rather than come out of your trial.
(MREC 1)
People frequently sometimes take part in a 
study thinking they have been quote, unquote 
‘given a new treatment’.
(MREC 4)
Discussing exactly what and how prospective 
trial participants should be informed about the 
proposed study, the chairpersons focused on 
three broad areas: (a) the potential ‘risks’ to the 
individual from participating; (b) the potential 
‘benefits’ to the individual from participating; and 
(c) their ‘rights’ should they decide to participate. 
Again, despite suggestions that participants are 
potentially being exposed to similar risk/benefit 
ratios, the emphasis was on making sure that the 
potential risks from receiving the placebo surgery 
were made particularly apparent. These are 
discussed in turn below.
(a)  The potential ‘risks’ to participants 
from participating
All the chairpersons stated that prospective 
participants should be clearly told that 
participation might mean receiving placebo 
surgery (that would also entail having a general 
anaesthetic):
That is quite common. What I think my 
MREC would probably say is that there should 
be a special paragraph perhaps outlined in 
highlighted words or perhaps boxed in with 
a black border, it is I think it is very unusual 
thing that is happening and it is important 
for them to realise that they are having an 
anaesthetic under which no treatment or any 
other procedure whatsoever will be done.
(MREC 2)
Normally we say well there are some things 
that don’t need to be spelt out but I think that 
[general anaesthetic] would need to spelt out 
very clearly and very fully.
(MREC 4)
The extent of any potential risk from the proposed 
placebo ‘incisions’ as well as from general 
anaesthesia was also considered important to 
highlight and it was discussed that how information 
is presented can also affect interpretation and 
ultimately recruitment:
… additional slightly higher than minimal 
risk of having three incisions … they will have 
obviously have to have explained to them the 
standard problems of a general anaesthetic so 
that they do agree to that.
(MREC 1)
… and obviously make it very clear, I suppose 
as well, thinking of patient information, that 
there would be, if they were in the placebo 
group they would be getting a general 
anaesthetic and obviously explaining the 
risks of, the potential risks of the general 
anaesthetic … there is transparent and more 
murkier ways of doing that so you would say 
that any general anaesthetic will carry potential 
risks, is one way of saying it which is slightly 
different to saying we can assure you that 
the risks of having a general anaesthetic are 
extremely small … Now the words sound very 
similar but the flavour of one is to encourage 
people to take part, in the flavour of the other, 
it is laying it on the line and making sure DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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people understand exactly what they may be 
letting themselves in for.
(MREC 3)
Other potential inconveniences involved in 
participating, such as hospital visits and time off 
work, were also highlighted as being important 
information.
(b)  The potential ‘benefits’ to 
participants from participating
No chairperson argued that potential participants 
should be told about how their individual 
participation might help other people with 
osteoarthritis. However, one chairperson stated 
that prospective participants should know the 
potential personal benefits from taking part (but 
the focus here was on being randomised to the 
non-surgical arm rather than one of the surgical 
arms) by getting access to extra ‘care’:
On the other hand of course, that extra 
attention and visits I would have said may 
be quite valuable to them so your third arm 
who doesn’t get any sham procedure at all but 
gets that probable care if you like, therefore 
will be, it will be very important to explain to 
those people that they are actually, they are 
potentially getting a possible benefit because 
they are going to have that attention but of 
course there is no way that anybody is going 
to guarantee that they are going to be actually 
better in the result of it, as long as that is 
actually very well explained to them.
(MREC 1)
Another indicated that it would not be unethical 
to suggest in the information leaflet that patients 
might receive personal benefit if they were 
randomised to the arthroscopic lavage arm, despite 
the lack of scientific evidence of effectiveness:
If you had a surgeon was carrying out lavage 
as a standard procedure on a very regular 
basis then you would be justified in saying 
your surgeon would be either Mr Price or Mr 
Jones who carries out 200 of these operations 
every year and the evidence suggests that it is 
one standard approach and the likelihood of 
success is and they would be able to give it and 
the weight of improvement and the weight of a 
successful outcome and also say that it may be 
unpredictable and that there may actually be 
no benefit of this procedure either.
(MREC 3)
However, the same interviewee was adamant that in 
no way should we state any potential benefit from 
receiving the placebo:
I think if that was made clear with language 
like, you must appreciate that following 
this general anaesthetic and mock surgical 
procedure, if you, if that’s what you get you 
will not benefit at all as far as osteoarthritis of 
the knee is concerned and that would have to 
be done honestly and really upfront. And you 
can’t say it is unlikely that, this presumably with 
superficial cuts above the knee which is all it is 
would be an absolute, this will not be a benefit 
to you at all
[facilitator] What was interesting,… they might 
get some benefit but it might just be from 
actually thinking that they’ve had this surgery, 
if you see what I mean.
[interviewee] Which you can’t … can’t imply, if 
you did that you would be strung up by painful 
bits and … you cannot assume a placebo effect.
(MREC 3)
(c)  The ‘rights’ of participants
In addition to the need to provide prospective 
participants with clear information about 
the potential risks and benefits involved in 
participating, MREC interviewees also talked in 
detail about the need to provide information about 
their ‘rights’ as participants. A range of issues were 
highlighted as being important, and several of the 
chairpersons argued that participants should be 
made aware about the following:
The ease with which patients can access the ‘active’ 
treatment (i.e. lavage) out-with the study:
Whether there are options if they decide 
not to go into the trial because there will be 
a situation of course, I don’t know what the 
waiting list is in NHS hospitals for arthroscopic 
lavage. If they actually are able or likely to get 
a 30% possibility of getting arthroscopic lavage 
straightaway if they go into the trial and they 
are told they will have to wait 18 months if 
they don’t go into the trial it may be slightly 
coercive … if they were told they can have 
arthroscopic lavage next week anyway on the 
NHS without going into the trial they do need 
to know what those options are. So very often 
what we do for them sometimes that they have 
a study explained to them, they don’t realise Formal exploration of the acceptability of a placebo-controlled trial
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that they could have actually had the treatment 
part of it sooner and definitely without them 
being randomised, they wouldn’t go into 
the trial at all … that may be quite a factor in 
making people not be recruited but they have 
to be honestly told about it.
(MREC 1)
Whether or not participants can withdraw from the 
study:
And I would also think would have to be 
explained to them is again whether a withdraw 
option at some stage during the follow-up, 
they decided well actually my knee is getting 
worse for some other reason a reason which 
you might have a cartilage problem and if 
they feel that they are limited to staying in a 
2-year follow-up they have agreed to do it and 
they want to do it so they will not be able to 
have other surgery during that time if they are 
going to actually fulfil your sort of intention to 
treat group and actually going to go through 
right through to the follow up … patients tend 
to be terribly loyal once they are in a trial and 
they sort of put themselves through things 
that perhaps they shouldn’t do if they feel they 
actually must not have more surgery during 
whatever that might be the follow-up you will 
be designing for them.
(MREC 1)
Whether or not participants can access surgery 
during the follow-up period of the trial:
When would they receive any first line or 
surgical treatment for correction of any 
problems that they may have which if 
presumably they have osteoarthritis of the knee 
they would have … And are the people who 
are having the placebo going to have surgery 
ultimately?
(MREC 3)
The usual thing is then that people that have 
been in the placebo arm should in courtesy 
should be offered the treatment as soon as 
possible because they have actually gone 
through the trials to prove that point and have 
not received any benefit, and it is usual in the 
patient information sheet to state whether that 
is your intention.
(MREC 1)
Are you going to offer them the real operation 
if the first one doesn’t work?
(MREC 6)
Whether or not participants would ever be told what 
surgery they had received (and if so, when):
There’s multiple things, for example, what 
exactly do you tell the patients, when would 
they find out what they’ve had.
(MREC 3)
If arthroscopic lavage is found to be effective, 
whether or not the placebo group of patients 
can get access it.
(MREC 1)
Component 4 – Surveys of 
health professionals
Methods
Postal surveys of orthopaedic surgeons (all 
members of BASK) and anaesthetists (all members 
of the BSOA) were conducted. Formal permission 
to mail the questionnaire to society members 
was received from both organisations. Approval 
was received for single mailings only – therefore, 
follow-up reminders were not possible.
The aim of these short surveys was to investigate 
the distribution of attitudes towards the proposed 
trial, and ascertain rates of expressed willingness 
among these groups to support the trial in their 
professional capacities. The questionnaires are 
reproduced in Appendix 9.
In an attempt to maximise our survey response, we 
also utilised a number of the methods proposed 
in the review of Edwards et al.,38 which had 
explored the impact of different interventions 
on response rates to postal questionnaires. We 
kept the questionnaire short (one A4 sheet), used 
coloured ink, gave an assurance of confidentiality, 
highlighted the importance of the topic to the 
respondents and also highlighted the university/
HTA programme sponsorship of the research.
Results
Survey of orthopaedic surgeons
One hundred and seventy-three (45%) of the 382 
surgeon questionnaires issued were returned; 
five of these were returned blank – giving a 
denominator of 168 questionnaires (Table 2). 
Eighty-five (51%) supported the idea that a 
placebo-controlled trial of arthroscopic lavage 
should be conducted and 71 (43%) indicated that 
they would be willing to take part in such a trial. 
Sixty-seven (40%) indicated that, if a friend or a 
member of their family had osteoarthritis, they DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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TABLE 2  Surgeons’ perspectives on different types of trials of arthroscopic lavage
n (%)
Potential trial of arthroscopic lavage vs placebo surgery vs conservative management
Supportive of trial with placebo arm being mounted (N = 168) 85 (50.6)
Would consider taking part in a trial with a placebo arm (N = 166) 71 (42.8)
Would encourage a friend or family member to sign up for a trial with a placebo arm (N = 168) 67 (39.9)
Potential trial of arthroscopic lavage vs conservative management only (i.e. no placebo)
Supportive of trial with no placebo arm research being mounted (N = 164) 111 (67.7)
Would consider taking part in a trial with no placebo arm (N = 161) 93 (57.8)
Would encourage a friend or family member to sign up for a trial with no placebo arm (N = 160) 95 (59.4)
Preferred randomisation ratio should a trial with a placebo arm go ahead (N = 147)
Equal randomisation (1:1:1 to arthroscopic lavage, placebo surgery and conservative management) 88 (59.9)
Unequal randomisation (2:1:1 to arthroscopic lavage, placebo surgery and conservative management) 15 (10.2)
No preference 37 (25.2)
Other randomisation ratio   7  (4.8)
would encourage them to participate in such 
a trial. Surgeons were asked their opinion on 
different randomisation ratios (i.e. 1:1:1 or 2:1:1 
for arthroscopic lavage, placebo surgery and non-
surgical management) should a placebo trial go 
ahead. The majority of surgeons (60%) felt equal 
randomisation would be appropriate, with a further 
25% expressing no preference.
Results from the survey indicated that 62 (37%) of 
the surgeons did not routinely undertake lavage. Of 
these, 23 used to undertake lavage but now did not. 
The main reasons cited for stopping arthroscopic 
lavage were unpredictability of outcome and 
the Moseley trial report. Ninety-nine surgeons 
provided open comment on the questionnaire. 
These comments were consistent with the range 
of views expressed in the focus groups with health 
professionals, including both negative views:
Proposed trial is immoral if not unethical to 
give a general anaesthetic with no procedure. 
I would not ask nor expect my anaesthetist to 
compromise himself.
I cannot support the idea of giving an 
anaesthetic for a placebo arm of a trial.
and positive views:
About time.
Although I do not believe in arthroscopic 
lavage for knee OA [osteoarthritis], I will 
be more than happy to participate and 
also encourage other knee surgeons in the 
department to do so to help sorting this issue 
once and for all.
Concerns that lavage may be a waste of NHS 
resources. If a randomised/placebo trial showed 
this it may change NHS practice …
This trial needs to be done!
Others provided comments on their preferred 
role for arthroscopic lavage – mainly only in the 
presence of mechanical symptoms – and provided 
suggestions on how the trial designed might be 
refined, e.g. allow hyaluronic acid injection in the 
conservative arm, restrict to early osteoarthritis, 
etc.
Survey of anaesthetists
One hundred and thirty-six (34%) of the 398 
anaesthetist questionnaires were returned (Table 3). 
Fifty-four (40%) anaesthetists directly supported the 
idea that a placebo-controlled trial of arthroscopic 
lavage should be conducted, although a greater 
percentage (47%) indicated that that they would 
agree to coparticipate if their orthopaedic surgeon 
colleague wished to take part in such a trial. 
Forty-eight (36%) indicated that, if a friend or a 
member of their family had osteoarthritis, they 
would encourage them to participate in such a Formal exploration of the acceptability of a placebo-controlled trial
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TABLE 3  Anaesthetists’ perspectives on different types of trials of arthroscopic lavage
n (%)
Potential trial of arthroscopic lavage vs placebo surgery vs conservative management
Supportive of trial with placebo arm being mounted (N = 135)  54 (40.0)
Would agree to coparticipate in a trial with a placebo arm if orthopaedic colleague wished to take 
part (N = 134)
63 (47.0)
Would encourage a friend or family member to sign up for a trial with a placebo arm (N = 135) 48 (35.6)
Potential trial of arthroscopic lavage vs conservative management only (i.e. no placebo)
Supportive of trial with no placebo arm research being mounted (N = 135) 119 (88.1)
Would agree to coparticipate in a trial with no placebo arm if orthopaedic colleague wished to take 
part (N = 134)
120 (89.6)
Would encourage a friend or family member to sign up for a trial with no placebo arm (N = 132) 107 (81.1)
Preferred randomisation ratio should a trial with a placebo arm go ahead (N = 121)
Equal randomisation (1:1:1 to arthroscopic lavage, placebo surgery and conservative management) 56 (46.3)
Unequal randomisation (2:1:1 to arthroscopic lavage, placebo surgery and conservative management)   12  (9.9)
No preference 49 (40.5)
Other randomisation ratio   4  (3.3)
trial. As with the surgeons, anaesthetists were also 
asked their opinion on different randomisation 
ratios (i.e. 1:1:1 or 2:1:1 for arthroscopic lavage, 
placebo surgery and non-surgical management) 
should a placebo trial go ahead. The majority 
of anaesthetists expressed a wish for equal 
randomisation or expressed no preference. Most 
anaesthetists (88%) indicated they would also be 
supportive of a trial where no placebo would be 
involved.
Many of the anaesthetists (82) provided comments 
on the questionnaires. For those who were not 
supportive of a trial that included a placebo 
procedure, many commented that they would find 
it unethical to give a general anaesthetic for a 
placebo procedure. Comments such as:
Sounds unethical to put a patient under risk 
by anaesthetising them (even if the risk is 
1:100,000,000) for placebo surgery!
I feel strongly that placebo surgery is unethical 
– anaesthesia has risks!
I do not understand how placebo surgery can 
be ethical. If persuaded of this I would be 
happy to participate.
Unethical!
typified their sentiments.
Other comments indicated the complexity of the 
issues. For example:
‘Unnecessary’ anaesthetics for placebo surgery 
are justified: if the trial shows lavage to be 
ineffective then subsequently anaesthetics for 
ineffective surgery would be avoided.
If the placebo effect is significant, but found to 
be statistically similar to washout, are we going 
to give general anaesthesia for knee stabbing 
alone as a beneficial therapy?…
Whilst the outcome of arthroscopic lavage is 
uncertain, it remains a recognised procedure. 
However, placebo surgery exposes the patient 
to all the risks and side effects of a general 
anaesthetic knowing that no procedure is 
being undertaken. I could not justify giving 
a GA [general anaesthetic] under these 
circumstances. Should the patient suffer 
serious consequences I do not believe it can be 
justified.
A difficult dilemma re the small risks of GA 
[general anaesthetic].
… the idea of placebo surgery is tricky to 
implement because anaesthesia of one sort or 
another is inevitable.
Those supportive of a potential placebo-controlled 
trial made suggestions to refine the study design DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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(for example, confining the population to those 
in ASA grades 1 and 2, standardising on the use 
of local anaesthetic within the knee space at the 
end of surgery). The importance of the patient-
informed consent was also stressed.
Comments on the 
acceptability phase
The findings from the acceptability phase 
of our study have shed light on the views of 
key stakeholder groups (including surgeons, 
anaesthetists, prospective participants and 
members of research ethics committees). The 
following is an overview of the key findings from 
both within and across the stakeholder groups.
Views about the rationale 
for more research into the 
effectiveness of arthroscopic 
lavage
There was a broad general acceptance across all 
stakeholder groups of the need to find out more 
about the effectiveness or otherwise of arthroscopic 
lavage, given information about the trial conducted 
by Moseley et al.24 Whilst prospective trial 
participants who had osteoarthritis of the knee 
tended to make favourable comments about the 
role of research in determining ‘best’ treatments in 
general terms (a finding supported by other studies 
that have explored lay understandings of clinical 
trials39,40), health professionals and chairpersons 
of MRECs made more specific comments relating 
to the current general uncertainty with regard to 
the effectiveness of arthroscopic lavage and the 
number/cost of procedures performed.
Within the health professional groups, although 
there was a broad general acceptance of the need 
to find out more, some individuals were more 
and some less inclined to be optimistic about the 
effectiveness of arthroscopic lavage in the face of 
uncertainty from research evidence. This variation 
in opinion reflected different ideas and experiences 
relating to the usefulness of arthroscopic lavage in 
clinical practice. Those who were more optimistic 
about the effectiveness of arthroscopic lavage were 
more likely to question whether both proposed 
trial arms (arthroscopic lavage and placebo) could 
be regarded as equal in terms of potential harm or 
benefit to participants (they were concerned that 
the placebo intervention would be worse), whereas 
those who were more sceptical about arthroscopic 
lavage were more likely to consider that the two 
arms were comparable. Other studies investigating 
views about clinical trials have found that health 
professionals may hold views about trial treatments 
that are based on different interpretations of the 
available scientific evidence.41
Ethical acceptability of proposed 
trial
Despite this general acceptance of the need to find 
out more, there was variation in opinion within all 
the groups about how researchers should approach 
this and whether or not it would be acceptable to 
investigate the effectiveness of arthroscopic lavage 
using placebo surgery.
Within the health professional groups, there tended 
to be a split between (1) those who were strongly 
opposed to the inclusion of a placebo surgery 
arm on the grounds that it could lead to potential 
harm among individuals who could expect no 
personal benefit and (2) those who were more 
in favour on the grounds that they believed the 
small risks that relatively few people in a placebo 
surgery trial arm would be exposed to were justified 
because they were outweighed by the potential 
benefit (i.e. potential benefit to future patients and 
broader society of helping to ensure either that 
a demonstrably effective surgical procedure was 
used or that a demonstrably ineffective procedure 
was not). Although a few clinicians apparently 
thought their professional ethical codes/personal 
views would rule out any placebo surgery, most 
considered issues specific to the proposed trial 
(including evidence about the intervention to be 
tested; about the kinds of outcome that might be 
anticipated; about current practices; about the 
strength and utility of knowledge that might be 
derived from placebo-controlled trial versus other 
methods in this case; and views about optimising 
the placebo procedure).
The MREC chairpersons attempted to reflect 
broadly on how they thought their committees 
would view the proposed trial. Within this group, 
there was general acceptance that there were some 
‘good’ ethical and methodological arguments 
for incorporating a placebo component into the 
proposed design, and that the health professionals 
we had consulted had made good suggestions 
about how best to minimise any potential risks 
of harm from the placebo. However, no surgical 
placebo procedure can be completely risk free, and 
MREC chairpersons noted that because MREC Formal exploration of the acceptability of a placebo-controlled trial
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members tended to focus primarily on the interests 
of prospective trial participants rather than broader 
society, exposing individuals to potential harm for 
no personal benefit would be deemed particularly 
problematic.
For prospective trial participants who had 
osteoarthritis of the knee, the question of 
whether or not it would be acceptable to conduct 
the proposed trial was discussed from a more 
personalised perspective in the sense that they 
specifically reflected on their own potential 
participation and their reasons for or against 
participating. Most of this group said they would 
consider taking part and, as well as expressing a 
desire to help others through their participation, 
there was a general tendency to down-play any 
potential risk of harm from their participation 
whilst emphasising the potential to gain some 
form of personal benefit (through either the 
interventions being given within the trial or trial 
processes). This observation that willingness to 
take part is amplified by a perception of benefit 
to self has also been noted by other authors.42,43 A 
minority stated that whilst they were supportive 
of research in general and expressed a desire to 
help others through research participation, they 
would be unwilling to take part because of reasons 
relating to perceptions of uncertainty regarding 
the potential to benefit (as well as the potential to 
be harmed) from the interventions being given 
within the trial. Several previous studies that 
have explored people’s willingness to participate 
in a randomised trial have reported that people 
often express unwillingness to take part despite 
expressing positive attitudes towards research in 
general.39,40,44
The importance of people expecting to benefit 
personally from a trial has been highlighted in 
previous studies as having an influence on levels 
of participation.45 In agreement with some of our 
findings, these studies have suggested that some 
trial participants make assumptions about trial 
interventions being effective and do not appear to 
fully appreciate key aspects of clinical trials.
The nature of information 
that should be provided to 
prospective participants
Given the nature of our proposed trial, the health 
professionals and MREC chairpersons we spoke 
with recognised that particular attention should 
be paid to the informed consent process when 
attempting to recruit participants.
The MREC chairpersons in particular discussed 
in some detail the nature of information that, in 
their opinion, should be provided to prospective 
participants. Here, attention was focused on 
disclosure of the potential harms that may result 
from participation as well as discussion of the 
‘rights’ of prospective participants. Contributing 
to furthering medical knowledge and helping 
future patients was an important consideration 
for the people with osteoarthritis whom we spoke 
to (both for those who stated that they would 
consider participating in the proposed trial and 
those who expressed reluctance). Several other 
studies have reported that the potential to help 
others may be an important motivator for research 
participation.46 However, none of the MREC 
chairpersons highlighted the importance of 
discussion within trial information of the potential 
benefits of an individual’s participation for others 
(and perhaps their future selves). This is perhaps 
unsurprising given MREC members’ tendency to 
focus on protecting the rights of individual trial 
participants. Indeed, other commentators have 
noted the tendency for legislation and guidance 
around research recruitment information to 
emphasise discussion of potential harms and 
benefits to individual participants and pay less 
attention to the importance and acceptability of 
messages that highlight the potential to help others 
through research participation.47 Given that clinical 
trials are not designed to benefit participants 
directly and often expose them to risks that are not 
outweighed by known medical benefits, perhaps 
there is some scope to incorporate reference to the 
potential to help others within trial recruitment 
information.
When discussing the nature of information that 
should be provided to prospective participants, 
there was recognition among the MREC 
chairpersons that ensuring informed consent 
can be problematic for researchers (for reasons 
relating to the tendency for trial participants 
to fail to understand or remember information 
about uncertainty and randomisation). Indeed, 
within our interviews with prospective trial 
participants, despite all of them indicating that 
they had understood the written information 
about the proposed trial, some made comments 
that suggested they had not fully appreciated all 
the key points. In particular, some participants 
made assumptions about arthroscopic lavage 
being an effective treatment. Previous studies 
that have explored participants’ understanding 
of trial information have reported a higher level 
of subjective (or perceived) understanding than 
objective (or measured) understanding.48,49DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
41
Strengths of the 
acceptability phase of our 
study
Although we accessed the in-depth views of a 
relatively small number of stakeholders within the 
qualitative component of the acceptability phase of 
our study, we nevertheless gained valuable access to 
the multiple perspectives of a range of key people. 
The survey provided information about the views 
of larger numbers of surgeons and anaesthetists. As 
borne out by MREC chairpersons’ comments, by 
involving all key stakeholders early in the planning 
of such a trial we were able to explore important 
issues relating to: attitudes to the use of a placebo 
procedure in the proposed evaluation; the range of 
placebo procedures that could be considered for a 
trial comparing arthroscopic lavage with a placebo 
procedure; whether attitudes to the proposed trial 
differ depending on the type of placebo proposed 
and/or key trial design features; and initial 
suggestions for ensuring recruitment and other 
procedures are appropriate from a participant 
perspective.
Potential limitations of the 
acceptability phase of our 
study
Facts and arguments incorporated into our initial 
slide presentations (which were delivered at the 
start of focus groups) and our information leaflets 
about the acceptability phase (which were sent 
out to interviewees) were drawn on by several 
participants in subsequent discussions, and may 
have influenced the nature of stakeholders’ views. 
In addition, the KORAL clinicians who assisted 
in the facilitation of the health professional focus 
groups played an active part in discussions and 
may have influenced what other participants 
felt able and/or willing to say. However, we were 
careful to provide a balanced overview and to 
stress that we wanted to investigate whether, and 
why, a placebo-controlled trial would (or would 
not) be acceptable. Practical considerations led us 
to hold focus group discussions in centres where 
KORAL clinicians worked and at conferences where 
members of the relevant professional groups were 
already convened. We had little control over, and 
did not monitor, the extent to which participants 
represented clinicians with particular demographic, 
professional or work situation characteristics. 
However, this seems unlikely to have impaired 
our ability to identify the key issues relating 
to the proposed trial for health professionals. 
Within the focus groups and interviews a range 
of different views were expressed and there was 
often disagreement within the groups, particularly 
around the key ethical issues of our proposed trial.
Despite setting out to purposively select our 
sample for the patient interviews and focus groups, 
there was, inevitably, an element of convenience 
(or ‘opportunistic’) sampling in our study in that 
ultimately we had no control over who agreed to be 
interviewed from our initial sampling ‘framework’. 
It is possible that this may have influenced our 
findings; for example, responders’ views may 
have differed from those of non-responders. For 
example, our sample was generally positive with 
regard to the rationale for the proposed trial (with 
most stating that they would consider taking part) 
and the views of non-responders may have differed. 
However, we were reassured that despite the 
general acceptance of the need to find out more, 
there was variation in opinion within our patient 
group about how researchers should approach this 
and about whether or not it would be acceptable to 
investigate the effectiveness of arthroscopic lavage 
using placebo surgery (and a minority stated that 
they would be unwilling to take part for a variety of 
reasons).
We also observed relatively low response rates 
to our surveys (45% to the surgeon survey and 
34% to the anaesthetist survey). It is possible that 
those who were particularly interested in the topic 
responded; however, we were reassured by the 
fact that a range of opinions was expressed (both 
positively and negatively) in the questionnaire 
responses. It is often the case that response rates 
to surveys of health professionals are low;50 in 
our case, this was not helped by the fact that only 
single mailings were authorised by the professional 
bodies, so we could not send out reminders about 
the questionnaire.
We also asked people to discuss a hypothetical 
trial. It is possible to speculate that views might 
have differed if stakeholders had been invited to 
enter and/or comment on a real trial involving 
placebo surgery. However, for reasons outlined 
above, the value of accessing opinions about key 
elements of the trial before actually proceeding 
is that researchers can attempt to ensure that the 
real trial is as acceptable as possible to prospective 
participants.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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T
wo elements are presented in this chapter. In 
the first we seek to explore and describe the 
underlying ethical dilemmas that relate to, and 
were often experienced in, the KORAL project, and 
in the second we describe the formal ethics review 
process for the study.
Ethical debate around 
placebo-controlled trials
The ethical aspects of placebo controls have 
been under intense global scrutiny in recent 
years. Following lengthy deliberation, both the 
World Medical Association and the Council of 
International Organisations of Medical Sciences 
have revised their guidance regarding placebo 
use in the past decade. Most of the debate has 
been around the question of whether it is ever 
acceptable to assign research participants to receive 
a placebo when a proven active treatment exists. 
In the context of the KORAL study, the evidence 
presented in the early chapters of this document 
showed that considerable debate remains as 
to the effectiveness of arthroscopic lavage for 
osteoarthritis of the knee and, therefore, that it 
cannot be described as proven active treatment. 
However, whilst it could be argued that this ethical 
question does not apply to the KORAL study, 
we recognised that it would be naive not to take 
account of the recent intense scrutiny of the ethics 
of placebo controls.
There has also been considerable debate in the 
literature as to the ethical acceptability of using 
placebo procedures in surgery. The use of a placebo 
in an non-pharmacological context is not new – as 
early as 1959, a placebo procedure was used in 
a trial of internal mammary artery ligation for 
angina pectoris where, in a trial of 17 participants, 
eight participants had their arteries tied (the 
Fieschi technique) and the other nine underwent 
only surgical incisions.51 There was also a series 
of placebo-controlled trials of electro-convulsive 
therapy (ECT) in the late 1970s and early 1980s 
which compared active ECT with simulated 
treatment.52–56 Patients in the simulated ECT 
groups received identical anaesthetic regimens to 
those receiving ‘active’ ECT.
The most recent debate on the ethics of placebo 
surgery was largely triggered by the Moseley 
trial,24 as described earlier, and trials of cellular-
based therapies for Parkinson’s disease.57,58 In the 
Parkinson’s trials those patients allocated to the 
placebo intervention had burr holes drilled in the 
frontal bone of the skull, but not penetrating the 
inner cortex of the skull. The principal areas of 
debate have been around whether placebo surgery 
fulfils two main ethical requirements for research: 
(1) that risks to participants are minimised; and (2) 
that risks to participants are reasonable in relation 
to anticipated benefits.59
Several commentators have argued that placebo 
procedures are ethical for certain trials of surgery60 
and have identified the Moseley trial as an 
exemplar of good practice in this field.61–64 The 
main components of their arguments are that:
•  Clinical trials are not designed to promote 
the medical best interests of enrolled patients, 
and often expose them to risks that are not 
outweighed by known medical benefits – 
accordingly the use of placebo surgery must 
be evaluated in terms of the ethical principles 
appropriate to clinical research.
•  Surgical procedures of unproven benefit that 
are currently in routine use also pose a risk to 
patients.
•  Placebo controls are especially appropriate 
for the evaluation of surgical innovation that 
has not previously been associated with robust 
scientific validation and where subjective 
symptoms of the patient are relied upon as 
outcome measures.
Others have argued strongly, however, that the use 
of placebo procedures cannot be justified in the 
surgical setting, as any surgical procedure carries 
risks of harm that are greater than those associated 
with no surgical interventions, – i.e. it fails to 
fulfil the criterion that risks to participants are 
minimised.65,66
The most comprehensive consensus statement 
relating to the use of placebo surgery in research 
contexts was issued by the American Medical 
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Association (AMA).67 They suggested that four 
criteria should be met. In summary, these are that:
1.  Surgical ‘placebo’ controls should be used 
only when no other trial design will yield the 
requisite data.
2.  Particular attention must be paid to the 
informed consent process when enrolling 
participants in trials that use surgical ‘placebo’ 
controls.
3.  The use of surgical ‘placebo’ controls may be 
justified when an existing, accepted surgical 
procedure is being tested for efficacy. It is not 
justified when testing the effectiveness of an 
innovative surgical technique that represents 
only a minor modification of an existing, 
accepted surgical procedure.
4.  When a new surgical procedure is developed 
with the prospect of treating a condition for 
which no known surgical therapy exists, using 
surgical ‘placebo’ controls may be justified, 
but must be evaluated in light of whether the 
current standard of care includes a non-surgical 
treatment and the benefits, risks and side 
effects of that treatment.
Ethical issues specific to the 
KORAL study
The term ‘placebo’ is the common label used to 
describe any substance or procedure a patient 
accepts as medicine or therapy, but which has no 
known therapeutic activity. These ‘placebos’ can, 
therefore, describe a wide spectrum of substances 
and therapies from completely inert substances 
(such as a dummy pill) or more ‘active’ placebo 
procedures (such as the placebo procedure 
described in the KORAL study) when there are 
no inert procedures available to mimic the active 
intervention. These more ‘active’ placebos are 
designed to mimic the range of non-specific effects 
(both beneficial and detrimental) experienced 
by the patient whilst undergoing the active 
intervention.
For the KORAL study, therefore, this raised the 
question of whether the use of an ‘active’ placebo 
– placebo surgery in this instance – was ethical in 
this specific situation. On initial consideration, 
this approach would seem to violate the principle 
of non-maleficence (i.e. do no harm). On deeper 
examination of the issues, however, the situation is 
more complex. In this instance, not conducting the 
proposed trial also risks one of two further types of 
harm: dispensing with what is in fact an effective 
treatment or continuing to offer what is in fact an 
ineffective surgical procedure (and thus violating 
the principle of beneficence).
In medical practice, there is often a trade-off 
between short-term harms with the prospect of 
a longer term gain – for example, even a simple 
venepuncture is not without risk – but the risk 
is accepted if the importance of the test result 
outweighs the potential harm done. However, this 
short-term risk is accepted by the actual individual 
for his or her own longer term benefit, and much 
of the ethical complexity around the entire field 
of research ethics centres around the fact that this 
one-to-one relationship between persons accepting 
risk of harm and persons hoping for benefit is 
not necessarily direct. Rather, the weighing up of 
benefits and risks is done across a group of people. 
In the KORAL study, we were required to weigh 
up whether someone who is potentially not the 
direct beneficiary could reasonably be asked to take 
the risk related to placebo surgery. The project 
team believed that, in this case, it was reasonable. 
This judgement was based primarily on two main 
arguments:
1.  The nature of the condition: Osteoarthritis is 
a chronic and generally progressive, or at 
least recurring, condition. Whilst there is no 
guarantee that an individual would directly 
benefit from the answers this study aimed to 
achieve, there was a reasonable likelihood he 
or she would benefit over the longer term. He 
or she would in future have the opportunity to 
receive the active treatment (if it were shown 
to be effective) or to not have an ineffective 
form of surgical intervention offered. As 
patients often live with the consequences of 
osteoarthritis for many years it can reasonably 
be anticipated that a sizeable proportion of the 
trial participants could potentially benefit from 
the results of this trial.
2.  The results of the KORAL acceptability phase: The 
empirical findings from the acceptability phase 
of our study (see Chapter 2) indicated that 
such a study design was indeed acceptable to 
many of the patient group who would qualify 
for inclusion in the trial. These results, which 
appeared to suggest that patients were more 
likely to give a favourable view of the proposed 
design than surgeons or anaesthetists, were a 
powerful argument in favour of the study. In 
such a situation, it could even be argued that 
not to proceed to trial would be unacceptably 
paternalistic given these results. This needs to 
be tempered, however, with some thoughts as DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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to why the patients appeared to find the study 
more acceptable than the relevant clinicians. 
The clinicians, whilst appreciating that the 
risks of an individual procedure may be low 
were much more likely than any individual 
patient to have encountered the more extreme 
consequences of what can go wrong, even 
with what appears to be a low-risk procedure 
(for example, life-threatening adverse events 
or severe wound infections unexpectedly 
arising in such circumstances). Therefore, 
the recourse to the immediate conclusion 
that this represents paternalism is not 
straightforward and should be tempered by the 
reasonable impact of professional experience 
and expertise. However, the fact that, in the 
KORAL study, there was a reasonable degree of 
acceptance among surgeons and anaesthetists 
that the trial did not ask for an unethical level 
of risk in proportion to the potential benefits of 
the trial was important.
These arguments, therefore, formed the basis on 
which the study team believed it was ethical to 
consider undertaking this research, and formed 
the basis for their formal application for ethics 
approval for a formal pilot study of the trial.
Whilst it was not used as an ethical argument, the 
fact that all groups in the Moseley trial (including 
the placebo group) reported significant symptom 
improvement after the procedure also provided 
some empirical evidence that, in this specific 
setting, patients might experience benefit from 
participation in the trial (although the mechanism 
of that benefit was not fully understood).
The principles of 
independent ethical review
Before we formally describe the ethics process 
for the KORAL study, it is useful to revisit the 
underlying importance of such an independent 
ethical review, as it provides important contextual 
information against which the experience of 
the KORAL study is interpreted (however, 
those with expert knowledge of this field may 
choose to move directly to the description of the 
KORAL experience below). Even with the best 
ethical intentions, any clinician or scientist, by 
virtue of individual experience may develop a 
skewed sense of the balance of risks and benefits 
involved in a field of research to which he or she 
is particularly devoted. An orthopaedic surgeon, 
accustomed to seeing the most severe effects 
that osteoarthritis can have on individuals, could 
understandably develop a skewed attitude to the 
risks and benefits based on his or her experience. 
Similarly, anaesthetists, accustomed to continually 
attempting to minimise risk for their patients, 
may understandably develop an attitude to the 
risks and benefits that might be skewed in the 
other direction. Subjecting the research proposal 
to independent scrutiny by a group of individuals 
with a much broader outlook safeguards against 
the risk that individuals may be asked to take risks 
in research that are out of proportion with the 
potential benefits even where the motivation of the 
researchers is beyond ethical question.
The need for appropriate informed consent on 
the part of the participants is ethically beyond 
question.68 Having to present the detailed methods 
by which appropriate informed consent is proposed 
to be achieved is another safeguard for both 
patients and researchers alike.
Finally, an independent committee, in taking 
into account possible competing interests, can 
both protect patients from research that may be 
motivated by factors of which they should (at 
the very least) be made aware and protect the 
researchers from subsequent accusations of less 
than ethical or questionable professional motives 
for the study.
Application for ethics 
approval for the conduct of 
the pilot study
It was against this background of controversy 
relating to placebo-controlled trials that the 
KORAL team sought ethics approval to conduct 
a formal pilot study to assess the full feasibility of 
mounting a multicentre placebo-controlled trial to 
evaluate the effectiveness of arthroscopic lavage for 
osteoarthritis of the knee. As it sought to reflect the 
design of a full trial, the pilot was to include full 
consent and randomisation to a placebo surgical 
arm.
 
The pilot (full details of the design are presented in 
Chapter 4) was designed as a two-centre, three-arm 
trial with randomisation to one of:
•  arthroscopic lavage (with or without 
debridement as the surgeon saw fit);
•  placebo surgery; orThe ethics process
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•  non-operative (medical) management with 
specialist reassessment.
The components of the proposed placebo surgery 
were informed by the extensive discussions with the 
surgeons and anaesthetists (see Chapter 2). As with 
the arthroscopic lavage, the placebo surgery was to 
be performed as a day case and undertaken in an 
operating theatre under general anaesthesia.
Eligible patients were to be recruited from hospital 
clinics, and if they consented to participate, 
randomised to one of the three interventions. 
Participants were to be followed up at 2, 6, 12 and 
24 months.
Multicentre Research Ethics 
Committee approval
An application was submitted for national MREC 
approval to conduct the pilot study in June 2006 
(the application was submitted, as had been agreed, 
to the MREC that had approved the original 
acceptability study).
The Multicentre Research Ethics Committee 
members discussed the application at an initial 
meeting in June 2006 at which they gave the 
pilot a ‘provisional favourable response’ subject 
to receiving the full report of the initial feasibility 
phase (preliminary findings had been included, 
but final data were not available at the time of 
application submission) and some minor changes 
to the information sheet. The KORAL team 
provided this extra information and agreed to 
attend the following meeting of the MREC to 
address any outstanding queries.
At the next MREC meeting in August 2006 (which 
the KORAL Chief Investigator, MKC, attended) 
the MREC informed the team that a ‘provisional 
favourable response’ was assigned only to allow the 
application to be retained in the system and that 
the Committee had a number of major concerns 
about the project. There was extensive discussion 
about the place of general anaesthesia in such a 
study, concerns about centres that had stopped 
carrying out arthroscopic lavage on a routine 
basis taking part in the pilot and concerns about 
indemnity for non-negligent harm. They were also 
concerned about the extent to which this study 
would add to the original Moseley trial.
Following that meeting, the Committee’s written 
conclusion was that they were unable to give a 
favourable ethical opinion to the study. An extract 
from their letter, outlining the reason for this, is 
presented in Figure 1.
The KORAL team reviewed this ethical judgement 
closely and, following extensive discussions with the 
lead ethicist (RVC) and consultation with a wider 
group of ethicists, decided to appeal this decision. 
It was still felt, based on all of the arguments 
presented above, that the potential benefits to 
patients with osteoarthritis of the knee justified the 
risks associated with the study.
We were particularly concerned that approval 
for the trial hinged on the issue of whether 
patients would, or would not, have been routinely 
offered surgery had the trial not been in place. 
Two particular issues seemed to be important in 
the ethics committee’s ruling: (1) the inclusion 
of surgeons who would not normally offer 
arthroscopic lavage and (2) the inclusion of centres 
where arthroscopic lavage was being phased out 
and was no longer a routine treatment choice. In 
our opinion, surgeons who would never consider 
offering arthroscopic lavage would be highly 
unlikely to take part in the trial. Therefore, we 
could assume that, for patients recruited from 
surgeons who would take part in the trial, there 
was at least a theoretical possibility that they 
might have been offered lavage had the trial not 
been in place. For those centres that had stopped 
undertaking routine arthroscopic lavage, but that 
wished to take part in KORAL to find out whether 
lavage was truly effective/ineffective (i.e. to find 
out whether they were making the correct decision 
to phase out lavage), we believed that this was a 
further justification for proposing the research, 
rather than an ethical objection to it. In addition, 
the empirical evidence from the HES indicated that 
arthroscopic lavage was still being undertaken in 
significant numbers across a wide range of centres.
Essentially, it seemed to us that participation in the 
trial should be deemed either ethical or not, be 
based on sound ethical principles and not be based 
on where the patient lived. Consider a hypothetical 
patient who is eligible for inclusion into the trial 
living near a centre where lavage was falling out 
of favour and was no longer routinely performed, 
but where the clinicians had decided to take part 
in KORAL as mentioned above. Under the MREC 
ruling it would be unethical for this patient to be 
entered into the trial (even if fully informed and 
wishing to participate). However, if that patient 
moved to the catchment area of a hospital where 
lavage was still routinely undertaken this would DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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Ethical opinion
The Committee is unable to give a favourable ethical opinion of the research as presently designed,
for the following reasons:
“The Committee could accept the need for a trial and understand the choice of comparator. It
recognised that a feasibility study was necessary properly to assess the acceptability to patients of
this approach.  It accepted that this could be ethical, provided that patients had been fully informed
about risks and chose the trial after proper discussion and time for reflection.  However, as there
would remain a small risk from the anaesthetic and procedure the Committee considered it unethical
to recruit potential participants who would not routinely have been offered surgery and/or whose
treating clinician would not routinely carry out an arthroscopic lavage procedure, thus exposing
them to the potential risks of surgery purely for research purposes.”
FIGURE 1  Extract from MREC decision letter.
indicate that, purely by moving house, entry to 
the trial would become ethical for that patient. 
This seemed inappropriate and appeared to have 
parallels with so-called ‘postcode’ lotteries for 
treatment whilst still leaving the question of the 
effectiveness of lavage unanswered.
As such, we appealed the MREC decision – an 
appeal was allowed and assigned to be heard by a 
different MREC. The KORAL Chief Investigator 
(MKC) and Lead Anaesthetist (BHC) attended the 
appeal meeting on behalf of the KORAL team. 
This meeting took place in November 2006, where 
the study documentation was reviewed in detail 
again and further clarification was provided by the 
KORAL team where necessary.
In the appeal we stressed again that in the absence 
of the proposed trial the evidence base available to 
surgeons would remain dominated by the original 
Moseley trial24 – a trial in which all the procedures 
were carried out by a single surgeon, in a single 
US centre, in an atypical group of patients. As 
indicated earlier, generalisation of the results 
from the Moseley trial to the practice of multiple 
surgeons in multiple centres in a different health-
care setting has significant limitations.
In addition, we re-emphasised the 12 months of 
feasibility work that had contributed to the work-up 
of the pilot protocol, reiterating the findings and 
especially the acceptability of the trial to potential 
participants, and to a range of anaesthetists and 
surgeons, given appropriate informed consent.
Following this meeting, the appeal MREC ruled 
that they were content to give a favourable ethical 
opinion of the research subject to ‘receiving 
a significantly revised and extended patient 
information leaflet’. The appeal committee 
deemed that the ‘quality of the informed consent 
was crucial in this study’ and as such wished the 
patient information leaflet to be extensive, with 
particular emphasis to be placed on outlining any 
potential disadvantages of taking part.
This extensive revision of the patient information 
leaflet was undertaken by the KORAL team, 
following which full ethics approval for the pilot 
study was received in March 2007. A copy of 
the final version of the MREC-approved patient 
information leaflet is presented in Appendix 10.
Indemnity
Following the concerns raised in the feasibility 
phase and in the open discussion at the initial 
MREC meeting about the issues of indemnity and 
non-negligent harm, the KORAL team sought to 
clarify the situation for NHS patients. We sought 
clarification from the Department of Health, the 
HTA programme, the Medical and Dental Defence 
Union of Scotland and the lead institution’s clinical 
trials’ insurers.
Our discussions with these multiple agencies 
highlighted that the issue of indemnity (and 
particularly non-negligent harm) was rather 
opaque and that delineation of liability was 
somewhat unclear. Whilst the NHS institutions 
accept liability for negligent harm caused by the 
design of studies they initiate, NHS indemnity 
does not provide no fault compensation for non-
negligent harm.69 In the KORAL project, whilst the 
Department of Health was the study sponsor (note 
– the Department of Health no longer takes on The ethics process
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sponsor responsibility for projects funded through 
the HTA programme), it was indicated that the 
primary responsibility for ensuring indemnity 
cover lay with the ‘contractor’ (the person who had 
been awarded the research contract) and his or her 
employing organisation, rather than remaining a 
sponsor activity.
For the KORAL pilot, we ensured that the project 
had written confirmation from the lead institution’s 
clinical trials’ insurers that appropriate insurance 
arrangements were in place for the study. In 
addition, the host institution held a ‘no fault’ 
insurance policy. This policy covered all employees 
of the institution and those working under their 
direction.
Comments on the ethics 
process
Placebo-controlled trials give rise to complex 
ethical questions. These are intensified when it 
is proposed that an ‘active’ placebo be used to 
mimic the range of non-specific effects (beneficial 
and potentially detrimental) that a patient might 
experience under the active intervention. For 
some conditions, however, without such trials it will 
never be possible to know whether or not a specific 
procedure is more effective than placebo. As such, 
it may be ethically justified to use surgical placebo 
in some situations, provided the potential risks 
have been carefully evaluated and are outweighed 
by the potential benefits.
The ethical review process is a crucial safeguard 
for studies such as this. Understandably it can 
become long and complex. This has the drawback 
of postponing the answers to the research question 
proposed. Whilst bureaucratic delays to this 
process should be minimised, it is essential that the 
genuine ethical dilemmas be explored and debated 
fully.
Genuine informed consent is particularly 
important in the context of ‘active’ placebos, as 
patients must be fully aware that they are accepting 
certain risks of the treatment (in this case general 
anaesthetic) and will not receive any of the benefits 
(except for those based on the placebo effect itself).
In our case, the indemnity procedures were unduly 
complex. It would be helpful if the national 
arrangements for indemnity and non-negligent 
harm are clarified for all researchers involved in 
the conduct of clinical trials – particularly those 
trials that might involve a placebo arm – and 
perhaps NHS-wide indemnity procedures could be 
developed by the respective Health Departments.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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Aim and objectives of the 
pilot study
The overarching aim of the pilot study was to assess 
the feasibility of mounting a multicentre placebo-
controlled trial to evaluate the effectiveness of 
arthroscopic lavage for osteoarthritis of the knee. 
The design of the pilot was informed by the 
extensive qualitative feasibility work (presented in 
Chapter 2) and the specific ethical issues discussed 
in Chapter 3.
The specific objectives of the pilot study were to:
•  examine whether the trial processes as planned 
were appropriate, feasible and acceptable to 
patients, clinicians and the trial office staff;
•  quantify the throughput of eligible patients;
•  quantify the number of patients approached 
and the proportion of patients who would 
accept randomisation to the trial (reasons for 
refusal were collated to examine whether they 
were influenced by the inclusion of a placebo 
procedure); and
•  examine the acceptability of the trial 
information material to patients.
Design of the pilot
The pilot was designed as a two-centre, three-arm 
randomised trial comparing:
•  arthroscopic lavage (with or without 
debridement at the clinical discretion of the 
surgeon)
•  placebo surgery
•  non-operative (medical) management with 
specialist reassessment.
Eligible patients were recruited from hospital 
clinics and, if they consented to participate, 
randomly allocated to one of the three 
interventions. Participants were to be followed 
up at 2, 6, 12 and 24 months. A schematic 
summarising the design of the pilot study is 
presented in Figure 2.
Descriptions of interventions 
used in the pilot
Arthroscopic lavage
Arthroscopic lavage (with or without debridement 
as deemed clinically necessary) was to be 
performed as a day case (unless there were medical 
or geographical reasons for an overnight stay) and 
undertaken in an operating theatre under general 
anaesthesia. A tourniquet could be used on the 
upper thigh, with either formal exsanguination 
of the leg or elevation (in line with the surgeon’s 
standard practice). After sterile preparation 
and draping, the arthroscope was to be inserted 
into the knee joint via a lateral parapatellar stab 
arthrotomy, and a probe inserted via a medial 
parapatellar stab arthrotomy. A further lateral 
suprapatellar arthrotomy would allow insertion of 
a drainage cannula. An ordered inspection of the 
joint and the intra-articular structures would follow. 
The joint was to be lavaged with several (at least 3) 
litres of warm saline and any loose debris washed 
out. A further debridement to remove larger loose 
bodies and trim frayed meniscal edges, minor tears 
or osteophytes could then be carried out at the 
surgeon’s discretion. The irrigation fluid was then 
to be drained from the knee and the arthroscope 
removed. According to clinical judgement, the 
arthroscopy portal incisions could be sutured or 
closed with suture strips, and then dressed. Local 
anaesthesia would be inserted into the knee space 
at the end of surgery for postoperative analgesia.
Placebo surgery
The components of the proposed placebo surgery 
were informed by the extensive discussions with the 
surgeons and anaesthetists (see Chapter 2). As with 
the arthroscopic lavage, the placebo surgery was 
to be performed as a day case (unless there were 
medical or geographical reasons for an overnight 
stay) and undertaken in an operating theatre under 
general anaesthesia. A tourniquet could be used on 
the upper thigh, with either formal exsanguination 
of the leg or elevation (in line with the surgeon’s 
standard practice). After sterile preparation 
and draping, three small (1 cm) skin incisions, 
penetrating only the epidermis, were to be made 
Chapter 4  
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Patients identified in orthopaedic out-patient clinic.
Verbal and written information given about study.
Check eligibility for inclusion to trial 
Randomise 
Arthroscopic 
lavage  Placebo 
Non-surgical 
management 
Follow up at 2, 6, 12, and 24 months 
Patient eligible and willing to take part: 
• Obtain signed consent. 
• Participant complete baseline questionnaire. 
Patient ineligible and willing to take part: 
• Complete ineligible or declined form. 
FIGURE 2  Schematic representation of the design of the pilot study.
in the same medial and lateral parapatellar and 
lateral suprapatellar positions as for a standard 
arthroscopy. There was to be no penetration of 
the knee space. As with arthroscopic lavage, the 
incisions could be sutured or closed with suture 
strips (depending on clinical judgement) and then 
dressed. Local anaesthesia would be inserted into 
the incisions for post-operative analgesia. Patients 
were to be kept in theatre for a similar time to that 
required for lavage (approximately 20 minutes).
Non-operative (medical) 
management with specialist 
reassessment
Management of osteoarthritis of the knee 
incorporates a range of options, and the 
management in the ‘non-operative’ management 
group was, therefore, based on a specialist 
reassessment and recommendation of care (other 
than arthroscopic lavage), taking into account 
previous management. The expectation was, 
however, that the management recommendation 
would include a form of treatment that had 
not been tried before but which seemed most 
appropriate to the surgeon responsible for 
care. The specific ‘non-operative’ management 
regimen for an individual patient was left to the 
discretion of the enrolling surgeon. It could draw 
from a range of management options, including 
pharmacological management, physiotherapy and 
the provision of intra-articular injections. Details of 
the ‘non-operative’ management for each patient 
were to be routinely recorded.
Permissible changes to treatment 
following randomisation
Once patients had been randomised to a particular 
intervention arm, no change in treatment was 
allowed for 3 months (other than in analgesia 
use). This was to ensure that the short-term effects 
of each intervention could be examined, without 
imposing a longer term treatment embargo on 
patients for whom the allocated procedure had 
not resulted in relief of symptoms. A 3-month 
timeframe also fitted well with current UK practice, 
as many patients are reviewed by the orthopaedic 
surgeon 3–4 months after arthroscopy.
Eligibility criteria
Patients were eligible for inclusion if they were: 
(1) adults (18 years or older) with radiological 
evidence of osteoarthritis of the knee who might 
be considered for arthroscopic lavage; (2) fit for 
general anaesthetic – defined by the ASA grade 1 
and 2; and (3) able to give informed consent.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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Excluded patients were those for whom the 
orthopaedic surgeon judged that arthroscopic 
lavage was clearly indicated; for whom 
arthroplasty was clearly indicated; who had clear 
contraindication to general anaesthesia; who were 
unable to speak English; and who had an inability 
to complete follow-up questionnaires.
Obtaining consent
Potentially eligible patients were provided with 
the patient information sheet (see Appendix 
10) in the outpatient clinic. The dedicated local 
recruitment co-ordinator discussed the study and 
went through the patient information sheet with 
the patients. If required, the patient was given 
time to decide whether or not to participate. If the 
patient wished to join the trial, the recruitment co-
ordinator checked that the consent form had been 
understood, and obtained written consent (see 
Appendix 11).
The participant was also asked to complete a 
baseline questionnaire whilst at the clinic or, if 
necessary, at home (see Appendix 12).
If the potential participant did not wish to join 
the trial, the reason for this decision was explored. 
It was stressed that this information was sought 
for the benefit of the trial rather than to try to 
encourage participation.
Randomisation and 
allocation to trial group
Once consent was received, patients were 
randomised to one of the three trial groups 
using a fully automated computerised telephone 
randomisation provided by the Centre for 
Healthcare Randomised Trials (CHaRT), based 
in the Health Services Research Unit, Aberdeen, 
UK. CHaRT was the accredited clinical trials 
unit supporting the KORAL study. Allocation 
incorporated minimisation on centre and key 
prognostic factors including age group (≤ 50 
or > 50 years), gender, extent of osteoarthritis 
(whether radiological evidence indicated ‘bone-
on-bone’ or ‘non bone-on-bone’) and whether 
mechanical symptoms were present or not. For 
patients who presented with osteoarthritis in both 
knees (and for whom arthroscopic lavage might be 
considered for both knees), the knee indicated by 
the patient to be the most painful was the knee that 
was designated the study knee for the purposes of 
randomisation and subsequent study.
Outcome measures
The primary aim of the pilot was to assess the 
feasibility and acceptability of procedures for a 
full trial. However, if it transpired that a decision 
was made to proceed to full trial, it was hoped 
that any participant recruited to the pilot would 
be later integrated into the full trial; thus we 
planned to follow up pilot participants up at the 
timings proposed in the main trial (at time points 
equivalent to 2, 6, 12 and 24 months after surgery) 
using full trial paperwork.
The outcome measures proposed for the full 
trial were informed by a study investigating the 
priorities of patients with osteoarthritis of the knee 
which showed that the outcomes that mattered 
most to patients were limitations of activities 
and pain.70 Further work71 on osteoarthritis 
outcome measures indicated that pain falls 
within the impairment component of the World 
Health Organization International Classification 
of Function (i.e. impairment, activities and 
participation)72 and that the recognised knee 
quality of life score – the Oxford Knee Score73 
– contains items giving pure assessment of 
pain impairment and activity limitation. By 
including the Oxford Knee Score and the Short 
Form (12 questions; SF-12),74 the full trial would 
record measurements on all three components 
(impairment, activities and participation), whilst 
focusing on the patient’s perspective through the 
use of self-completion questionnaires.
Reflecting this approach the following outcome 
measures were chosen:
•  Primary outcome measures: condition-specific 
pain and disability, as measured by the Oxford 
Knee Score; knee pain, as measured by a 10-
cm visual analogue pain score (and the pain 
dimensions of the Oxford Knee Score and the 
SF-12 scales).
•  Secondary outcome measures: general quality 
of life, as measured by SF-12; patient utility, 
as measured by the EuroQol-5 dimensions 
(quality of life instrument; EQ-5D);75 non-
steroidal anti-inflammatory drug or analgesic 
use; use of other treatments outside the trial 
interventions; use and cost of health services; 
cost-effectiveness – as measured by the 
incremental cost per quality-adjusted life-year 
gained.
Questionnaires are reproduced in Appendix 12.The pilot study
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Sample size and feasibility
As this was a pilot study with the explicit aim of 
refining estimates of likely throughput of patients 
and the proportion of eligible patients who would 
consent in a given time period (both of which 
would inform a sample size calculation for a full 
trial), a formal sample size calculation at this stage 
was inappropriate.
Analysis plans
A single principal analysis was planned for the end 
of the pilot phase. Analysis was to consist primarily 
of descriptive statistics including throughput per 
month, proportion of eligible patients randomised, 
and reasons for refusing to take part in the trial. 
Reflecting the small sample size, no analysis was to 
be conducted by randomised group.
Pilot experience
Local approvals – Centre 1
Following receipt of MREC approval, the KORAL 
team moved to complete internal authorisations 
for the study to proceed in Centre 1. Local ethics 
and research and development approvals were 
received relatively easily, although there were 
some discussions about the treatment costs for 
placebo surgery should this pilot eventually move 
to a full trial. Clinical approval for the study was 
not so straightforward, however, as there were 
significant concerns raised at directorate level 
about authorising such a trial (which included 
a placebo surgical arm, and especially one that 
involved general anaesthesia for the placebo) to 
be conducted within the hospital. The Directorate 
refused to authorise the study without full 
discussion of the study by the Regional Anaesthesia 
Senior Staff Committee – this meeting took place 
in May 2007. The KORAL Chief Investigator 
(MKC) and Lead Anaesthetist (BHC) attended 
that meeting on behalf of the KORAL team and 
presented the findings of the feasibility study to 
the committee. The meeting generated extensive 
discussion, with a range of opinions expressed 
(both strongly positive and strongly negative). A 
private vote was taken by the membership of the 
committee as to whether the trial should be allowed 
to proceed, which resulted in the trial receiving 
majority approval. Caveats were applied to the 
conduct of the study however – only consultant 
anaesthetists would be allowed to take part in the 
study and surgery must be undertaken in the main 
hospital theatre suite (some orthopaedic operations 
were being undertaken in a mobile unit at that 
time).
Local approvals – Centre 2
Clinical authorisation also proved challenging in 
Centre 2. As per local procedures, authorisation 
was initially referred to the Surgical Directorate. 
Given the potentially controversial nature of 
the trial, the study was then referred up to the 
Divisional Directorate for approval. As in Centre 
1, authorisation was deferred until there was full 
discussion by the Anaesthetic Committee Meeting. 
The KORAL Chief Investigator (MKC) and Lead 
Anaesthetist (BHC) wrote a briefing paper for 
the Committee summarising the results of the 
feasibility study and the plans for the pilot phase. 
The Anaesthetic Committee met in October 2007, 
at which the decision was made that the study could 
proceed in Centre 2.
A further issue was then raised by Centre 2. In 
the period since KORAL was originally funded, 
the centre had stopped undertaking arthroscopic 
lavage as a routine procedure. As such the centre 
could now become a recruiting centre only if 
commissioners agreed to pay the normal ‘Payment 
by Results’ tariff for cases (including placebo 
cases). This led to extended negotiations with 
the commissioners, who finally agreed to provide 
funding for a maximum of five cases within the 
pilot (further negotiations would have been 
required if the pilot had progressed to full trial).
These local approvals were only finalised in 
November 2007, and whilst this eventually allowed 
the site-specific ethics form for the centre to be 
submitted, a response was not received within the 
planned duration of the pilot. The local ethics 
committee requested further information about the 
centre co-ordinators, but this was not followed up 
as the decision had, by that time, been taken not 
to progress to full trial (see Chapter 5). As such, we 
could not proceed to formal recruitment in Centre 
2 in the timeframe of the pilot.
Identification of patients
Referral letters to KORAL surgeons in Centre 
1 were assessed for potentially eligible patients, 
and dedicated KORAL study clinics were set up. 
The centre’s lead surgeon led the majority of 
the clinics with support from the local KORAL 
recruitment co-ordinator. The first clinic took place 
in July 2007. During the period of recruitment DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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(July–November 2007), eight KORAL clinics were 
held. Of the 49 patients who were given a clinic 
appointment, 40 attended (Figure 3). Twenty-
seven patients were found to be ineligible. Nine 
of those had minimal pain and were discharged, 
four were referred for magnetic resonance imaging 
scan, three had mechanical symptoms (and were 
referred for arthroscopy), three were given review 
appointments for a later date, two were listed for 
knee replacements and two required hyaluronic 
acid injections. Two of the other ineligible patients 
had other chronic conditions, another had a 
meniscal tear and the final patient was referred to 
the pain clinic.
Of the 13 eligible patients, nine were recruited 
into the pilot study in Centre 1. Six of these were 
randomised to some form of surgery (placebo 
or active) and three were randomised to non-
surgical management. Reasons given by those four 
patients who declined were: one felt the research 
was important but was not for them; one indicated 
their pain had reduced since referral (but if it had 
remained at the same level they would have taken 
part); one had a new job and had ‘plenty to cope 
with already’; and one did not like the idea of the 
study.
Table 4 shows the baseline characteristics of the 
pilot participants. Four patients were male and 
five female. Of the nine patients recruited, eight 
completed a baseline questionnaire, comprising 
the Oxford Knee Score, SF-12 and EQ-5D. One 
participant, who took the questionnaire home to 
complete, failed to return it.
Baseline scores on the Oxford Knee Score ranged 
from 13 to 31 [possible scores range from 12 (least 
difficulties) to 60 (most difficulties)], with a mean 
score of 26.5 and a median score of 29. The range 
of EQ-5D scores was 0.66–0.80, with the mean 
score 0.74 [standard deviation (SD) 0.06] and 
median score 0.76 [interquartile range (IQR) 0.69 
to 0.80]. Possible scores for EQ-5D range from 
–0.59 to 1.00 (with higher scores indicating better 
quality of life).
Seven people completed all questions contained 
within the SF-12 (possible scores range from 0 to 
100, with higher scores indicating better quality of 
life). On the physical component summary scale, 
the range of scores was 33.9–49.8, the mean score 
42.1 (SD 6.1) and the median score 43.1 (IQR 37.1 
to 49.3). On the mental component summary scale, 
the range of scores was 29.2–61.1, mean score 53.3 
TABLE 4  Baseline characteristics of trial participants
Characteristic Description
Gender 4 male, 5 female
Age
Range 43–63 years
Mean 57 years
Median 61 years
Affected knee 6 right, 3 left
Oxford Knee Score
Range 13–31
Mean score (SD) 26.5 (6.2)
Median score (IQR) 29.0 (24.5 to 30.5)
EQ-5D
Range 0.66–0.80
Mean score (SD) 0.74 (0.06)
Median score (IQR) 0.76 (0.69 to 0.80)
SF-12 – physical
Range 33.9–49.8
Mean score (SD) 42.1 (6.1)
Median score (IQR) 43.1 (37.1 to 49.3)
SF-12 – mental
Range 29.2–61.1
Mean score (SD) 53.3 (11.2)
Median score (IQR) 57.5 (49.7 to 60.2)
Pain – visual analogue scale
Range 2–6
Mean score (SD) 3.88 (1.36)
Median score (IQR) 3.5 (3.0 to 5.0)
(SD 11.2) and the median score 57.5 (IQR 49.7 to 
60.2).
Patients were also asked to rate their pain ‘today’ 
on a visual analogue scale from 0 (no pain) to 
10 (worst pain imaginable). The scores reported 
ranged from 2 to 6, with mean score 3.88 (SD 1.36) 
and median score 3.5 (IQR 3.0 to 5.0).
What happened to the 
participants after randomisation
The three patients randomised to non-surgical 
management were reassessed on the same day 
as the recruiting clinic, following randomisation. 
All three were advised on analgesic use. Two The pilot study
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49 patients given appointment at 
one of 8 recruitment clinics 
40 patients attended
13 patients eligible 
9 patients recruited and 
randomised 
9 patients failed to attend 
27 patients ineligible/unsuitable 
3 randomised non-surgical management
• 2 surgeries undertaken November 2007
  (1 placebo, 1 active)
• 1 surgery undertaken February 2008 (following
  decision not to proceed to main trial)
• 1 participant discharged (following decision not
  to proceed to main trial)
2 subsequent withdrawals 
– reasons: 
• 1 anxious about possibility 
  of getting placebo 
• 1 anxious about possibility 
  of placebo and of MRSA 
4 patients declined, reason: 
• Research important but not for them 
• Pain reduced since referral. If pain had 
  remained at same level as when referred, 
  would have taken part 
• New job and plenty to cope with already 
• Did not like idea of the study 
6 randomised surgery 
FIGURE 3  Flow diagram of patients through the pilot. MRSA, methicillin-resistant Staphylococcus aureus.
participants were given lifestyle modification advice 
and exercise information. The use of a walking 
stick was suggested to one participant but this was 
declined. Two participants were advised to use an 
elastic knee brace and one was advised on the use 
of heat and ice.
Two out of the six patients randomised to receive 
surgery subsequently withdrew from the pilot 
prior to surgery – both cited anxieties about the 
possibility of receiving placebo rather than active 
surgery among their reasons for withdrawal. One 
participant who withdrew also reported anxieties 
about the risk of contracting methicillin-resistant 
Staphylococcus aureus (MRSA).
The first KORAL surgical procedures were 
undertaken in November 2007 when one placebo 
and one active surgery were performed. The 
placebo surgery followed closely that laid out in 
the protocol: the patient was taken into theatre and 
arthroscopic equipment set up; a tourniquet was 
applied, the leg exsanguinated and the tourniquet 
inflated; the three standardised skin incisions were 
made with a scalpel, taking care not to penetrate 
the joint capsule; local anaesthetic was injected 
via a lateral parapatellar approach, dressings and 
bandages were applied, the tourniquet was deflated 
and anaesthesia was reversed before the patient 
was taken to recovery. The patient undergoing 
active surgery underwent the same process, except 
that the incisions were completed into the joint, 
to allow passage of arthroscope, instruments 
and drainage port; the interior of the joint was 
examined thoroughly and findings noted. There 
was no requirement for debridement in this case, 
and so the joint was lavaged with 3 litres of saline, 
before completion of the procedure with removal 
of instruments; dressings were then applied, 
local anaesthetic injected and bandages applied, 
before release of the tourniquet and reversal of 
anaesthesia, as for the placebo patient. Postsurgery, 
discussion with both patients followed the pre-
agreed approach: ‘you know that I cannot tell you 
whether you had the active surgery or the placebo, 
but I can tell you that the procedure went well DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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and we will now need to see how well this helps 
your knee’. This approach was maintained during 
follow-up clinic appointments.
The two remaining patients who were scheduled 
for surgery had their management reviewed when 
the decision was made not to progress to full trial 
(see Chapter 5), as the decision to stop occurred 
before their scheduled surgery date.
The three non-surgical participants were all 
followed up in a hospital clinic approximately 
2 months after randomisation. Two of the 
participants were referred for hyaluronic acid 
injections and one was placed on the waiting list for 
knee arthroscopy.
The surgeon reported that the practicalities of the 
surgical interventions (both active and placebo) 
presented no significant problems.
The anaesthetist also shared his views with us 
about administering general anaesthetic to these 
first two patients. In discussing his views about 
the ethical acceptability of the trial, in similarity 
to the position held by several other anaesthetists 
and surgeons who took part in our focus group 
discussions, he indicated that although the trial 
might not result in any personal benefit for 
individual trial participants, the likely benefits 
would be that it would provide robust evidence 
of whether arthroscopic lavage was effective or 
not for future patients with osteoarthritis of the 
knee. Although he stated that anaesthetists are 
trained to avoid risk (and by implication therefore, 
some anaesthetists would be uncomfortable with 
anaesthetising a patient for a placebo procedure 
that would carry a degree of risk), he argued the 
additional point that, out with clinical trials, many 
surgical procedures that require general anaesthetic 
are performed on patients who are unlikely to 
receive any personal benefit (for example, for 
reasons relating to the skill level of the operating 
surgeon, or the appropriateness of the procedure 
for a particular patient). He also argued that 
as long as health professionals have attempted, 
wherever possible, to limit risks to patients, the 
crucial issue is the extent to which informed 
consent is obtained from the patient before any 
operation takes place.
In terms of his experience of taking part in the 
pilot trial, he discussed how he had been unaware 
of the patients’ group allocation until after they 
had been anaesthetised and brought into the 
operating theatre (where the allocation was then 
revealed to both the surgeon and the anaesthetist). 
Although the anaesthetist stated that he personally 
did not feel any differently towards the two 
patients after their allocation was revealed (and 
was primarily focused on getting them through the 
operation and into recovery as safely as possible), 
he discussed how the theatre staff had expressed 
some concern when it was revealed that one of the 
patients was to receive placebo surgery (despite the 
fact that the theatre staff had been fully aware of 
the nature of the trial prior to their participation).
Postal follow-up
The randomised participants who remained in 
the pilot were followed up at the intended time 
points (the two patients who had surgery and the 
three who had conservative management). Of 
the two patients who had surgery (one active, one 
placebo), in the 2-month follow-up questionnaire, 
neither patient reported that they thought they 
had undergone placebo surgery. At this point, both 
patients reported their pain as ‘1’ on the visual 
analogue scale (out of 10). Of the three patients 
randomised to conservative management, two 
reported their pain as ‘7’ on the visual analogue 
scale at their 2-month follow-up, the other reported 
a rating of ‘2’.
Comments on the pilot 
study
The pilot study showed that, in principle, 
a placebo-controlled trial in surgery can be 
conducted. It showed that a significant proportion 
of patients were willing to participate in a trial 
that would involve a placebo surgical arm, and 
that it was possible to undertake placebo surgery 
successfully and blind patients to their allocation.
The experience of the pilot, however, showed that, 
despite full MREC approval, the study required 
major discussion and negotiation before local 
clinical approvals could be obtained. Many of the 
arguments raised at MREC level were raised again 
at local level, and the fact that ethics approval had 
been granted did not mean that clinicians would 
automatically accept that the process was ethical. 
The ethics of a placebo-controlled trial in surgery 
remained contentious and there was a number of 
individuals (mainly anaesthetists) who retained 
strong negative perceptions of the ethics of the 
trial. However, we would anticipate that the wide 
airing the ethical arguments received through 
the process of securing consent for the pilot The pilot study
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stage would make the process of obtaining ethics 
approval for a full trial less onerous.
Once clinics were under way, a significant 
percentage of eligible patients appeared willing to 
participate in the study – although once patients 
knew their allocation, some of those allocated 
to surgery became more concerned about the 
possibility of undergoing placebo surgery, and 
some withdrew. This suggested that higher than 
normal rates of postrandomisation withdrawal 
might have been expected in those randomised 
to some form of surgery should the study have 
progressed to full trial. However, the number of 
patients involved in the pilot was small, and as 
such strong conclusions cannot be made as to the 
true proportion of patients who would agree to 
participate and the proportion who might drop out 
of a full trial.
The issue of how, in a full trial, a placebo procedure 
would be funded in the context of different local 
commissioning arrangements remained unclear. 
This would have to be addressed on a case-by-
case basis which is logistically cumbersome in a 
multicentre trial.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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The decision-making 
process
Because of the multiphase nature of the study and 
the need to move rapidly between stages, a bespoke 
decision-making process for the project was set 
up with the NIHR Evaluation, Trials and Studies 
Coordinating Centre (NETSCC; formerly known as 
NCCHTA). At the start of the project it was agreed 
that special decision-making teleconferences would 
be held for the end of each of the distinct phases of 
the study to allow decisions to be made in a timely 
manner. At each teleconference a recommendation 
would be made as to whether the project should 
continue on to the next planned phase or the study 
should close. The grant holder team undertook 
to deliver specific project reports ahead of these 
teleconferences in addition to the standard 
progress reports required every 6 months. These 
decision teleconferences involved staff from the 
NETSCC, an independent scientific chairperson 
and the grant holder team. Final decisions were 
made by the NETSCC (in consultation with the 
independent scientific chairperson) and fed back to 
the grant holder team in writing.
The first decision teleconference was planned 
for the end of the feasibility phase. The aim of 
this teleconference was to review the findings of 
the (mainly qualitative) feasibility phase and to 
decide if there was sufficient support from those 
interviewed to allow the project to continue to a 
formal pilot phase.
The second teleconference was planned for the 
end of the formal pilot phase. The aim of this 
teleconference was to review the results of the pilot 
and to decide if the pilot experience, set against 
the current clinical climate, was conducive to 
progressing to a full-scale trial.
The first decision-making 
teleconference – end of the 
feasibility phase
The first decision-making teleconference took 
place in June 2006. At this point, data were 
available from all the qualitative components 
of the study and from the surveys of surgeons 
and anaesthetists. As highlighted in Chapter 
2, these data showed that a range of views 
had been expressed on the acceptability of a 
placebo-controlled trial. A number of surgeons, 
anaesthetists and potential participants, however, 
had shown willingness to participate in such a trial 
if it went ahead.
Nevertheless, we were aware that all the 
responses in the feasibility phase were related to 
a hypothetical scenario. No one was being asked 
to actually participate in such a trial, and it was 
possible that, if a placebo-controlled trial were 
mounted, attitudes might change (or that there 
might be a mismatch between the attitudes of the 
surgeon and his or her corresponding anaesthetist 
in different centres), leading to very different sign-
up rates. It was difficult to predict take-up rates 
without moving to a ‘real-life’ scenario.
At the teleconference, these issues were fully 
discussed and the conclusions reached that:
•  There appeared to be sufficient numbers 
of health professionals willing to consider 
participation in a placebo-controlled trial.
•  Potential participants also showed willingness 
to take part.
•  It was crucial that better estimates of realistic 
‘take-up’ rates be explored and that this would 
be best achieved through progression to the 
small-scale formal pilot study.
As such, the decision was made at that time to 
progress, as initially planned, to the formal pilot 
phase.
The second decision-making 
teleconference – end of the pilot 
phase
The second decision-making conference took place 
in January 2008. At this point data were available 
on: the experience of gaining ethics approval; the 
experience of gaining local approvals at the two 
pilot centres; the flow of patients from all eight 
KORAL clinics that had been held in Centre 1; all 
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randomisations (and any subsequent withdrawals); 
the initial experience of all the non-surgical 
management patients; the experiences of the 
first two surgical procedures (one active and one 
placebo procedure); and information on the trends 
of arthroscopic lavage use in the UK over recent 
years.
This pilot study had shown that:
•  The perceived ethics of a placebo-controlled 
trial in surgery remained contentious (even 
after ethics approval was received). There were 
a number of individuals (mainly anaesthetists) 
who retained strong negative perceptions of 
the ethics of the trial. However, given that the 
ethical principle of the trial had been given 
an extensive airing through the pilot study, 
one would expect that ethics approval for a 
continuation of pilot to full trial would be less 
onerous.
•  Even when ethics approval had been 
received, approval at a local level was not 
straightforward. Many of the arguments 
considered at the ethics committee stage were 
raised again at local level. Had the study 
progressed to full trial, the experience of the 
pilot suggested that ensuring appropriate 
authorisations in multiple centres could have 
been a lengthy and time-consuming process.
•  The issue of how, in a full trial, a placebo 
procedure would get funded in the context of 
different local commissioning arrangements 
was unclear.
•  Eligible patients were open to the idea of 
participating in a placebo-controlled trial, 
and most of those approached were willing to 
consent.
•  It was possible to undertake placebo surgery 
successfully and to blind patients to their 
allocation.
•  Had the study progressed to full trial, 
however, higher than normal rates of post-
randomisation withdrawal might have been 
observed in those randomised to some 
form of surgery – in the pilot two out of the 
six randomised to surgery withdrew citing 
increasing concerns about the possibility of 
receiving placebo surgery.
The decision whether to proceed to full trial was 
also informed by data on trends in the usage of 
arthroscopic lavage (and debridement) in the UK. 
Data were available from the HES13 for England 
and Wales, and data available from 1998–9 to 
2005–6 are presented in Figure 4. These data 
showed that the use of arthroscopic lavage, and 
its associated procedures such as debridement, 
was steadily declining with a slightly more marked 
decrease after the publication of the Moseley trial 
in 2002.
Taking the results of the pilot experience and 
the trend data on the background usage of 
arthroscopic lavage together, the conclusion was 
made that whilst the KORAL pilot had shown that, 
in principle, a placebo-controlled trial in surgery 
could be conducted (and that conducting a full-
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There were a number of key points arising from the discussion that influenced our
decision.
• The difficulty in gaining local ethical approval in order to bring new treatment
  centres to the trial adds a considerable amount of time and cost to the original
  estimates for the recruitment phase.
• Even with ethical approval, the evidence from [Centre 1] suggests that
  recruitment will be slower than anticipated.
• The predicted high rate of dropout of patients randomised to one of the
  surgical arms of the trial makes comparison between the surgical and non
  surgical arms unacceptably biased.
• The extended length of the trial should be considered against a background of
  the falling use of arthroscopic lavage.
FIGURE 5  Extract from the KORAL decision letter.
scale trial in the field was likely to be possible), the 
anticipated time, energy and cost required to bring 
multiple centres on board against a background of 
falling use of the technique was not justified. An 
extract from the formal decision letter summarising 
these points is shown in Figure 5.
Thus, the decision was made not to proceed to full 
trial.
Close down
In light of the decision not to proceed to full trial, 
the KORAL study rapidly moved into a close down 
phase. Decisions on how to deal with randomised 
patients still active in the trial had to be made 
quickly. As the KORAL team knew that close 
down was always a possibility, close down plans for 
different scenarios had already been made within 
the group, which greatly facilitated the transition 
to close down. These plans were agreed with the 
MREC.
When the decision was made not to progress 
beyond the pilot stage, pilot participants fell into 
three distinct groups. Management of the patients 
differed according to their grouping:
1.  Those who had already undergone surgery. Two 
participants had been randomised to, and had 
undergone, surgery (one placebo, one active) 
before the decision not to proceed to full trial. 
In line with the protocol and the information 
they were given before their entry into the 
trial, they were not subsequently informed of 
the type of surgery that they had undergone. 
Both patients were invited to attend (as per 
protocol) follow-up 3 weeks after their surgery; 
one attended and one did not (despite being 
offered more than one appointment). If a 
clinical need arises at some point in the future, 
plans have been put in place allowing them 
to be told, if necessary, what procedure they 
underwent.
2.  Those who had been randomised to surgery, but had 
not yet undergone surgery. Two participants had 
been randomised to surgery (one to placebo 
surgery, one to active surgery), but at the 
time of the decision teleconference they had 
not yet received their surgery. In light of the 
decision not to proceed, it was agreed that 
these participants would not progress within 
the KORAL framework. This was agreed with 
the MREC. In Centre 1, these patients would 
not routinely have undergone arthroscopic 
lavage outside of the trial. It was agreed that 
these participants would be seen again by 
the surgeon at the outpatient clinic. At this 
appointment he would explain that the pilot 
had been stopped so they would not have 
surgery as part of KORAL. He would explain 
that the treatment options were now medical 
management or arthroscopic lavage (although 
the evidence for the latter was weak), and 
that the patient could choose between having 
arthroscopic lavage or medical management. 
One of the participants opted to proceed with 
surgery, subsequently underwent this surgery 
and was discharged from routine care. The 
other participant did not attend a number of 
clinic appointments to discuss the options, and 
was subsequently discharged.The decision-making process
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3.  Those who had been randomised to non-surgical 
management. Three participants had been 
randomised to non-surgical management, and 
this management was already under way before 
the decision teleconference. Because these 
patients were allocated to the non-surgical arm, 
they knew (by default) the group to which they 
had been allocated. They were invited to attend 
follow-up clinics 3 months after recruitment, as 
described in the pilot protocol.
Participants in all groups subsequently followed 
normal discharge procedures as appropriate.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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T
he KORAL study addressed the specific 
issue of the role of a placebo control for the 
evaluation of arthroscopic lavage (with or without 
debridement). The research resulted in a number 
of new insights into arthroscopic lavage and how 
a placebo-controlled study of the procedure might 
be conducted in the UK. The study also identified 
some wider issues relevant to placebo-controlled 
trials of non-drug therapies in general (particularly 
placebo-controlled trials of interventional 
procedures), and thus allows further exploration 
of the circumstances in which a placebo-controlled 
trial should and could be mounted. We accept, 
however, that the numbers of participants included 
in some phases of the study were small and as such 
strong conclusions on the basis of these data are 
limited. Similarly our study was based within the 
UK NHS and involved a predominantly Caucasian 
population and as such the applicability of the 
results to different cultural and ethical frameworks 
is potentially limited.
Arthroscopic lavage – specific 
lessons from KORAL
Identification of a potential 
placebo-surgical technique for 
arthroscopic lavage
The focus groups with the surgeons indicated that 
agreement could be reached relatively quickly 
on a surgical placebo for arthroscopic lavage. 
The preferred placebo procedure involved three 
superficial incisions with no penetration of the 
knee capsule and was very similar to the procedure 
adopted by Moseley et al.24 in their trial. Given 
the active comparator, arthroscopic lavage, it 
was perhaps not surprising that surgeons were 
relatively comfortable with a placebo procedure for 
this intervention, as the only outward indications 
of active arthroscopic lavage are the three small 
incisions indicating the access routes for the 
instruments. If the active procedure had involved 
a larger incision, it is reasonable to expect that 
consensus would have been harder to achieve. 
Under those circumstances, other mechanisms 
for masking the allocation might have been put 
forward more actively, for example, as in the trial 
of laparoscopic versus open cholecystectomy where 
large dressings were used to mask the procedure 
that had been undertaken.76
Clinical importance of the 
anaesthetic
Very early in the KORAL process the clinical 
importance of the anaesthetic became apparent. 
Whilst the surgical dimensions of the proposed 
placebo were relatively straightforward, the 
question of which form of anaesthesia to adopt 
was not so readily apparent. The anaesthetists 
in our study rejected the idea of using hypnotic 
agents (as in the Moseley trial), which might 
superficially be considered to be ‘less risky’ than 
general anaesthesia, because they were not all 
convinced the agents would produce adequate 
anaesthesia for the proposed placebo surgery, and 
they did not consider them to be safer than general 
anaesthesia. There was also a clear consensus that, 
if the trial proceeded, participants in both trial 
arms (the active and the placebo surgery) should 
receive the same general anaesthetic regimen. The 
anaesthetists favoured having each anaesthetist 
who participated in the trial use the form of 
general anaesthesia that they customarily used for 
a simple arthroscopic procedure, as they would 
have more experience with this approach and thus 
would be less likely to make errors when adhering 
to it. The wider literature on clinician learning, 
expertise and performance supports this stance as 
it suggests that the success of a procedure is directly 
related to the number of procedures undertaken 
by that individual (the so-called ‘volume–outcome’ 
relationship77) and his or her position on his or her 
individual learning curve.78 As such, anaesthetists 
are more likely to have a beneficial outcome if they 
adopt the anaesthetic regimen with which they 
have most experience.
Postrandomisation withdrawals
When choosing between conducting a placebo-
controlled and an ‘open’ trial, researchers are 
required to consider the implication of the choice 
of design on a number of factors that may affect 
the subsequent validity and generalisability of 
the results of the trial. One of the most common 
concerns when considering a placebo-controlled 
design is that the design may reduce recruitment 
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to the trial, as patients may be reluctant to accept 
the possibility of receiving the placebo treatment. 
The results of the KORAL pilot, however, did not 
support this view and showed that the majority 
of those approached (9/13) agreed to join the 
trial, and none of those who refused identified 
the placebo as a reason for not taking part. This 
finding was also echoed in the focus groups with 
people who had osteoarthritis, with the majority 
indicating that they would consider taking part in 
such a study. The main reason for this willingness 
to participate (put forward by those who were 
interviewed) was a perceived need from those with 
the disease to find out, once and for all, whether 
arthroscopic lavage was truly effective.
A further consideration when choosing whether 
to adopt a placebo-controlled design is the 
possibility of increased withdrawal of patients 
following randomisation, as patients come to terms 
with the reality of allocation to the placebo or a 
dissatisfaction with outcome borne from a belief 
that they have been randomised to placebo and 
that it has not improved symptoms. The KORAL 
pilot showed that whilst the majority of individuals 
approached were willing to consent to participate 
in the full pilot, withdrawal rates increased in 
the surgery arm after randomisation. Two out of 
the six patients randomised to surgery (active or 
placebo) withdrew postrandomisation, both citing 
amongst other reasons heightened anxiety about 
the possibility of receiving the placebo treatment 
(no patients withdrew from the non-surgical arm). 
This concurs with the findings of previous research 
which formally explored the effects of a placebo-
controlled design on recruitment and retention 
rates,79 and showed that withdrawal rates following 
randomisation were higher in those randomised 
to a placebo-controlled design than in those 
allocated to an open trial design. This suggests 
that those planning for a placebo-controlled trial 
need to accommodate for greater withdrawal rates 
in their sample size calculations, and to assess the 
implication of the increased withdrawal rates on 
the validity of their results.
Role of external data
The decision not to progress to full trial was 
informed not only by the direct experience of 
the KORAL feasibility data, but also by external 
national trend data available on the usage of 
arthroscopic lavage. At the start of the project, 
national HES indicated that around 34,000 
procedures could be classified as arthroscopic 
lavages (or related therapeutic procedures). Wider 
trend data (see Figure 4) suggested a steady, albeit 
slow, decrease in the use of arthroscopic lavage 
over recent years, with a slightly faster rate of 
decline in usage following the publication of the 
Moseley trial in 2002. This external evidence was a 
crucial component in the decision not to progress 
to full trial, as any trial (especially one involving a 
placebo arm) would face increasing difficulties with 
recruitment against a background of falling use 
of a technique. The question of the effectiveness 
of arthroscopic lavage for osteoarthritis of the 
knee thus remains unanswered,  although other 
(non placebo-controlled) studies are still being 
conducted which will add to the cumulative 
evidence base for the technique. Indeed, as this 
monograph was being written a further trial 
comparing arthroscopic lavage and debridement 
(in addition to optimised medical and physical 
therapy) compared with optimised medical and 
physical therapy alone was published,80 showing no 
evidence of a benefit of arthroscopic lavage over 
non-surgical management.
The influence of external evidence in the decision-
making process has many parallels with the role of 
external evidence in the decision-making processes 
of trial data monitoring committees (DMCs). 
A trial DMC meets regularly over the course of 
a trial and it is its responsibility to recommend 
whether the trial should continue according to 
the planned protocol or be stopped early. Whilst 
the DMC primarily reviews the emerging data 
from the specific trial, this is often augmented 
by evidence from other trials and other external 
sources. The importance placed on this extra 
external evidence is not uniform across all DMCs, 
but commentators suggest that external evidence 
should be routinely taken into account in the 
decision-making process.81,82 A clear implication 
of this is that researchers must have close-down 
procedures worked through early in the life of a 
trial, allowing rapid response to any decision to 
terminate the study early. Pre-planning of close-
down procedures was crucial to the smooth close 
down of the KORAL study, and it is recommended 
that all trialists prioritise this planning activity.
Generic issues related to 
placebo-controlled trials in 
surgery
Terminology
The research undertaken in this feasibility 
study highlighted the spectrum of language 
that has been used in the published literature 
to refer to an inactive control manoeuvre that DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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mimics the experimental (or placebo) treatment. 
The interviews and focus groups with health 
professionals and potential participants also 
highlighted that different words give rise to 
different connotations as to the motives behind the 
use of a placebo.
In medical research, a placebo is generally used 
to evaluate the efficacy of a drug or intervention 
whilst attempting to equalise any perceived 
positive effects induced through exposure to a 
treatment.83 A placebo attempts to mimic the 
intervention under study, but has no known 
inherent mechanism of action such as to promote 
any expected benefits. An effective placebo, 
whilst attempting to maximise the mimic of the 
intervention, should also seek to minimise any 
potential harm to the recipient. The classic placebo 
used within a pharmacological research setting is 
the ‘sugar pill’ – a formulation that is manufactured 
to mimic the drug under study, but which has no 
known mechanism of action and whose ingredients 
have been selected to minimise any potential 
harm. Because of the long tradition of this type of 
placebo in the pharmacological research setting, 
the words ‘placebo’ and ‘dummy’ have become 
synonymous with formulations that are perceived 
to be completely inert and benign, despite many 
trials observing adverse events (e.g. gastrointestinal 
upsets) in those patients allocated to the placebo.
In trials of surgical interventions, however, it is 
harder to achieve an effective mimic that minimises 
potential harm to the extent of the sugar pill. 
Because the placebo in this setting cannot be 
inert, the word ‘sham’ has become commonplace 
to describe the use of a placebo procedure in this 
setting. The word ‘sham’, however, derives from 
the terminology of deception and is synonymous 
with wilful deceit (with its inherent negative 
connotations).84 We found that the choice of 
word (sham or placebo) can lead to very different 
perceptions, despite the rationale behind their use 
being the same in both settings.
In the KORAL study, we chose to adopt the 
terminology of ‘placebo surgery’. We chose 
this in an attempt to describe as accurately as 
possible the intention behind the procedure – i.e. 
to mimic the ‘active’ surgery being undertaken 
in the arthroscopic lavage arm of the trial (and 
hence the indirect effects of receiving surgery), 
whilst minimising the risk. This terminology 
was discussed with the potential participants in 
the focus groups and found to be an acceptable 
descriptor for the procedure.
The words ‘placebo’ and ‘placebo effect’ have also 
been shown to have some positive connotations in 
the clinical setting, as they can be used to describe 
the positive (but unexplained) improvement 
observed in a proportion of patients allocated 
to the placebo treatment,83 as was observed in 
the Moseley trial.24 We realise, however, that 
perceptions of the control technique might 
not have been so favourable had we used the 
terminology of ‘sham surgery’; however, we did not 
want our results to be artificially skewed by the use 
of a term which we knew a priori to be negatively 
loaded.
Blinding
A particular complication of trials in surgery is that 
the surgeon cannot be blinded to the procedure. 
The surgeon and his team will always know which 
procedure a particular patient has received, and 
this can have consequences for the scientific rigour 
of the design and potentially for the doctor–patient 
relationship. The concept of the surgeon not being 
blinded to the allocated intervention within an 
RCT is not new,85,86 and many commentators note 
that, for valid assessment of the outcome of the 
procedure, care must be taken to have objective 
measures by which improvement can be measured 
(or at least measures which do not rely on the 
subjective opinion of the operating surgeon).87 
In the KORAL study, the primary outcome was 
function as measured by the Oxford Knee Score – a 
patient reported outcome – and hence one that was 
not influenced by the operating surgeon.
With a placebo-controlled trial in surgery, 
however, there is an added issue of the surgeon 
knowing which patients have been given the 
placebo treatment and which have had the ‘active’ 
treatment. In the focus groups, the surgeons 
discussed the ethical dilemma this raised for the 
doctor–patient relationship, and the need to have 
a pre-planned script for managing the patients 
in the trial to avoid having to ‘lie’ to patients 
about the type of surgery they had received. In 
the KORAL pilot, a plan for how the surgeon 
would communicate with patients was developed 
before any patients were recruited to the pilot. 
The surgeon indicated to the patients prior to 
the operation that he or she would not be able to 
tell them which procedure they had undergone in 
theatre, but would tell them if the procedure had 
progressed as planned.
Both the surgeon and anaesthetist were unaware of 
the allocation until the patient was in theatre. This 
minimised the need for the health professionals Discussion
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to conceal information about the allocation 
from the patient prior to the operation, and 
also allowed them to prepare for the surgery 
in the normal fashion. This had the added 
benefit of maximising the scientific rigour of 
the design as the recommended practice is to 
delay the randomisation to as close to the time of 
intervention as possible. The experience of the 
pilot study showed however, that, despite extensive 
pre-planning, some theatre staff expressed 
concerns about proceeding with a placebo 
surgery when confronted with the reality of the 
action. This suggests that researchers planning 
placebo-controlled trials in surgery in the future 
should actively develop communication plans 
specific for all those who might contribute to the 
process: surgeons, anaesthetists, theatre nurses, 
recovery staff, etc. This individualised approach to 
communication is commonly used in marketing, 
and recent research into the potential role of 
business and marketing theory in RCTs suggests 
that this approach is crucial to ‘buy-in’ to the trial 
from all stakeholders.88
Lay understanding of technical 
terms and informed consent
The KORAL study found that whilst most 
participants in the focus groups understood 
the role of the placebo, others found the 
concept somewhat confusing. This finding is 
consistent with other literature that has identified 
difficulties experienced by lay individuals in 
fully understanding technical terms such as 
randomisation and equipoise.45 Given the 
perceived complexity for potential trial participants 
in understanding the role of placebo, the placebo-
controlled trial may be a fruitful context in which 
to research the potential usefulness of decision 
aids in the consent process.89 A decision aid is a 
formal tool to help people decide what course of 
action – in this case whether or not to participate 
in a placebo-controlled trial – is right for them. 
Decision aids attempt to spell out in a lay-
friendly manner the arguments for and against 
each decision option, and allow the individual 
to attach personalised ratings for each, thus 
allowing the individual to build up a cumulative 
picture of which decision is right for him or her. 
In a recent study, Juraskova et al.90 found that 
the use of a formal decision aid to help potential 
participants decide whether or not to take part 
in a breast cancer prevention trial improved 
understanding of the trial without provoking 
anxiety (although they noted that individuals still 
had problems understanding technical terms such 
as randomisation). To our knowledge, the role 
of formal decision aids is as yet untested in the 
context of a placebo-controlled trial.
Collective versus individual 
ethics
The experience of the KORAL pilot showed that, 
despite full MREC approval, the study required 
major discussion and negotiation at an individual 
centre level before local clinical approvals could 
be obtained. Many of the arguments raised at 
MREC level were raised again at local level, and 
the fact that ethics approval had been granted 
did not mean that clinicians would automatically 
accept that the process was ethical. This raised the 
issue of how the different perspectives by which 
individuals can view the ethics of a topic can lead 
to different conclusions being made. For example, 
the qualitative work undertaken with the health 
professionals and potential trial participants 
highlighted that there were a number of different 
ethical perspectives at play even in our limited 
setting. Some individuals adopted ‘consequentialist’ 
reasoning when considering the ethics of KORAL 
– they were considering the morality of the placebo 
by assessment of its consequences – whereas others 
adopted more ‘deontological’ reasoning (where the 
rightness or wrongness of the placebo was being 
determined by the characteristics of the placebo 
itself rather than the consequences of it). The 
tensions and disagreements raised by the adoption 
of these different approaches were apparent in the 
discussions.
Most clinicians in the UK adopt a professional code 
of conduct derived from the ‘principlist’ approach59 
to ethics – they are guided by the four principles of 
beneficence, non-maleficence, justice and respect 
for autonomy – and it was interesting to note that a 
number of those health professionals who adopted 
consequentialist reasoning when considering the 
ethics of the placebo within KORAL recognised 
that aspects of their professional codes of conduct 
were in tension with this.
It is important that those planning trials that 
involve complex ethical issues (such as placebo-
controlled trials) recognise that a range of ethical 
perspectives are likely to be encountered when 
setting up a complex study over a number of sites, 
and that these different perspectives can influence 
the perceived acceptability of the intervention 
in those settings and may lead to delays and 
protracted negotiations within these sites.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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Arrangements for indemnity
The KORAL study highlighted the lack of clarity 
that exists with regard to arrangements for 
indemnity (in particular for non-negligent harm) 
in clinical research. Our discussions with multiple 
agencies highlighted that the delineation of 
liability was not clear. Whilst the NHS institutions 
accept liability for negligent harm caused by 
the design and conduct of studies they initiate, 
NHS indemnity does not provide for ‘no-fault’ 
compensation for non-negligent harm.69 It is 
unclear whether every clinical site participating in 
a trial is required separately to arrange for this or 
whether the Sponsor organisation is responsible 
for arranging this for all sites and individuals 
participating within the trial. For the limited case 
of the KORAL pilot, ‘no-fault’ compensation was 
arranged through the lead institution’s insurers; 
however, had the pilot progressed to full trial these 
arrangements would have been revisited.
It would be helpful if the national arrangements 
for indemnity and non-negligent harm were 
clarified for all researchers involved in the conduct 
of clinical trials, particularly those trials that may 
involve a placebo arm, and perhaps NHS-wide 
indemnity procedures could be developed by the 
respective Health Departments.
Implications of staged-funded 
projects for trials units
Conditional, staged funding of trials such as 
KORAL, incorporating feasibility then a formal 
pilot, culminating in a definitive confirmatory trial, 
provides a flexible approach to managing the risks 
of a large-scale research project. It can provide 
protection for both the funder and research group 
from continued and unproductive involvement in 
a project that no longer has a meaningful chance 
of success. Such a design does, however, create 
extra challenges for a trials unit – particularly in 
integrating this type of study into a portfolio of 
mainly conventional, single-stage, unconditionally 
funded confirmatory trials.
Typically, a trials unit will have a business model 
that identifies its capacity – the number of trials 
that can be taken on at any one time given staffing 
and other constraints. So, despite the uncertainty 
within KORAL as to whether a full-scale trial would 
go ahead, a ‘slot’ had to be set aside for one in the 
capacity planning for CHaRT (the clinical trials 
unit supporting the KORAL study) at the start 
of the study. As we now know, KORAL did not 
progress to full trial, but for the 2 years whilst the 
feasibility and pilot phases were being conducted, 
the ongoing prospect of a full-scale trial was an 
important factor in CHaRT’s decision whether 
to bid for further trials. In this type of situation, 
which is likely to become more commonplace in 
the future, the complexity of the decision-making 
process for trials units will inevitably increase 
(especially for trials units that have a number of 
‘KORAL-type’ staged-funding projects in play 
at various stages of maturity). It is an interesting 
challenge for those managing trials units to weigh 
up the likelihood of progression of conditionally 
funded, staged trials such as KORAL (in which the 
progress of internal issues, but not the funder’s 
response to these issues is known) against the 
competitiveness of supporting a ‘de novo’ proposal 
for a different trial. There is the obvious danger 
of not securing enough trials to sustain the trials 
unit, holding over too many slots for conditional 
staged-funded trials that do not progress to full 
trials, coupled with lower than anticipated success 
in funding conventional trials. It will be a challenge 
for trials units to integrate the management of the 
submission and conduct of pilot and full studies, 
in particular the staged conditionally funded trials 
such as KORAL.
A further major issue in conditional staged-funded 
designs is the increased uncertainty in the timelines 
for the early phases of the project, reflecting the 
degree of uncertainty and perhaps also the likely 
controversies in the trial question and design. In 
full-scale trials, whilst commonplace, delays tend 
to be both expected (occurring at established 
bottlenecks) and fixable (usually by simple 
solutions). However, in a challenging pilot like 
KORAL, the delays were more unpredictable and 
more difficult to solve. For example, it was difficult 
for CHaRT to speedily react and resolve an issue 
of refusal at a local level to proceed on the grounds 
that the study is not ethical, despite it having ethics 
committee approval. The uncertainties of roles and 
responsibilities this entails are awkward, and can 
require considerable time and diplomacy by the 
trials unit to achieve a resolution that enables the 
study to go forward at that centre.
Thus, whilst conditional staged funding is an 
attractive and flexible model for publicly funded 
trials, and may be particularly attractive for the 
development of more complex studies such as 
KORAL, integrating such designs into a mixed 
portfolio of conventional trials presents challenges 
to a trials unit. Trials units considering running 
these types of studies in the future should be aware 
of these challenges and plan for them.Discussion
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When, and how, should a 
placebo-controlled trial 
be mounted in a surgical 
context?
The KORAL study provided a number of insights 
into the question of when and how a placebo-
controlled trial should be mounted in a surgical 
setting. Commentators agree that the ethical 
principles appropriate to all clinical research must 
be satisfied as a minimum when considering the 
acceptability and feasibility of a placebo-controlled 
design. These principles are that the study must: 
(1) have scientific merit, (2) be acceptable to 
participants in terms of the risk-to-benefit ratio of 
participation and (3) be respectful of the autonomy 
of participants to determine whether they should 
participate.91 The results of the qualitative 
component within the KORAL study showed that 
these three factors were raised and discussed in 
depth for the particular case of arthroscopic lavage. 
The scientific merit of the proposed study – the 
evaluation of the true effectiveness of arthroscopic 
lavage – and the need for informed consent were 
readily accepted. Whether the proposed study 
design provided an acceptable balance of risks 
and potential benefits for participants, however, 
generated much wider debate.
The discussion of an acceptable risk-to-benefit 
ratio in a placebo-controlled study is not 
straightforward. As Horng and Miller61 argue, 
the risks must be considered in the context of 
alternative study designs to answer the research 
question: could an evaluation of arthroscopic 
lavage be conducted without the use of a placebo 
control and without compromising scientific 
rigour? In any trial of arthroscopic lavage, the 
subjective measure of pain is the primary outcome 
of interest. It is a well-recognised phenomenon 
that subjective outcomes are prone to bias when 
the allocation is known to the outcome assessor.87 
Any open trial that compared arthroscopic lavage 
with a control group that received no treatment 
or non-surgical treatment would thus have been 
prone to potentially biased results. This may go 
some way to explain the differences seen in the 
early studies of the effectiveness of arthroscopic 
lavage, where those open studies that compared 
arthroscopic lavage against no surgery (or non-
surgical management) showed some evidence of 
benefit, whereas those studies that were conducted 
in a blinded manner showed none. This suggests 
that a placebo-controlled trial is most relevant in 
a surgical context when the primary outcome of 
interest is subjective (and thus prone to bias in 
other designs).
An additional consideration in the risk-to-benefit 
ratio for participants is the nature of the proposed 
placebo – how ‘risky’ the proposed placebo is 
perceived to be. A placebo must be able to mimic 
the intervention under evaluation, but must 
minimise the risks to those who might take part in 
the trial. Edwards et al.92 suggest that perceptions 
of the acceptability of a placebo are likely to 
vary depending on the nature of the placebo in 
question. They suggest that when an active placebo 
is very intrusive or confers significant potential 
harm, participants need to display high levels of 
altruism to enter a trial. In the KORAL study there 
was consensus from all parties that, from a surgical 
perspective, the proposed placebo demonstrated 
not only high potential to mimic the active 
intervention but also low intrusiveness (three small 
skin incisions), and thus yielded high acceptability. 
The primary issue of concern was rather the 
perceived intrusiveness of the anaesthetic 
component of the placebo – the recommendation 
to have a general anaesthetic for those undergoing 
the placebo procedure. This raised concerns among 
many of the stakeholders within the study, and was 
the factor that caused most discussion with local 
decision-makers when seeking formal approval to 
conduct the KORAL pilot. It is interesting to note, 
however, that the subject experts, the anaesthetists, 
who contributed to our research viewed the use of 
a general anaesthetic in the placebo group as the 
option that did minimise the risk. They contended 
that the technique with which they would have 
more experience, a routine general anaesthetic, 
would be safer and that they would be less likely 
to make errors when administering it. We have 
discussed earlier how this assessment is borne out 
by the wider literature on expertise and errors.
Even when a placebo-controlled trial might be 
deemed to be an acceptable design, it must also be 
a feasible course of action. The experience of the 
KORAL study highlighted this issue well as, even 
when national approval for the study was gained, 
the trial faced a number of practical hurdles before 
it commenced. Inability to surmount any of these 
practical difficulties would have led directly to the 
failure of the study. The particular issues faced 
by KORAL highlighted that: (1) stakeholders in 
every trial centre need to be fully briefed about 
any proposed trial and any concerns need to 
be resolved prior to trial commencement; (2) 
arrangements need to be put in place to cover the 
costs of the placebo before any trial can go ahead; DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
67
and (3) appropriate indemnity arrangements need 
be instituted. Whilst these issues were particularly 
relevant to KORAL, they are not unusual and are 
likely to be faced by any researcher planning a 
placebo-controlled trial. In particular, the crucial 
importance of local stakeholders (those who might 
be affected by the research) and gatekeepers (those 
who give formal permission for the organisation to 
be involved in the research) has been outlined by 
a number of authors,93,94 and the need to develop 
explicit recruitment and communication strategies 
has been identified.
These insights suggest, therefore, that the optimal 
place for a placebo-controlled trial in surgery is in 
situations in which the following conditions can be 
satisfied:
•  Alternative designs would provide inferior (and 
potentially biased) results, particularly where 
the primary outcome is of a subjective nature 
and blinding cannot be sustained beyond the 
time of any placebo effect.
•  A placebo surgical procedure and type of 
anaesthesia can be devised that adequately 
mimic the active intervention with a level of 
intrusiveness and risk that is acceptable to 
surgeons, anaesthetists, ethics committees and 
potential participants.
•  Appropriate practical arrangements can be 
instituted in local centres to ensure that the 
delivery of such a design would be feasible.
•  Sufficient numbers of potential participants 
(after assessment of clear descriptions and 
careful explanations in patient information 
leaflets of the advantages and disadvantages of 
taking part) judge for themselves that the risk-
to-benefit ratio of participation is acceptable to 
them.
•  Levels of compliance with the allocation are 
sufficiently high to sustain scientific rigour.
Overall conclusion
The KORAL feasibility study showed that, in 
principle, a placebo-controlled trial of arthroscopic 
lavage could be conducted in the UK, albeit 
with difficulty. It also showed, however, that the 
design remains controversial, and for some health 
professionals the use of placebo surgery can never 
be justified. It highlighted the importance of the 
surgeon–anaesthetist relationship in this context 
and how acceptance of the trial design by both 
parties is essential to successful participation. 
It also highlighted the importance of informed 
consent for trial participants and the strength and 
influence of individuals’ ethical perspectives in 
addition to collective ethics provided by MRECs. 
All these factors need to be accounted for in the 
planning of future placebo-controlled trials.
The wider conclusion from the KORAL study is 
that the optimal place for a placebo-controlled trial 
in surgery is likely to be for situations in which the 
strict conditions listed above can be satisfied.
Implications for practice
•  A placebo-controlled trial of arthroscopic 
lavage could be conducted in the UK, albeit 
with difficulty.
•  Those conducting trials in surgery must 
consider the surgeon–anaesthetist partnerships 
when planning clinical trials, especially trials 
including a placebo arm.
•  People taking part in, and authorising the 
conduct of, trials have their own individual 
ethical perspectives which can influence their 
practice (in addition to the collective ethics 
assessment provided by MRECs). Researchers 
need to be aware of these, and work with them, 
when planning clinical trials – especially trials 
involving a placebo arm.
•  Terminology referring to ‘placebos’, ‘shams’, 
‘dummies’, etc. should be investigated and then 
standardised across trials – each has different 
connotations that may influence participation.
•  The importance of including clear descriptions 
and careful explanations in patient information 
leaflets was reinforced in this study. All trials 
should ensure that any advantages and 
disadvantages of participation are explained as 
fully as possible.
•  Patient information leaflets within placebo-
controlled trials should explicitly state that 
whilst benefit might be seen within a placebo 
group, the underlying mechanism proposed for 
the placebo has no known scientific rationale to 
support benefit.
•  National arrangements for indemnity and 
non-negligent harm should be clarified for all 
researchers involved in the conduct of clinical 
trials, particularly those trials that might 
involve a placebo arm.
•  The HTA programme should consider the 
routine use of staged funding (with integrated 
rapid decision-making) for more complex 
research projects.Discussion
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Implications for research
•  Research is required into the impact of 
different terminology referring to placebos 
(e.g. placebo, sham, dummy) on understanding 
the role and function of a placebo.
•  Research is required into the usefulness of 
formal decision aids to aid participant consent 
in the context of a placebo-controlled trial.
•  Research is required into the impact of 
individual versus collective ethics on the 
conduct of placebo-controlled trials.DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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Thanks/introductions
Purpose of focus group – acceptability of proposed 
trial …
Introduce yourself, where based, current surgical 
position
Who currently offers arthroscopic lavage?
•  Yes – who gets it?
•  No – have you ever done it/what changed?
AS presents the Moseley trial and bit about our 
study
Explore reactions to Moseley trial – should we be 
asking this question?
If FOR arthroscopic lavage, what would convince 
you to stop?
If AGAINST arthroscopic lavage, what would 
convince you to start?
Explore views about placebo surgery in general, in 
different research contexts. Is there any role for it? 
Trials of unproven procedures?
What about the use of placebo surgery in the 
context of a trial of arthroscopic lavage? Main 
concerns:
•  surgery
•  anaesthetic
•  other.
Best placebo:
•  one that would maximise the mimic
•  one that would minimise the risks.
Explore reasons FOR taking part in a two-arm trial
Explore reasons AGAINST taking part in a two-
arm trial:
•  barriers
•  legal or risk management issues.
Show of hands – willing to participate as recruiting 
clinician/member of clinical team.
If FOR use of placebo – what would patients need 
to know?
Show of hands – if you or close friend/relative had 
osteoarthritis, would you take part as a patient or 
recommend friend to take part?
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Appendix 3  
Topic guide – 
focus group (anaesthetists)
Thanks/introductions
Purpose of focus group – acceptability of proposed 
trial …
Introduce yourself, where based, current position
Explore reactions to Moseley trial –should we be 
asking this question?
Explore views about placebo surgery in general, in 
different research contexts. Is there any role for it? 
Trials of unproven procedures?
What about the use of placebo surgery in the 
context of a trial of arthroscopic lavage? What are 
the main concerns:
Best placebo:
•  one that would maximise the mimic
•  one that would minimise the risks.
Explore reasons FOR taking part in a two-arm trial
Explore reasons AGAINST taking part in a two-
arm trial:
•  barriers
•  legal or risk management issues.
What about modification to the basic two-equal 
arm trial design, e.g. a three-arm trial (is there a 
role for non surgical management as a control); 
different randomisation ratios; waiting lists rather 
than placebo …
Show of hands – willing to participate as recruiting 
clinician/member of clinical team?
If there is to be some form of placebo – what would 
patients need to know?
Show of hands – if you or a close friend/relative had 
osteoarthritis, would you take part as a patient or 
recommend your friend to take part?DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
83
Appendix 4  
Presentation made to anaesthetists 
prior to focus groupAppendix 4
84
 DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
85
 Appendix 4
86
 DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
© 2010 Queen’s Printer and Controller of HMSO. All rights reserved.
87
Introductions
(1)  If you could just start by introducing yourself, 
say how long you have had osteoarthritis for, 
and briefly describe the types of treatments you 
have tried already.
  – Probes – so you’ve mentioned X, Y and Z. 
Are there any other treatments available do 
you know of?
  – For X, Y and Z, what are your opinions 
about how well the different treatments 
work [where did you get this info from]
  – And what about problems/side effects
(2)  I mentioned the trial in the US that has already 
investigated the effectiveness of the common 
procedure arthroscopic lavage for people with 
osteoarthritis of the knee.
  – Were you aware of this trial – if so, where 
did you find out about it?
  – What do you think about it?
(3)  Now, I spoke about why the NHS has suggested 
that there should be another placebo 
controlled trial. I just want to put you on the 
spot and ask if you think you would take part in 
a study in which half were randomly allocated 
to get arthroscopic lavage and half were 
randomly allocated to get a placebo procedure.
  – If yes (why?)
  – If no (why?)
(4)  Do you think this trial should go ahead – do 
you think that it is a good thing that we are 
proposing to do this?
Key rationales (use as probes if 
necessary)
Arthroscopic lavage has become a common 
treatment for osteoarthritis of the knee without 
there having been any proper scientific 
investigation of whether it is effective or not. 
(Some doctors offer it because they believe that it is 
effective, whereas others are more sceptical about 
its effectiveness and so do not offer it.)
So some people have argued that in order to 
improve the care of patients in the future it is 
important to investigate this properly, in other 
words, because of the uncertainty of current 
scientific evidence in general, i.e. a lot of the 
doctors that we’ve spoken to believe that we are 
attempting to answer an important question. What 
do you think?
Also, in light of this uncertainty with regard to the 
scientific evidence, if arthroscopic lavage is not 
effective, you could argue that a number of patients 
are currently being given an ineffective treatment.
Conversely, if it is an effective treatment then you 
could argue that some patients are being denied an 
effective treatment by doctors who do not currently 
offer it?
What do you think about these arguments?
(5)  What about the problems related to trying to 
conduct this kind of trial?
Key ethical issues
Some people have argued that doctors should not 
expose patients to risks (in the case of this trial, 
there would be a risk from the general anaesthetic 
if there is no prospect of possible benefits).
Patient recruitment – would patients take part
What do you think?
(6)  What kinds of things would have to be put in 
place to make a trial like this acceptable?
(7)  OK, imagine you were approached to take 
part, what would be the potential advantages 
of you taking part? What about the potential 
disadvantages?
(8)  Obviously we want to make the proposed trial 
‘as good as possible’ for participants – would 
any modifications/changes to the nature of 
the placebo surgery make any difference to 
whether or not people would be willing to take 
part? As I mentioned, we’ve already spoken 
with surgeons and anaesthetists and there was 
a general consensus that the placebo group 
should receive two/three superficial cuts to the 
knee about that all should receive a general 
Appendix 5  
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anaesthetic. The main reason for this was the 
need to standardise as much as possible across 
the groups.
  – What about the study design. What about 
if instead of half getting the placebo and 
half the �arthroscopic lavage, what if there 
was an extra group who would get given, 
say physiotherapy (so patients had only a 
one in three chance of getting the placebo 
surgery) … would any of that make a 
difference?
  – What if we got rid of the placebo group 
altogether and we had say one group that 
got arthroscopic lavage and another group 
who were simply put on a waiting list. This 
would mean that for our trial the waiting 
list would act as a control group and we 
could compare the two groups in order to 
see if arthroscopic lavage was effective or 
not?
Try and sum up.
[quick break] I have a draft of a possible patient 
info leaflet about the trial (the kind of one that 
might go out to people when we are trying to 
recruit them) and what we’ll do is take a quick 
break and I’ll let you have a look over this and then 
we’ll start the tape and just go through it if that’s 
OK.
OK, so you’ve had a look at the leaflet.
(9)  What do you think about it?
  – Do you think it covers what people would 
need to know before they can decide 
whether or not to take part?
  – What bits should be kept?
  – What should be deleted?
  – What should be added?
  – Anything that could be worded better?
(10)  Is there anything else that you’d like to say in 
relation to this trial?DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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What if something goes wrong? 
 
In the very unlikely event that you are harmed by taking part in this study, there are special insurance 
arrangements being put in place.  
 
 
Who is organising and funding the research? 
 
The  study  is  funded  by  the  Department  of  Health  Research  and  Development  Health  Technology 
Assessment Programme. A team based in Aberdeen is responsible for the day to day management of 
the study. However, this hospital is one of several throughout the UK taking part and your doctor is 
part of the collaborating team. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The KORAL study is funded by the UK NHS R&D Health 
Technology Assessment Programme 
CONTACT DETAILS 
Zoë Skea 
Health Services Research Unit 
University of Aberdeen 
Polwarth Building, Foresterhill 
Aberdeen, AB25 2ZD 
 
Tel: 01224 554674 
Fax: 01224 554580 
Email: z.skea@abdn.ac.uk 
Thank you for reading this DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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What is osteoarthritis of the knee? 
 
Osteoarthritis (OA) is a disease that affects the joints in the body. 'Osteo' means bone and 'arthritis' 
means joint damage and swelling (inflammation). When joints are swollen and damaged they can be 
painful and can affect mobility. Osteoarthritis of the knee is a very common form of osteoarthritis. 
 
 
How can osteoarthritis of the knee be treated? 
 
There are a range of treatments available for people have OA of the knee. These include painkillers 
(such as paracetamol), anti-inflammatory drugs or creams, steroid injections, and surgery. 
Sometimes, 'keyhole' surgery techniques are used to 'wash out' loose fragments of bone and other 
tissue from the joint. This is called arthroscopic lavage. Sometimes, during a lavage, additional 
procedures may be carried out – such as smoothing the surfaces of the joint, removing flaps of 
damaged hard cartilage, or trimming of torn soft cartilage. This is called debridement. These 
techniques may offer pain relief in the early stages of OA, but previous studies do not tell us if these 
surgery techniques really work. 
 
Introduction to the study 
 
You are being invited to take part in a research study that aims to find out if arthroscopic lavage for 
osteoarthritis really works. Before you decide, it is important for you to understand why the research 
is being done and what it will involve. Please take time to read the enclosed information carefully and 
discuss it with your family, friends or General Practitioner if you wish. Do not hesitate to contact us if 
there is anything you do not understand or if you would like more information. Please take time to 
decide whether or not you wish to take part. 
 
What is the purpose of the study? 
 
The purpose of this study is to find out if arthroscopic lavage or debridement is an effective treatment 
for people with OA of the knee. In this study, doctors, researchers and patient representatives are 
working together to compare three options against each other:  
 
-  ‘arthroscopic lavage’ 
-  ‘placebo’ procedure (simulated surgery) 
-  Management without surgery (e.g. physiotherapy). 
 
 
What treatment will I receive? 
 
If you agree to take part in the study, your type of treatment will be chosen randomly by a computer. 
You will not know which treatment group you are in if you are allocated to receive either ‘arthroscopic 
lavage’  or  the  ‘placebo’  procedure  (simulated  surgery).  You  will  have  a  one  in  three  chance  of 
receiving either: 
 
1. Arthroscopic lavage 
If you are allocated to this group you will receive arthroscopic lavage (with some debridement if your 
surgeon thinks it is necessary). Arthroscopic lavage is a  'keyhole' surgery technique. A small camera 
will be inserted into your knee to allow the surgeon to see.  The surgeon will then 'wash out' any 
loose fragments of bone and other tissue from the joint. Debridement involves smoothing the surfaces 
of the joint, removing any flaps of damaged hard cartilage, and trimming torn soft cartilage. This 
procedure would not usually require an overnight stay in hospital but approximately 2 to 3 days off 
work (depending on nature of work). This procedure requires a general anaesthetic. 
2. ‘Placebo’ procedure (simulated surgery) 
If you are allocated to this group you will receive a ‘placebo’ procedure. Placebo, or dummy, tablets 
are regularly used in studies to evaluate new medicines. This study will use a surgical placebo. 
Placebo surgery simulates or mimics a surgical procedure, but the person allocated to receive it does 
not actually undergo the full surgical procedure. 
If you are allocated to this group, your surgeon will make three very small incisions in the skin on your 
knee. No instrument would be inserted into your knee.  These incisions would be very similar to the 
ones given to people in the ‘arthroscopic lavage’ group, but they would not be as deep. This 
procedure would not usually require an overnight stay in hospital but approximately 2 to 3 days off 
work (depending on nature of work). This procedure requires a general anaesthetic. 
 
3. Management without surgery 
If you are allocated to this group, you will not receive any surgery. Instead, the surgeon responsible 
for your care will recommend the standard form of treatment such as, for example, physiotherapy.  
 
What will I be asked to do if I take part? 
If you agree to take part in this study you will be randomly allocated to receive one of the three 
treatments. The treatment will be given by the same doctors and nurses who would treat you if you 
were not taking part. You will then be followed-up at 6, 12 and 24 months. You will sent a 
questionnaire which will ask about any pain in your knee, your general health and any visits you have 
had to the GP or hospital about your knee arthritis. 
 
Why have I been approached? 
This hospital is one of several centres throughout the UK taking part in this study. As a person 
currently receiving care for OA of the knee, you may be eligible to take part in the study. We plan to 
involve about 500 patients who have OA of the knee throughout the UK. 
 
What are the advantages and disadvantages of taking part?  
Advantages 
The treatments, including the placebo procedure, may offer some relief from the painful symptoms of 
early OA of the knee. A similar study carried out on a small scale in the US has found that all 
treatments offered some benefit (Moseley 2002). The information we get from this study may help us 
to provide better treatment in the future for patients with OA of the knee.  
 
Disadvantages  
The disadvantages of either surgical operation (arthroscopic lavage or the placebo procedure) are: 
-  it requires approximately 2 to 3 days off work (depending on nature of work) 
-  as with all surgery that involves a general anaesthetic, there is a risk, albeit a very low risk, 
of serious complications or operative death. 
 
We want to reassure you that: 
-  Your involvement in the study is entirely voluntary. 
-  You are free to withdraw at any time and this would not affect your current or future 
medical treatment. Although we do not expect participation to affect private medical 
insurance, if you have insurance, please check with the company before agreeing to take 
part in the study. 
-  All information collected for the study will be treated as confidential and used only for the 
purpose of the study. 
-  We will inform your GP that you are taking part. 
-  All people taking part will be kept informed about the study and will be sent a summary of 
the results. The results of the study will be published in medical journals. Participants will 
not be identifiable in any of the study reports. 
-  This study has been approved by all the appropriate agencies. 
-  This study is being undertaken on behalf of the NHS. 
-  This study is being developed with full collaboration of Arthritis Care. 
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What is osteoarthritis of the knee? 
 
Osteoarthritis (OA) is a disease that affects the joints in the body. 'Osteo' means bone and 'arthritis' 
means joint damage and swelling (inflammation). When joints are swollen and damaged they can be 
painful and can affect mobility. Osteoarthritis of the knee is a very common form of osteoarthritis. 
 
 
How can osteoarthritis of the knee be treated? 
 
There are a range of treatments available for people have OA of the knee. These include painkillers 
(such as paracetamol), anti-inflammatory drugs or creams, steroid injections, and surgery. 
Sometimes, 'keyhole' surgery techniques are used to 'wash out' loose fragments of bone and other 
tissue from the joint. This is called arthroscopic lavage. Sometimes, during a lavage, additional 
procedures may be carried out – such as smoothing the surfaces of the joint, removing flaps of 
damaged hard cartilage, or trimming of torn soft cartilage. This is called debridement. These 
techniques may offer pain relief in the early stages of OA, but previous studies do not tell us if these 
surgery techniques really work. 
 
Introduction to the study 
 
You are being invited to take part in a research study that aims to find out if arthroscopic lavage for 
osteoarthritis really works. Before you decide, it is important for you to understand why the research 
is being done and what it will involve. Please take time to read the enclosed information carefully and 
discuss it with your family, friends or General Practitioner if you wish. Do not hesitate to contact us if 
there is anything you do not understand or if you would like more information. Please take time to 
decide whether or not you wish to take part. 
 
What is the purpose of the study? 
 
The purpose of this study is to find out if arthroscopic lavage or debridement is an effective treatment 
for people with OA of the knee. In this study, doctors, researchers and patient representatives are 
working together to compare three options against each other:  
 
-  ‘arthroscopic lavage’ 
-  ‘placebo’ procedure (simulated surgery) 
-  Management without surgery (e.g. physiotherapy). 
 
 
What treatment will I receive? 
 
If you agree to take part in the study, your type of treatment will be chosen randomly by a computer. 
You will not know which treatment group you are in if you are allocated to receive either ‘arthroscopic 
lavage’  or  the  ‘placebo’  procedure  (simulated  surgery).  You  will  have  a  one  in  three  chance  of 
receiving either: 
 
1. Arthroscopic lavage 
If you are allocated to this group you will receive arthroscopic lavage (with some debridement if your 
surgeon thinks it is necessary). Arthroscopic lavage is a  'keyhole' surgery technique. A small camera 
will be inserted into your knee to allow the surgeon to see.  The surgeon will then 'wash out' any 
loose fragments of bone and other tissue from the joint. Debridement involves smoothing the surfaces 
of the joint, removing any flaps of damaged hard cartilage, and trimming torn soft cartilage. This 
procedure would not usually require an overnight stay in hospital but approximately 2 to 3 days off 
work (depending on nature of work). This procedure requires a general anaesthetic. 
2. ‘Placebo’ procedure (simulated surgery) 
If you are allocated to this group you will receive a ‘placebo’ procedure. Placebo, or dummy, tablets 
are regularly used in studies to evaluate new medicines. This study will use a surgical placebo. 
Placebo surgery simulates or mimics a surgical procedure, but the person allocated to receive it does 
not actually undergo the full surgical procedure. 
If you are allocated to this group, your surgeon will make three very small incisions in the skin on your 
knee. No instrument would be inserted into your knee.  These incisions would be very similar to the 
ones given to people in the ‘arthroscopic lavage’ group, but they would not be as deep. This 
procedure would not usually require an overnight stay in hospital but approximately 2 to 3 days off 
work (depending on nature of work). This procedure requires a general anaesthetic. 
 
3. Management without surgery 
If you are allocated to this group, you will not receive any surgery. Instead, the surgeon responsible 
for your care will recommend the standard form of treatment such as, for example, physiotherapy.  
 
What will I be asked to do if I take part? 
If you agree to take part in this study you will be randomly allocated to receive one of the three 
treatments. The treatment will be given by the same doctors and nurses who would treat you if you 
were not taking part. You will then be followed-up at 6, 12 and 24 months. You will sent a 
questionnaire which will ask about any pain in your knee, your general health and any visits you have 
had to the GP or hospital about your knee arthritis. 
 
Why have I been approached? 
This hospital is one of several centres throughout the UK taking part in this study. As a person 
currently receiving care for OA of the knee, you may be eligible to take part in the study. We plan to 
involve about 500 patients who have OA of the knee throughout the UK. 
 
What are the advantages and disadvantages of taking part?  
Advantages 
The treatments, including the placebo procedure, may offer some relief from the painful symptoms of 
early OA of the knee. A similar study carried out on a small scale in the US has found that all 
treatments offered some benefit (Moseley 2002). The information we get from this study may help us 
to provide better treatment in the future for patients with OA of the knee.  
 
Disadvantages  
The disadvantages of either surgical operation (arthroscopic lavage or the placebo procedure) are: 
-  it requires approximately 2 to 3 days off work (depending on nature of work) 
-  as with all surgery that involves a general anaesthetic, there is a risk, albeit a very low risk, 
of serious complications or operative death. 
 
We want to reassure you that: 
-  Your involvement in the study is entirely voluntary. 
-  You are free to withdraw at any time and this would not affect your current or future 
medical treatment. Although we do not expect participation to affect private medical 
insurance, if you have insurance, please check with the company before agreeing to take 
part in the study. 
-  All information collected for the study will be treated as confidential and used only for the 
purpose of the study. 
-  We will inform your GP that you are taking part. 
-  All people taking part will be kept informed about the study and will be sent a summary of 
the results. The results of the study will be published in medical journals. Participants will 
not be identifiable in any of the study reports. 
-  This study has been approved by all the appropriate agencies. 
-  This study is being undertaken on behalf of the NHS. 
-  This study is being developed with full collaboration of Arthritis Care. 
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What if something goes wrong? 
 
In the very unlikely event that you are harmed by taking part in this study, there are special insurance 
arrangements being put in place.  
 
 
Who is organising and funding the research? 
 
The  study  is  funded  by  the  Department  of  Health  Research  and  Development  Health  Technology 
Assessment Programme. A team based in Aberdeen is responsible for the day to day management of 
the study. However, this hospital is one of several throughout the UK taking part and your doctor is 
part of the collaborating team. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The KORAL study is funded by the UK NHS R&D Health 
Technology Assessment Programme 
CONTACT DETAILS 
Zoë Skea 
Health Services Research Unit 
University of Aberdeen 
Polwarth Building, Foresterhill 
Aberdeen, AB25 2ZD 
 
Tel: 01224 554674 
Fax: 01224 554580 
Email: z.skea@abdn.ac.uk 
Thank you for reading this DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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(1)  Quick summary of proposed trial and 
preliminary findings from discussions that 
we’ve already had with surgeons/anaesthetists/
patients.
(2)  Ask chairperson to introduce themselves and 
say a bit about role within their MREC.
(3)  Thinking about our proposed trial, based on 
the written information that you have received 
along with my brief summary, what are your 
initial thoughts about it from an ethical 
perspective?
Probes:
  – Arthroscopic lavage has become a common 
treatment without there having been any 
proper scientific investigation of whether 
it is effective or not. So, because of the 
uncertainty of current scientific evidence, 
several of the health professionals that 
we’ve talked with believe we are attempting 
to answer an important question. What do 
you think?
  – What about the argument that surgical 
procedures of unproven benefit that are 
currently in routine use also pose a risk to 
patients?
  – Some people have argued that placebo 
controls are especially appropriate for the 
evaluation of surgical innovation that has 
not previously been associated with robust 
scientific validation and where subjective 
symptoms of the patient are relied upon as 
outcome measures. What do you think?
(4)  What do you think about the nature of the 
placebo we are proposing (two/three superficial 
cuts, no scope used, general anaesthetic given)? 
Would any modifications to this make it more 
or less acceptable from an ethical standpoint?
(5)  What about the nature of the trial design 
that we are proposing (one in three chance 
of receiving: arthroscopic lavage, placebo or 
management without surgery)? Would any 
modifications to this make it more or less 
acceptable from an ethical standpoint?
(6)  What criteria would a trial that included 
simulated surgery need to satisfy to be ethically 
acceptable?
(7)  What about patient information material? What 
would patients need to be told from the point 
of view of MRECs if they were approached to 
take part?
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  Outline data on patients who are ineligible or who decline participation 
 
Q1  Date of attempted recruitment   DD/MM/YY      /      /     
                   
Q2  Gender                 
    Male    Female                 
                   
Q3  Age                 
                   
                     
                   
Q4  Centre                 
                   
                     
 
 
 
Q5  Reasons for non-inclusion - tick all that apply 
     
Arthroscopic lavage clearly indicated    
Arthroplasty clearly indicated    
Clear contra-indication to anaesthesia    
Patient does not understand English    
Patient unable to complete follow-up questionnaires    
Patient does not want to participate in the study:    
  - does not like the idea of the study    
  - does not like the idea of a placebo    
Other    
If other, please state:   
 
 
 
 
 
 
Signature: _______________________________ 
 
ISRCTN02328576 
Version 1, May 2006 
 
Ineligible or Declined 
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CONFIDENTIAL CONFIDENTIAL   
 
 
 
 
KORAL STUDY 
 
ARTHROSCOPIC LAVAGE IN THE TREATMENT OF 
OSTEOARTHRITIS OF THE KNEE 
 
 
 
 
PARTICIPANT DETAILS FORM 
 
 
 
Thank you for helping us with our research 
We would be very grateful if you could complete and return this form. 
 
 
ISRCTN02328576 
 
Version 1 May 2006 
STUDY No.           Appendix 12
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PERSONAL INFORMATION 
 
Title (Mr, Mrs etc)  Surname                                           
                                                                               
 
First Names                                                     
                                                                                       
 
Date of Birth  Day  Month  Year                                   
          /      /                                                   
 
Gender  Maiden name if female and ever married                                     
                                    Male    Female                                   
                                       
Address                                                                           
                                             
                                                                                       
                                             
                                                                                       
                                             
                                                                                       
 
Postcode  Telephone Number (including  code)                                             
                                                                                       
 
Mobile Number                           
                                                   
 
NHS Number  Hospital Number (if known)                                           
                                                                                   
 
CHI Number (Scotland only)                                             
                                                                                   
 
GENERAL PRACTITIONER  
 
Surname                                               
                                                                                       
 
First Name(s) (if known)                                               
                                                                                       
                                       
Address                                                                           
                                             
                                                                                       
                                             
                                                                                       
                                             
                                                                                       
 
Postcode  Telephone Number (including  code)                                           
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To be completed on withdrawal from the study 
 
 
 
  Study No 
           
 
1.   Date of withdrawal (dd/mm/yy)   
               
 
 
  Reason for withdrawal 
 
2.   Participant decided to withdraw (state reason)   
   
 
 
 
3.   Any medical reasons for withdrawal? (state reason)   
   
 
 
 
4.  Continued use of data   
Yes      No   Does the participant agree to relevant data being collected in  
the future through central sources (eg hospital notes)? 
 
 
 
 
 
 
 
 
 
 
ISRCTN02328576 
Version 1 July 2006 
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Study No           
 
 
Date of clinic (DD/MM/YY)      /     /    
 
1.  Study Knee    2.  ASA Grade – fit for surgery?   
  Right      Yes   
 
  Left      No   
 
3.  X-ray grading (Kellgren-Lawrence)    4.  Mechanical Symptoms present?   
  0    1      Yes (and therefore ineligible)   
 
  2    3      No   
 
  4 (ineligible)       
 
5.  Range of motion   
  Hyperextension 
o    Neutral  Yes    No   
 
  Flexion 
o    If No, fixed flexion deformity 
o 
 
 
6.  Effusion   
  0 none      ++ mod   
 
  + mild      +++ severe   
 
7.  Limb alignment 1 (with patient standing)   
  Normal (medial malleoli and medial femoral condyles touch)  Yes    No   
 
Varus  Yes 
  No      cms 
   
     
If Yes, gap between medial  
femoral condules 
   
 
Valgus  Yes 
  No      cms 
   
     
If Yes, gap between medial  
malleoli 
   
 
8.  Limb alignment 2  Femoro-tibial angle 
o 
 
9.  Height  cms    10.  Weight  kgs   
 
ISRCTN02328576 
Version 1 July 2007 
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MEDICAL MANAGEMENT 
 
Date                Study No           
 
 
    YES      YES 
 
1.  Analgesia    2.  Support   
  Simple      Walking stick   
 
  NSAID      Elastic knee brace   
 
  Other      Other   
 
If other, specify       
 
 
           
3.   Heat or Ice    4.  Lifestyle modification advice   
 
 
5.  Exercise    6.  Injection   
 
  Referral      Steroid   
 
  Exercise sheet       HA   
 
 
7.   Glucosamine    8.  Chondroitin   
 
 
9.   Other    If other, specify   
 
 
 
 
Version 1, July 2005 Appendix 12
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Study No           
 
Date of clinic (DD/MM/YY)      /     /    
 
1.  Study Knee     
  Right     
 
  Left     
   
 
2.  Range of motion   
  Hyperextension 
o    Neutral  Yes    No   
 
  Flexion 
o    If No, fixed flexion deformity 
o 
 
 
3.  Effusion   
  0 none      ++ mod   
 
  + mild      +++ severe   
 
4.  Weight  kgs     
 
5.  Any other treatment/surgery planned?   
  Yes   
 
  No     
 
6a.  If yes, what?   
 
 
6b.  If yes, when?   
 
 
7.  Any clinical follow-up planned?   
  Yes   
 
  No     
 
7a.  If yes, what?   
 
 
7b.  If yes, when?   
 
 
8.  Any  change  of 
symptoms? 
 
 
 
ISRCTN02328576 
Version 1 July 2007 
MEDICAL MANAGEMENT  
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  Date of clinic      /      /     
 
1.  Study number            
 
2.  Hospital number                        
 
3.  Surname    
 
4.  First Name(s)   
 
5.  Address   
 
   
 
   
 
6.  Surgery code          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ISRCTN02328576 
Version 1 July 2007 
RANDOMISED TO SURGERY -
PARTICIPANT DETAILS Appendix 12
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  Study No 
           
   
 
1  Grade of anaesthetist    2  Patient’s ASA grade   
  Consultant      I   
 
  Associate Specialist/Staff Grade      II   
 
  Specialist Trainee      III or above (ineligible)   
 
3  Induction agent    4  OPIOID   
  Propofol      Short acting (Fentanyl/Alfentanil)   
 
  Thiopentone      Long Acting (Morphine)   
 
  Other       
 
5  Maintenance    6  Analgesia (post-op)   
  Nitrous Oxide      NSAID   
 
  Volatile      Paracetamol   
 
  Volatile      OPIOID   
 
7  Airway         
  MASK         
 
  LMA         
 
  Tracheal Tube         
 
8  Time into Anaesthetic Room (hh:mm)      :     
 
9  Time into Theatre      :     
 
10  Time into Recovery      :     
 
ISRCTN02328576 
Version 1 July 2007 
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  Study No 
   
 
       
 
 
Date of surgery (DD/MM/YY)      /      /     
 
Randomised to:  Arthroscopy    Placebo operation   
 
Tourniquet   Yes    No    If Yes  Mins    mmHg   
 
 
EUA:               
Hyperextension  °    Extension 
deficit 
°    Flexion  ° 
 
 
Effusion   0 none    Lachman  0-2mm    Pivot  0 none   
  + mild      3-5mm    Shift  + glide   
  ++ mod      6-9mm      ++clunk   
  +++ severe      ≥10mm      +++ gross   
        Firm         
        Not Firm         
MCL  0-2mm    LCL  0-2mm    PCL  0-2mm   
  3-5mm      3-5mm      3-5mm   
  6-9mm      6-9mm      6-9mm   
  ≥10mm      ≥10mm      ≥10mm   
 
Other 
 
 
 
Grade of surgeon:  Confirm Consultant (as per protocol)   
 
Date of hospital discharge (DD/MM/YY)      /      /     
Surgical details 
If randomised to arthroscopic lavage, complete 
all pages.  If randomised to placebo operation, 
complete pages 1 and 2 only. Appendix 12
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LA  20ml 0.5% Marcain       
Dressing  Steristrips    Suture   opsite, gauze, wool, crepe 
Post-Op  Routine care, mobilise ASAP. Reduce dressing to DTG at 
discharge 
Follow-up    Physio     
         
Other         
         
Signed         
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LA  20ml 0.5% Marcain       
Dressing  Steristrips    Suture   opsite, gauze, wool, crepe 
Post-Op  Routine care, mobilise ASAP. Reduce dressing to DTG at 
discharge 
Follow-up    Physio     
         
Other         
         
Signed         
         
 
 
 
 
Modified Noyes Rating       
Lesion Score  10mm  15mm   
1  Chondromalacia:  A  soft,     1  2   
        B  softening, indentation  1  2   
2   Open Lesion  A Fissure/fragmentation half 
thickness 
2  3   
        B Fissure/fragmentation full 
thickness 
3  6   
3   Bone    A exposed,     5  10   
        B bone cavity  5  10   
             
Complex lesions - Examples 
 
 
 
 
 
             
             
 
Anatomical Score 
     
Score 
     
             
Patella             
  +    =       
Femoral sulcus             
             
Medial Femur          Total score   
  +    =       
Medial Tibia             
             
Lateral Femur             
  +    =       
Lateral Tibia             
             
 
 
           
  Was debridement done?    Yes      No       
           
 
 
If yes, please indicate type of debridement: 
   
           
  Miniscus         
  Articular cartilage         
  Other (please describe)         
           
1B (Chondromalacia, 15mm dia) 
2A (Fissures, 10mm dia) 
3 points 
2A (Fissures, 15mm dia)  
2B (Fissures, 10mm dia) 
4 points 
2B (Fissures, 15mm dia)  
3A (Bone, 10mm dia) 
7 points Appendix 12
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Subjective findings 
 
ARTHROSCOPY  Incisions :  Medial, lateral, lateral suprapatellar     
  Findings and Action   
Patello-femoral 
     
       
Gutters 
     
       
Medial 
     
       
Lateral 
     
       
Medial Meniscus 
     
       
Lateral Meniscus 
     
       
ACL/PCL/Notch 
   
Right Menisci 
 
 
Left Menisci 
 
 
         
 
ICRS rating 
Draw chondral lesions on appropriate diagram, then record lesion grade and size  
Right Knee Joint Surfaces 
 
Left Knee Joint Surfaces 
 
ICRS Grade 0 
– Normal 
 
 
 
 
ICRS Grade 1 – 
Nearly Normal 
Superficial lesions, 
Soft indentation (A) 
and/or superficial 
fissures and cracks 
(B) 
 
       A                B 
ICRS Grade 2 
– Abnormal 
Lesions 
extending down 
to <50% of 
cartilage depth 
 
ICRS Grade 3 - Severely Abnormal 
Cartilage defects extending down 
>50% of cartilage depth (A) as well as 
down to calcified layer (B) and down to 
Blisters are included in this Grade (D) 
 
       A            B            C            D 
ICRS Grade 4 – Severely Abnormal  
Osteochondral injuries, lesions extending just 
through the subchondral boneplate (A) or 
deeper defects down into trabecular bone (B).  
Defects that have been drilled are regarded as 
osteochondral defects and classified as ICRS-C 
 
       A                B 
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Study No           
 
Date of clinic (DD/MM/YY)      /     /    
 
1.  Study Knee 
  Left        Right     
 
2.  Wound healed? 
  Yes       
 
       
  No    If no, please    
      give details   
 
3.  Any evidence of inflammation? 
  No       
 
       
  Yes    If yes, please   
      give details   
 
4.  Have there been problems since surgery over and above normal post-operative issues 
(eg infection treated by antibiotics, persistent discharge)? 
  No       
 
       
  Yes    If yes, please   
      give details   
 
5.  Was the patient re-admitted to hospital? 
  No       
 
       
  Yes    If yes, please   
      give details   
 
6.  Was the patient discharged on the day of surgery? 
  Yes       
 
       
  No    If no, please    
      give details   
 
Surgical follow-up clinic Appendix 12
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7.  Range of motion 
Hyperextension  °    Extension 
deficit  
(0 if neutral) 
°    Flexion  ° 
 
 
8.  Effusion 
  0 none      ++ mod   
 
  + mild      +++ severe   
 
 
9.  Any other treatment/surgery planned? 
  Yes     
 
  No     
 
9a.  If yes, what?   
 
 
9b.  If yes, when?   
 
 
 
10.  Any clinical follow-up planned? 
  Yes     
 
  No   
 
10a.  If yes, what?   
 
 
10b.  If yes, when?   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
There will be additional patient follow-up (by postal questionnaire) –  
these questionnaires will be administered by the KORAL team. 
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To be completed for any serious adverse events 
 
  Study No 
               
 
1.   Date of report (dd/mm/yy)   
               
 
2.  Name of person initially reporting 
adverse event 
 
 
Contact details  Address   
 
 
 
 
Telephone     
 
Email     
 
  PATIENT DETAILS 
 
3.   Patient’s Initials   
       
 
4.  Date of birth   
                 
 
5.  Hospital number   
       
 
6.  Sex       
Male    Female   
 
 
7.  Place where adverse event took place/detected   
     
 
8.  Date of event   
                 
Version 1, July 2006 
Serious Adverse Event Report Appendix 12
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9  Brief details of adverse event   
   
   
   
 
10.  Cross all appropriate to adverse event – if any boxes are crossed the adverse 
event is “serious”.     
  Patient died      
  Involved or prolonged inpatient hospitalisation      
  Involved persistent or significant disability or incapacity      
  Life threatening      
 
11.  Is this serious adverse event one of XXXXXXX (eg post-operative infection) and 
therefore an “expected” serious adverse event? 
 
  Yes      
  No      
 
12.  Other relevant history (e.g. diagnostics, allergies, etc)   
   
 
 
 
 
Assessment of whether event was caused by trial participation 
 
13.  Is it reasonably likely that the adverse event was caused by taking part in 
KORAL 
 
  Yes      
  No      
 
14.  Why  
 
   
 
   
 
15.  Name and position of person making this judgment 
 
   
 
16.  Any subsequent information 
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STUDY No.           
 
 
 
 
 
 
 
 
 
 
 
 
 
CONFIDENTIAL CONFIDENTIAL   
 
 
 
KORAL STUDY 
 
 
ARTHROSCOPIC LAVAGE FOR TREATMENT OF 
OSTEOARTHRITIS OF THE KNEE 
 
 
BASELINE QUESTIONNAIRE 
 
 
Thank you for helping us with research into osteoarthritis 
of the knee. We would be very grateful if you could 
complete and return this questionnaire. 
 
ISRCTN02328576 ISRCTN02328576   
 
Version 1 May 2006 Version 1 May 2006   Appendix 12
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SECTION A - HEALTH PROBLEMS CAUSED BY YOUR KNEE 
 
 
The following questions ask about problems which may have been caused by your knee 
during the past 4 weeks.    
 
 
A1. During the past 4 weeks how would you describe the pain you have from your 
knee? 
 
  None   
  Very mild   
(Cross ONE box only)  Mild   
  Moderate   
  Severe   
 
A2. During  the  past  4  weeks  have  you  had  any  trouble  with  washing  and  drying 
yourself (all over) because of your knee? 
 
  No trouble at all   
  Very little trouble   
(Cross ONE box only)  Moderate trouble   
  Extreme trouble   
  Impossible to do   
 
A3. During the past 4 weeks have you had any trouble getting in and out of a car or 
using public transport because of your knee?  (whichever you tend to use). 
 
  No trouble at all   
  Very little trouble   
(Cross ONE box only)  Moderate trouble   
  Extreme difficulty    
  Impossible to do   
 
A4. During the past 4 weeks for how long have you been able to walk before the 
pain from your knee becomes severe?  (with or without a stick). 
 
  No pain at all, or no pain for more than 30 mins   
  16 to 30 mins   
(Cross ONE box only)  5 to 15 mins   
  Around the house only   
  Not at all - severe on walking   
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SECTION A - HEALTH PROBLEMS CAUSED BY YOUR KNEE 
 
 
A5. During the past 4 weeks after a meal (sat at a table), how painful has it been for you 
to stand up from a chair because of your knee? 
 
  Not at all painful   
  Slightly painful   
(Cross ONE box only)  Moderately painful   
  Very painful   
  Unbearable   
 
A6. During the past 4 weeks have you been limping when walking, because of your 
knee? 
 
  Rarely/never   
  Sometimes or just at first   
(Cross ONE box only)  Often, not just at first   
  Most of the time   
  All of the time   
 
A7. During  the  past  4  weeks  could  you  kneel  down  and  get  up  again  afterwards? 
(thinking of your knee) 
 
  Yes, easily   
  With little difficulty   
(Cross ONE box only)  With moderate difficulty   
  With extreme difficulty   
  No, impossible   
 
A8. During the past 4 weeks have you been troubled by pain from your knee in bed at 
night? 
 
  No, never   
  Only 1 or 2 nights   
(Cross ONE box only)  Some nights   
  Most nights   
  Every night   
 Appendix 12
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SECTION A - HEALTH PROBLEMS CAUSED BY YOUR KNEE 
 
 
A9. During the past 4 weeks how much has pain from your knee interfered with your 
usual work (including housework)? 
 
  Not at all   
  A little bit   
(Cross ONE box only)  Moderately   
  Greatly   
  Totally   
 
A10. During the past 4 weeks have you felt that your knee might suddenly "give way" 
or let you down? 
 
  Rarely/never   
  Sometimes or just at first   
(Cross ONE box only)  Often, not just at first   
  Most of the time   
  All of the time   
 
A11. During the past 4 weeks could you do the household shopping on your own? 
(thinking of your knee) 
 
  Yes, easily   
  With little difficulty   
(Cross ONE box only)  With moderate difficulty   
  With extreme difficulty   
  No, impossible   
 
A12.  During the past 4 weeks could you walk down a flight of stairs? (thinking of 
your knee) 
 
  Yes, easily   
  With little difficulty   
(Cross ONE box only)  With moderate difficulty   
  With extreme difficulty   
  No, impossible   
 
 
 
SECTION B – DESCRIBING YOUR OWN HEALTH TODAY 
 
The next two sections are about your general health. 
 
By placing a cross (X) in one box in each group below, please indicate which 
statement best describes your own health state today.  Do not X more than 
one box in each group. 
 
B1. Mobility   
 
I have no problems in walking about   
I have some problems in walking about   
I am confined to bed   
 
 
B2. Self-Care   
 
I have no problems with self care   
I have some problems washing and dressing myself   
I am unable to wash myself   
 
 
B3. Usual activities (eg work, study, housework, family or leisure activities)   
 
I have no problems with performing my usual activities   
I have some problems with performing my usual activities   
I am unable to perform my usual activities   
 
 
B4. Pain / Discomfort   
 
I have no pain or discomfort   
I have moderate pain or discomfort   
I have extreme pain or discomfort   
 
 
B5. Anxiety / Depression   
 
I am not anxious or depressed   
I am moderately anxious or depressed   
I am extremely anxious or depressed   
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SECTION A - HEALTH PROBLEMS CAUSED BY YOUR KNEE 
 
 
A9. During the past 4 weeks how much has pain from your knee interfered with your 
usual work (including housework)? 
 
  Not at all   
  A little bit   
(Cross ONE box only)  Moderately   
  Greatly   
  Totally   
 
A10. During the past 4 weeks have you felt that your knee might suddenly "give way" 
or let you down? 
 
  Rarely/never   
  Sometimes or just at first   
(Cross ONE box only)  Often, not just at first   
  Most of the time   
  All of the time   
 
A11. During the past 4 weeks could you do the household shopping on your own? 
(thinking of your knee) 
 
  Yes, easily   
  With little difficulty   
(Cross ONE box only)  With moderate difficulty   
  With extreme difficulty   
  No, impossible   
 
A12.  During the past 4 weeks could you walk down a flight of stairs? (thinking of 
your knee) 
 
  Yes, easily   
  With little difficulty   
(Cross ONE box only)  With moderate difficulty   
  With extreme difficulty   
  No, impossible   
 
 
 
SECTION B – DESCRIBING YOUR OWN HEALTH TODAY 
 
The next two sections are about your general health. 
 
By placing a cross (X) in one box in each group below, please indicate which 
statement best describes your own health state today.  Do not X more than 
one box in each group. 
 
B1. Mobility   
 
I have no problems in walking about   
I have some problems in walking about   
I am confined to bed   
 
 
B2. Self-Care   
 
I have no problems with self care   
I have some problems washing and dressing myself   
I am unable to wash myself   
 
 
B3. Usual activities (eg work, study, housework, family or leisure activities)   
 
I have no problems with performing my usual activities   
I have some problems with performing my usual activities   
I am unable to perform my usual activities   
 
 
B4. Pain / Discomfort   
 
I have no pain or discomfort   
I have moderate pain or discomfort   
I have extreme pain or discomfort   
 
 
B5. Anxiety / Depression   
 
I am not anxious or depressed   
I am moderately anxious or depressed   
I am extremely anxious or depressed   
 Appendix 12
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Please indicate on this scale        
how good or bad your own health  
state is today. 
 
The best health state you can 
imagine is marked 100 and the 
worst health state you can imagine 
is marked 0. 
  
Please draw a line from the box below 
to the point on the scale that best 
indicates how good or bad your health 
           state is today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Your own 
health state 
today DOI: 10.3310/hta14050  Health Technology Assessment 2010; Vol. 14: No. 5
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SECTION C – GENERAL HEALTH SF12 © 
 
The following questions ask for your views about your health in the last 4 weeks, how you 
feel and how well you are able to do your usual activities. 
 
Answer every question by placing a cross in one box only. If you are unsure about how to 
answer any questions please give the best answer you can. 
 
 
C1. In general, would you say your health is: 
 
Excellent   
     
  Very good   
     
(Cross ONE box only)  Good   
     
  Fair   
     
Poor   
 
 
 
C2. During a typical day does your health limit you in moderate activities, such as moving 
a  table, pushing a vacuum cleaner, bowling or playing golf?   If so, how much? 
 
  Yes, limited a lot   
     
(Cross ONE box only)  Yes, limited a little   
     
  No, not limited at all   
 
 
 
C3. During a typical day does your health limit you in climbing several flights of stairs?    
If so, how much? 
 
  Yes, limited a lot   
     
(Cross ONE box only)  Yes, limited a little   
     
  No, not limited at all   
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SECTION C – GENERAL HEALTH SF12 © 
 
 
C4. During the past 4 weeks, how often have you accomplished less than you would 
have liked in your work or other regular daily activities as a result of your physical 
health? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
 
 
C5. During the past 4 weeks, how often have you been limited in performing any kind of 
work or other regular daily activities as a result of your physical health? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
 
 
C6. During the past 4 weeks, how often have you accomplished less than you would 
have liked in your work or any other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
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SECTION C – GENERAL HEALTH SF12 © 
 
 
C7. During  the  past  4  weeks,  how  often  have  you  done  work  or  other  activities  less 
carefully  than  usual  as  a  result  of  any  emotional  problems  (such  as  feeling 
depressed or anxious)? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
 
 
C8. During the past 4 weeks how much did pain interfere with your normal work (both 
outside the home and housework)? 
 
  Not at all   
     
  A little bit   
     
(Cross ONE box only)  Moderately   
     
  Quite a bit   
     
  Extremely   
 
 
 
C9. How much during the past 4 weeks have you felt calm and peaceful? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 Appendix 12
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SECTION C – GENERAL HEALTH SF12 © 
 
C10.  How much during the past 4 weeks did you have a lot of energy? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
 
C11.  How much during the past 4 weeks have you felt downhearted and depressed? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
 
C12.  During  the  past  4  weeks  how  much  of  the  time  has  your  physical  health  or 
emotional  problems  interfered  with  your  social  activities  (like  visiting  friends, 
relatives, etc.)? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
None of the time   
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SECTION D – PAIN 
 
Please indicate on this scale how you would rate your pain today? The 
best rating is marked 0 (no pain) and the worst rating is marked 10 
(worst imaginable pain). Please draw a cross (X) on the line that best 
indicates the rating of your pain today. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Thank you for filling in this questionnaire, please post it back to us in the 
envelope provided  
 
 
If you would like any further information or have any queries about the study, please contact: 
 
 
 
  The KORAL Study Office in Aberdeen (Tel: 01224 554338) 
 
   
 
 
 
 
 
This study is taking place in centres across the UK but the questionnaires are being processed in Aberdeen at the Centre for 
Healthcare Randomised Trials (CHaRT), Health Services Research Unit, 3
rd Floor, Health Sciences Building, Foresterhill, 
ABERDEEN, AB25 2ZD. 
 
 
                     
                     
  0  1  2  3  4  5  6  7  8  9  10 
 
No pain 
             
Worst pain 
imaginable 
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SECTION A - HEALTH PROBLEMS CAUSED BY YOUR KNEE 
 
 
The following questions ask about problems which may have been caused by your 
knee during the past 4 weeks.    
 
A1. During the past 4 weeks how would you describe the pain you have from your 
knee? 
 
  None   
  Very mild   
(Cross ONE box only)  Mild   
  Moderate   
  Severe   
 
A2. During  the  past  4  weeks  have  you  had  any  trouble  with  washing  and  drying 
yourself (all over) because of your knee? 
 
  No trouble at all   
  Very little trouble   
(Cross ONE box only)  Moderate trouble   
  Extreme trouble   
  Impossible to do   
 
A3. During the past 4 weeks have you had any trouble getting in and out of a car or 
using public transport because of your knee?  (whichever you tend to use). 
 
  No trouble at all   
  Very little trouble   
(Cross ONE box only)  Moderate trouble   
  Extreme difficulty    
  Impossible to do   
 
A4. During the past 4 weeks for how long have you been able to walk before the pain 
from your knee becomes severe?  (with or without a stick). 
 
  No pain at all, or no pain for more than 30 mins   
  16 to 30 mins   
(Cross ONE box only)  5 to 15 mins   
  Around the house only   
  Not at all - severe on walking   
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SECTION A - HEALTH PROBLEMS CAUSED BY YOUR KNEE 
 
 
A5. During the past 4 weeks after a meal (sat at a table), how painful has it been for 
you to stand up from a chair because of your knee? 
 
  Not at all painful   
  Slightly painful   
(Cross ONE box only)  Moderately painful   
  Very painful   
  Unbearable   
 
A6. During the past 4 weeks have you been limping when walking, because of your 
knee? 
 
  Rarely/never   
  Sometimes or just at first   
(Cross ONE box only)  Often, not just at first   
  Most of the time   
  All of the time   
 
A7. During  the  past  4  weeks  could  you  kneel  down  and  get  up  again  afterwards? 
(thinking of your knee) 
 
  Yes, easily   
  With little difficulty   
(Cross ONE box only)  With moderate difficulty   
  With extreme difficulty   
  No, impossible   
 
A8. During the past 4 weeks have you been troubled by pain from your knee in bed at 
night? 
 
  No, never   
  Only 1 or 2 nights   
(Cross ONE box only)  Some nights   
  Most nights   
  Every night   
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SECTION A - HEALTH PROBLEMS CAUSED BY YOUR KNEE 
 
 
A9. During the past 4 weeks how much has pain from your knee interfered with your 
usual work (including housework)? 
 
  Not at all   
  A little bit   
(Cross ONE box only)  Moderately   
  Greatly   
  Totally   
 
 
A10.  During the past 4 weeks have you felt that your knee might suddenly "give 
way" or let you down? 
 
  Rarely/never   
  Sometimes or just at first   
(Cross ONE box only)  Often, not just at first   
  Most of the time   
  All of the time   
 
 
A11.  During the past 4 weeks could you do the household shopping on your own? 
(thinking of your knee) 
 
  Yes, easily   
  With little difficulty   
(Cross ONE box only)  With moderate difficulty   
  With extreme difficulty   
  No, impossible   
 
 
A12.  During the past 4 weeks could you walk down a flight of stairs? (thinking of 
your knee) 
 
  Yes, easily   
  With little difficulty   
(Cross ONE box only)  With moderate difficulty   
  With extreme difficulty   
  No, impossible   
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SECTION B – DESCRIBING YOUR OWN HEALTH TODAY 
 
The next two sections are about your general health. 
 
By placing a cross (X) in one box in each group below, please indicate 
which statement best describes your own health state today.  Do not X 
more than one box in each group. 
 
 
Mobility 
 
I have no problems in walking about   
I have some problems in walking about   
I am confined to bed   
 
 
Self-Care 
 
I have no problems with self care   
I have some problems washing and dressing myself   
I am unable to wash myself   
 
 
Usual activities (eg work, study, housework, family or leisure activities) 
 
I have no problems with performing my usual activities   
I have some problems with performing my usual activities   
I am unable to perform my usual activities   
 
 
Pain / Discomfort 
 
I have no pain or discomfort   
I have moderate pain or discomfort   
I have extreme pain or discomfort   
 
 
Anxiety / Depression 
 
I am not anxious or depressed   
I am moderately anxious or depressed   
I am extremely anxious or depressed   
 
 
 
 
 
 
 
Please indicate on this scale        
how good or bad your own health  
state is today. 
 
The best health state you can 
imagine is marked 100 and the 
worst health state you can imagine 
is marked 0. 
  
Please draw a line from the box below 
to the point on the scale that best 
indicates how good or bad your health 
            state is today. 
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Please indicate on this scale        
how good or bad your own health  
state is today. 
 
The best health state you can 
imagine is marked 100 and the 
worst health state you can imagine 
is marked 0. 
  
Please draw a line from the box below 
to the point on the scale that best 
indicates how good or bad your health 
            state is today. 
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SECTION C – GENERAL HEALTH SF12 © 
 
 
The following questions ask for your views about your health in the last 4 weeks, 
how you feel and how well you are able to do your usual activities. 
 
Answer every question by placing a cross in one box only. If you are unsure about 
how to answer any questions please give the best answer you can. 
 
 
C1. In general, would you say your health is: 
 
Excellent   
     
  Very good   
     
(Cross ONE box only)  Good   
     
  Fair   
     
Poor   
 
 
C2. During a typical day does your health limit you in moderate activities, such as moving 
a  table, pushing a vacuum cleaner, bowling or playing golf?   If so, how much? 
 
  Yes, limited a lot   
     
(Cross ONE box only)  Yes, limited a little   
     
  No, not limited at all   
 
 
C3. During a typical day does your health limit you in climbing several flights of stairs?    
If so, how much? 
 
  Yes, limited a lot   
     
(Cross ONE box only)  Yes, limited a little   
     
  No, not limited at all   
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SECTION C – GENERAL HEALTH SF12 © 
 
C4. During the past 4 weeks, how often have you accomplished less than you would 
have liked in your work or other regular daily activities as a result of your physical 
health? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
C5. During the past 4 weeks, how often have you been limited in performing any kind of 
work or other regular daily activities as a result of your physical health? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
C6. During the past 4 weeks, how often have you accomplished less than you would 
have  liked  in  your  work  or  any  other  regular  daily  activities  as  a  result  of  any 
emotional problems (such as feeling depressed or anxious)? 
 
   
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
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SECTION C – GENERAL HEALTH SF12 © 
 
C7. During  the  past  4  weeks,  how  often  have  you  done  work  or  other  activities  less 
carefully  than  usual  as  a  result  of  any  emotional  problems  (such  as  feeling 
depressed or anxious)? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
 
C8. During the past 4 weeks how much did pain interfere with your normal work (both 
outside the home and housework)? 
 
  Not at all   
     
  A little bit   
     
(Cross ONE box only)  Moderately   
     
  Quite a bit   
     
  Extremely   
 
 
C9. How much during the past 4 weeks have you felt calm and peaceful? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
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SECTION C – GENERAL HEALTH SF12 © 
 
C10.  How much during the past 4 weeks did you have a lot of energy? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
 
C11.  How much during the past 4 weeks have you felt downhearted and depressed? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
  None of the time   
 
 
C12.  During  the  past  4  weeks  how  much  of  the  time  has  your  physical  health  or 
emotional  problems  interfered  with  your  social  activities  (like  visiting  friends, 
relatives, etc.)? 
 
  All of the time   
     
  Most of the time   
     
(Cross ONE box only)  Some of the time   
     
  A little of the time   
     
None of the time   
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SECTION D – PAIN 
 
D1.  Please indicate on this scale how you would rate your pain today? The best 
rating is marked 0 (no pain) and the worst rating is marked 10 (worst 
imaginable pain). Please draw a cross (X) on the line that best indicates the 
rating of your pain today. 
 
 
 
 
 
 
 
 
 
 
 
D2.   If you are currently being PRESCRIBED any medication to manage your pain, 
please list below the name(s) of the medicine(s) and include the number of 
times you have taken it in the last two weeks.  
 
        
Name of medication  No. of times taken in the 
last 2 weeks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                     
                     
  0  1  2  3  4  5  6  7  8  9  10 
No pain              Worst pain 
imaginable 
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D3.  Please  list  below  the  names  of  any  NON  PRESCRIBED  (over  the 
counter) medication you take for your pain and include the number of 
times you have taken it in the last two weeks. 
 
Name of medication  No. of times taken in the last 2 
weeks 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
SECTION E – YOUR FOLLOW-UP 
 
E1.  In  the  study  you  were  randomised  to  surgery  or  to  non-surgical 
management.    People  who  were  randomised  to  surgery  either  had 
surgery  (arthroscopic  lavage)  or  placebo  surgery  (a  simulated 
arthroscopic lavage that mimics the surgical procedure). 
 
  If you had surgery on your knee as part of the KORAL study, which type 
of surgery do you think you had? 
 
  Surgery (arthroscopic lavage)   
     
  Placebo surgery (simulated arthroscopic lavage)   
     
(Cross ONE box only)  Don’t know   
     
 
 
 
 
Thank you for filling in this questionnaire, please post it back to us in 
the envelope provided  
If you would like any further information or have any queries about the study, please contact: 
 
 
The KORAL Study Office in Aberdeen (Tel: 01224 554338) 
 
 
This study is taking place in centres across the UK but the questionnaires are being processed in Aberdeen at the 
Centre for Healthcare Randomised Trials (CHaRT), Health Services Research Unit, 3
rd Floor, Health Sciences 
Building, Foresterhill, ABERDEEN, AB25 2ZD. 
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Feedback
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your views about this report.
The Correspondence Page on the HTA website 
(www.hta.ac.uk) is a convenient way to publish 
your comments. If you prefer, you can send your comments 
to the address below, telling us whether you would like 
us to transfer them to the website.
We look forward to hearing from you.